US20150119601A1 - Monofunctional mcr + 3-hp dehydrogenase - Google Patents

Monofunctional mcr + 3-hp dehydrogenase Download PDF

Info

Publication number
US20150119601A1
US20150119601A1 US14/215,442 US201414215442A US2015119601A1 US 20150119601 A1 US20150119601 A1 US 20150119601A1 US 201414215442 A US201414215442 A US 201414215442A US 2015119601 A1 US2015119601 A1 US 2015119601A1
Authority
US
United States
Prior art keywords
coli
mcr
enzyme
malonyl
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/215,442
Inventor
Hans Liao
Christopher Patrick MERCOGLIANO
Travis Robert WOLTER
Michael Tai Man LOUIE
Wendy Kathleen RIBBLE
Tanya LIPSCOMB
Eileen Colie SPINDLER
Michael D Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OPX Biotechnologies Inc
Original Assignee
OPX Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OPX Biotechnologies Inc filed Critical OPX Biotechnologies Inc
Priority to US14/215,442 priority Critical patent/US20150119601A1/en
Assigned to OPX BIOTECHNOLOGIES, INC. reassignment OPX BIOTECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOUIE, Michael Tai Man, WOLTER, Travis Robert, RIBBLE, Wendy Kathleen, SPINDLER, Eileen Colie, LIAO, HANS, LIPSCOMB, TANYA, MERCOGLIANO, Christopher Patrick, LYNCH, MICHAEL D.
Publication of US20150119601A1 publication Critical patent/US20150119601A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0008Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/40Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42Hydroxy-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/40Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52Propionic acid; Butyric acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y604/00Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01002Acetyl-CoA carboxylase (6.4.1.2)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Definitions

  • a common challenge faced in field of bio-produced chemicals in microorganisms is that any one modification to a host cell may require coordination with other modifications in order to successfully enhance chemical bioproduction.
  • the current invention provides methods, systems of fermentation, genetically modified microorganisms, modified enhanced enzymes for chemical production, all of which may be used in various combinations to increase chemical production of a desired chemical product.
  • the present invention relates to genetically modified organisms capable of producing an industrial chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding one or more of the following: (1) an acetyl-CoA carboxylase gene with one or more of its subunits fused together in the genetic structure of the organism; (2) an acetyl-CoA carboxylase gene having a predefined stoichiometric ratio of each of the four ACCase subunits relative to one another; (3) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde and one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD, rutE, and nemA; (4) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA
  • the present invention further relates to methods of producing a chemical product using the genetically modified organisms of the invention.
  • the present invention further includes products made from these methods.
  • product is acetyl-CoA, malonyl-CoA, malonate semialdehyde, 3-hydroxypropionic acid (3-HP), acrylic acid, 1,3 propanediol, malonic acid, ethyl 3-HP, propiolactone, acrylonitrile, acrylamide, methyl acrylate, a polymer including super absorbent polymers and polyacrylic acid, or a consumer product.
  • the present invention further relates to a method of producing a chemical product from a renewable carbon source through a bioproduction process that comprises a controlled multi-phase production process wherein the initiation and/or completion of one or more phases of the production process is controlled by genetic modifications to the organism producing the chemical product and/or is controlled by changes made to the cell environment.
  • the bioproduction process may include two or more of the following phases: (1) growth phase; (2) induction phase; and (3) production phase.
  • the present invention further includes products made from these methods.
  • FIG. 1 Depicts some embodiments of the metabolic pathways to produce 3-hydroxypropionic acid.
  • FIG. 2 Depicts some embodiments of the of various equilibrium states in the malonate semialdehyde to 3-HP reaction in a cell environment.
  • FIG. 3 Depicts some embodiments of the reaction catalyzed by acetyl-CoA carboxylase (ACCase)
  • FIG. 4 Shows the inhibition of ACCase enzyme activity by high salt concentration
  • FIG. 5 Depicts some embodiments of the fusion ACCase subunit gene constructs overexpressed in E. coli.
  • FIG. 6 Show improved production of 3-HP by genetically modified organism with DA fusion ACCase
  • FIG. 7 Shows improved production of 3-HP by genetically modified organism with overexpression of rhtA exporter.
  • FIG. 8 Shows various embodiments of the genetic modules used for optimizing expression in host cells.
  • FIG. 9 Shows various chemical products that can made from various embodiments of the invention.
  • Table 1 Lists the accession numbers for genes encoding ACCase subunits from Halomonas elongate.
  • Table 2 Depicts some embodiments of the RBS sequences used to enhance expression of H. elongate ACCase subunits.
  • Table 3 Shows the improvement in 3-HP production by RBS-optimized expression of H. elongata ACCase subunits.
  • Table 4 Shows some embodiments of the ACCase subunit fusions that increase and ACCase enzyme complex activity.
  • Table 5 Shows some of the genetic modifications of a host cell for increase chemical production.
  • homology refers to the optimal alignment of sequences (either nucleotides or amino acids), which may be conducted by computerized implementations of algorithms.
  • “Homology”, with regard to polynucleotides, for example, may be determined by analysis with BLASTN version 2.0 using the default parameters.
  • “Homology”, with respect to polypeptides (i.e., amino acids) may be determined using a program, such as BLASTP version 2.2.2 with the default parameters, which aligns the polypeptide or fragments (and can also align nucleotide fragments) being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid “homology” includes conservative substitutions, i.e.
  • substitutions those that substitute a given amino acid in a polypeptide by another amino acid of similar characteristics.
  • conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, VaI, Leu and He with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa; replacement of an acidic residue such as Asp or GIu with another acidic residue; replacement of a residue bearing an amide group, such as Asn or GIn, with another residue bearing an amide group; exchange of a basic residue such as Lys or Arg with another basic residue; and replacement of an aromatic residue such as Phe or Tyr with another aromatic residue.
  • homologs can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide identity to the gene or proteins of the invention; or can have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% amino acid or nucleotide to the essential protein functional domains of the gene or proteins of the invention; or at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential functional domain of the
  • sequence homology is intended to be exemplary and it is recognized that this concept is well-understood in the art. Further, it is appreciated that nucleic acid sequences may be varied and still provide a functional enzyme, and such variations are within the scope of the present invention.
  • enzyme homolog can also mean a functional variant.
  • Fusional homolog means a polypeptide that is determined to possess an enzymatic activity and specificity of an enzyme of interest but which has an amino acid sequence different from such enzyme of interest.
  • a corresponding “homolog nucleic acid sequence” may be constructed that is determined to encode such an identified enzymatic functional variant.
  • 3-HP means 3-hydroxypropionic acid.
  • heterologous DNA refers to a nucleic acid sequence wherein at least one of the following is true: (a) the sequence of nucleic acids is foreign to (i.e., not naturally found in) a given host microorganism; (b) the sequence may be naturally found in a given host microorganism, but in an unnatural (e.g., greater than expected) amount; or (c) the sequence of nucleic acids comprises two or more subsequences that are not found in the same relationship to each other in nature.
  • a heterologous nucleic acid sequence that is recombinantly produced will have two or more sequences from unrelated genes arranged to make a new functional nucleic acid.
  • Embodiments of the present invention may result from introduction of an expression vector into a host microorganism, wherein the expression vector contains a nucleic acid sequence coding for an enzyme that is, or is not, normally found in a host microorganism.
  • the nucleic acid sequence that codes for the enzyme is heterologous (whether or not the heterologous nucleic acid sequence is introduced into that genome).
  • heterologous is intended to include the term “exogenous” as the latter term is generally used in the art as well as “endogenous”.
  • an “expression vector” includes a single expression vector as well as a plurality of expression vectors, either the same (e.g., the same operon) or different; reference to “microorganism” includes a single microorganism as well as a plurality of microorganisms; and the like.
  • the present invention relates to various genetically modified microorganisms, methods for making the same, and use of the same in making industrial products. Any and all of the microorganisms herein may include a combination of genetic alterations as described herein.
  • the present invention contemplates, for example, a genetically modified microorganism having one or more of the following genetic modifications (i) an alteration that affects the stoichiometric ratio, expression or production of one or more ACCase enzyme genes (ii) a recombinant ACCase gene having at least 80% sequence homology to an ACCase gene from a salt tolerant organism (iii) a genetic alteration in one or more non-ACCase genes (iv) one or more genetic alterations that encodes for one or more exporters capable of exporting 3-HP out of a cell (v) new hybrid molecules or co-expressed of a mono-functional malonyl-CoA reductase enzyme with various 3-HP dehydrogenase proteins that
  • the present invention also relates to methods of fermentation.
  • the genetically modified microorganisms are cultured under conditions that optimized a host cell for increase chemical production.
  • the bio-production process may include two or more of the following phases of fermentation: (1) growth phase where the culture organism replicates itself and the carbon intermediate product is built up; (2) the induction phase, where the expression of key enzymes critical to the chemical production is induced and the enzymes accumulate within the organism to carry out the engineered pathway reactions required to further produce the chemical product (3) production phase is where the organism expresses proteins that provide for continuously production the desired chemical product.
  • the above phases are further controlled by (1) addition and amount of the initiating reactant added to the reaction vessel (2) key enzymes engineered into the organism using promoters that are sensitive to (e.g., activated by) the depletion of the initiating reactant. Addition details about the fermentation process of the invention are disclosed below.
  • ACCase acetyl-CoA carboxylase
  • the acetyl-CoA carboxylase complex (ACCase) is a multi-subunit protein. Prokaryotes and plants have multi-subunit ACCs composed of several polypeptides encoded by distinct genes. However, humans and most other eukaryotes, such as yeast, have evolved an ACC with CT and BC catalytic domains and biotin carboxyl carrier domains on a single polypeptide.
  • the biotin carboxylase (BC) activity, biotin carboxyl carrier protein (BCCP), and carboxyl transferase (CT) activity are each contained on a different subunit.
  • the ACCase complex is derived from multi polypeptide transcribed by distinct, separable protein components known as accA, accB, accC, and accD.
  • Acetyl-CoA carboxylase is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT).
  • BC biotin carboxylase
  • CT carboxyltransferase
  • the first reaction is carried out by BC and involves the ATP-dependent carboxylation of biotin with bicarbonate.
  • the carboxyl group is transferred from biotin to acetyl-CoA to form malonyl-CoA in the second reaction, which is catalyzed by CT.
  • CT carboxyltransferase
  • the main function of ACCase complex in the cell is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.
  • acetyl-CoA to malonyl-CoA is an important step in the bioconversion of a renewable carbon source (such as, for example, sugar or natural gas) to a useful industrial chemical (such as, for example, 3-hydroxypropionic acid (3-HP)).
  • a renewable carbon source such as, for example, sugar or natural gas
  • a useful industrial chemical such as, for example, 3-hydroxypropionic acid (3-HP)
  • the native ACCase expression from the chromosome alone is insufficient to enable the organism to produce chemicals such as 3-HP at a rate to support a commercial scale operation.
  • Overexpression of the ACCase complex has been shown to provide some advantage [U.S. Ser. No. 12/891,760 U.S. Ser. No. 12/891,790 U.S. Ser. No. 13/055,138].
  • fusion is the two gene products produced from a single polypeptide controlled by a single promoter, will further enhance an organism's bioproduction of an industrial chemical.
  • fusion is the two gene products produced by at least one promoter, will further enhance an organism's bioproduction of an industrial chemical.
  • fusion is the two gene products produced from a single polypeptide controlled by at least one inducible promoter, will further enhance an organism's bioproduction of an industrial chemical.
  • the subunit-fused ACCase may be an accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD or accA-accB-accC-accD fused subunit that have having at least 80% sequence homology to E. coli accA, accB, accC and accD or is a functional homolog thereof.
  • the organism may include any combination of these fused subunits, or any combination of these fused subunits together with one or more of the four non-fused subunits.
  • the subunits (fused and non-fused) may be expressed on the same plasmid or on different plasmids or on the chromosome of the organism.
  • an accA-accD fused subunit is introduced into an organism either alone or in combination with the accB-accC fused subunit, the accB gene, and/or the accC gene.
  • the organism is a bacteria, and preferably E. coli or Cupriavidus necator.
  • Composition stoichiometry is the quantitative relationships among elements that comprise a compound.
  • a stoichiometric ratio of a reagent is the optimum amount or ratio where, assuming that the reaction proceeds to completion.
  • stoichiometric terms are traditionally reserved for chemical compounds, theses theoretical consideration of stoichiometry are relevant when considering the optimal function of heterologous multi-subunit protein in a host cell.
  • the stoichiometric ratio of each of the four ACCase subunits relative to one another is important, and each such ratio can be between 0 and about 10, and preferably between about 0.5 to about 2 or about 7 to about 9.
  • the ratios for the protein subunits are accA:accB:accC:accD are 1:2:1:1.
  • an organism is genetically modified to include an accA-accD fused subunit, an accB non-fused subunit, and an accC non-fused subunit, with the molar ratios of the accDA fusion:accB:accC being about 1:2:1, which is close to the optimum for enzymatic activity.
  • an organism in order to get optimal function in a host cell of a heterologous ACCase enzyme complex it is important to engineer the stoichiometry of these subunits in such a way that provides maximal production of 3-HP such that the subunit can make a more stable enzyme complex when overexpressed in the cell.
  • the invention provides for the controlled expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD.
  • the invention provides for the inducible expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD.
  • the invention provides for the low, medium, high and/or inducible expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD.
  • the invention provides for the expression of the natural accC and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accB and accA subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accC and accD subunits with the accA subunit of E. coli or having at least 80% sequence homology to E.
  • the invention provides for the expression of the natural accC and accD subunits with the accB subunit of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression.
  • the invention provides for the expression of a fusion of two, three, or all of the four ACCase subunits in one polypeptide in low, medium, high or inducible expression.
  • Such fusion may include any of the following combinations of the ACCase subunits: accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD, and accA-accB-accC-accD have having at least 80% sequence homology to E. coli accA, accB, accC and accD or is a functional homolog thereof.
  • the invention provides for ACC complex in the stoichiometry of these subunits of the accCB and accDA in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • the invention provides for ACC complex in the stoichiometry of these subunits of the accDA and accCB in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • the invention provides for the stoichiometry of the accD-A subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • the invention provides for the stoichiometry of the accC-B subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • the invention provides for the stoichiometry of the accC-A subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • the invention provides for the stoichiometry of the accC-B subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • One of the steps in the biosynthesis of 3-HP involves the conversion of malonyl-CoA (MCA) to malonate semialdehyde (MSA) and the conversion of malonate semialdehyde (MSA) to 3-HP (WO2011/038364).
  • MCA malonyl-CoA
  • MSA malonate semialdehyde
  • MSA malonate semialdehyde
  • the present invention contemplates the use of novel enzymes and/or combinations of enzymes to catalyze the reaction in a microorganism from MCA to MSA, which results in enhanced cellular bioproduction of 3-HP in the host cell.
  • the invention provides novel enzyme compositions or co-expression of a combinations of enzyme compositions to catalyze the conversion of malonyl-CoA to 3-HP.
  • a general overview of the enzymes and the relevant reaction pathways methods are shown in FIG. 1 .
  • malonyl-CoA is converted to malonate semialdehyde by a malonyl-CoA reductase and malonate semialdehyde is converted to 3-HP through either or both of two alternative pathways.
  • malonyl-CoA is converted to malonate semialdehyde by a monofunctional malonyl-CoA reductase that catalyzes the malonyl-CoA conversion, but does not catalyze the malonate semialdehyde conversion.
  • the microorganism herein comprise a genetic modification that include the monofunctional malonyl-CoA reductase may be derived from Sulfolobus tokodaii (stMCR) (SEQ ID NO. 15 nucleic acid, SEQ ID NO. 16 protein sequence) or a functional homolog of stMCR or a homolog with at least 80% identity.
  • stMCR Sulfolobus tokodaii
  • the microorganism herein comprise a genetic modification that include the bi-functional malonyl-CoA reductase comprised of two protein fragments with one fragment having malonyl-CoA reductase activity and the other fragment having malonate semialdehyde dehydrogenase activity may be derived from Chloroflexus aurantiacus (caMCR).
  • Malonate semialdehyde Following the conversion of the malonyl-CoA to malonate semialdehyde, the malonate semialdehyde is converted to 3-HP through either or both of two alternative pathways.
  • Malonate semialdehyde may exist in at least three states; the keto form, the enol form, and hydrate form, as shown in FIG. 2 .
  • Malonate semialdehyde in the enol form which will stabilize this form when compared to other aldehydes where the enol form is highly unfavored in the equilibrium among the three forms.
  • the malonate semialdehyde keto form is converted to 3-HP utilizing a 3-hydroxy acid dehydrogenase enzyme (ydfG SEQ ID NO. 21 nucleic acid, SEQ ID NO. 22 protein), a 3-hydroxyisobutyrate dehydrogenase enzyme ( Pseudomonas aeruginosa mmsB, SEQ ID No 23 nucleic acid, SEQ ID NO. 24 protein), and/or NAD+-dependent serine dehydrogenase ( Pseudomonas NDSD, SEQ ID NO. 25 nucleic acid, SEQ ID NO. 26 protein).
  • a 3-hydroxy acid dehydrogenase enzyme ydfG SEQ ID NO. 21 nucleic acid, SEQ ID NO. 22 protein
  • a 3-hydroxyisobutyrate dehydrogenase enzyme Pseudomonas aeruginosa mmsB, SEQ ID No 23 nucleic acid, SEQ ID NO. 24 protein
  • Pseudomonas mmsB, Pseudomonas NDSD, and E. coli ydfG are used.
  • the gene, ydfG from E. coli is largely NADPH dependent, whereas mmsB and NDSD from Pseudomonas can utilize either NADPH or NADH.
  • the malonate semialdehyde enol form is converted to 3-HP utilizing an N-ethylmaleimide reductase (nemA, SEQ ID NO. 17 nucleic acid, SEQ ID NO. 18 protein), and/or a malonic semialdehyde reductase (rutE, SEQ ID NO. 19 nucleic acid, SEQ ID NO. 20 protein) from E. coli .
  • nemA N-ethylmaleimide reductase
  • rutE a malonic semialdehyde reductase
  • SEQ ID NO. 19 nucleic acid, SEQ ID NO. 20 protein
  • These enzymes does not directly utilize NADPH or NADH. Instead, these enzymes utilize a flavin mononucleotide that is cycled between oxidized and reduced states by NADPH or NADH.
  • the enol pathway also has advantages over the keto pathway in that equilibrium between the malonate semialdehyde enol form and
  • the malonate semialdehyde hydrated form may also be converted to 3-HP by either the 3-HP dehydrogenase or malonate semialdehyde reductase enzymes, although the hydrated form is more likely to be converted to the enol form as the equilibrium continuously readjusts.
  • the microorganism herein comprise a genetic modification that include (i.e., microorganism) includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; and (2) one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD, rutE, and nemA or a functional homolog or a homolog with at least 80% identity.
  • a genetic modification that include (i.e., microorganism) includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; and (2) one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD,
  • an organism that is genetically modified to make 3-HP, wherein the genetic modification includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; (2) one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP; and (3) one or more genes encoding one or more enzymes capable of converting either the malonate semialdehyde enol form or the malonate semialdehyde hydrated form to 3-HP.
  • a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; (2) one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP; and (3)
  • the invention provides monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is either: (1) primarily not NADPH-dependent; (2) primarily NADH-dependent; (3) primarily flavin-dependent; (4) less susceptible to 3-HP inhibition at high concentration; and/or (5) catalyzes a reaction pathway to 3-HP that is substantially irreversible.
  • the invention also provides monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is NADPH-dependent.
  • Suitable 3-HP dehydrogenase enzymes that are largely NADH-dependent that can be used with the claimed invention include, but are not limited to, mmsB or NDSD.
  • Suitable malonate reductase enzymes that are flavin-dependent include, but are not limited to, rutE and nemA.
  • Suitable 3-HP dehydrogenase enzymes that are less susceptible 3-HP inhibition at high concentration include, but are not limited to, ydfG and NDSD.
  • Suitable 3-HP dehydrogenase or malonate semialdehyde dehydrogenase enzymes that catalyze a reaction pathway to 3-HP that is substantially irreversible are rutE and nemA.
  • the invention provides monofunctional malonyl-CoA reductase enzyme fused to one or more dehydrogenase enzymes.
  • Malonate semialdehyde which is the intermediate product in the conversion of malonyl-CoA to 3-HP can be very reactive. Therefore, it is advantageous to have a reaction pathway wherein the residence time of malonate semialdehyde within the cell is minimized, and its conversion to 3-HP occurs quickly.
  • the invention provides first monofunctional malonyl-CoA reductase enzyme fused to a first dehydrogenase enzyme of one type and second monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme of a different type than the first dehydrogenase enzyme.
  • Suitable different dehydrogenase enzymes include, but are not limited to, enzymes that function on the different forms of malonate semialdehyde.
  • the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from S. tokadaii is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof).
  • the fused enzyme may include any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD-nemA, mcr-rutE-y
  • the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from C. aggregans is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof).
  • the fused enzyme may include any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD-nemA, mcr-rutE-y
  • the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from O. trichoides is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof).
  • the fused enzyme may include but are not limited to any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD-nemA, mcr
  • the invention provides for microorganisms comprising a genetic modification that include mutated form of stMCR that has enhanced activity at about 20° C. to about 44° C., about 30° C. to about 37° C., or about 32° C. to about 38° C.
  • mutate forms may be designed based on the crystal structure now available for stMCR [Demmer et al., J. Biol. Chem. 288:6363-6370, 2013].
  • carboxylase domains of the malonyl-CoA reductase derived from Chloroflexus aggregans, Oscillochloris trichoides can be enhanced by mutations in the carboxylase binding domain to provide increased 3-HP production over the natural occurring enzyme.
  • the carboxylase activity of the malonyl-CoA reductase derived from Chloroflexus aurantiacus can be enhanced activity.
  • the invention provides for mutated form of it carboxylase domain to provide increased 3-HP production over the natural occurring enzyme.
  • the invention provides for microorganisms comprising a genetic modification that include carboxylase domains of the malonyl-CoA reductase derived from C. aggregans is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof).
  • any of the enhanced MCR by mutation may be fused in any of the following configurations including but not limited to mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-NDSD-nemA,
  • Halophiles are characterized as organisms with a great affinity for salt.
  • a halophilic organism is one that requires at least 0.05M, 0.1M, 0.2M, 0.3M or 0.4M concentrations of salt (NaCl) for growth.
  • Halophiles live in hypersaline environments that are generally defined occurring to their salt concentration of their habitats.
  • Halophilic organisms that are defined as “Slight salt affinity” have optimal growth at 2-5% NaCl, moderate halophiles have optimal growth at 5-20% NaCl and extreme halophiles have optimal growth at 20-30% NaCl.
  • homologous enzymes of the invention specifically, for example, from a moderate halophiles or an extreme halophiles depending on the engineered cell's environment.
  • the invention provides for microorganisms comprising a genetic modification that includes enzymes of the invention provided herein from slight halophiles organisms. In certain aspects the invention provides for microorganisms comprising a genetic modification that includes enzymes of the invention provided herein from moderate halophiles organisms. In certain aspects the invention provides for microorganisms comprising a genetic modification that includes homologous enzymes of the invention provided herein from extreme halophiles organisms.
  • Homology with genes provided by the invention may be determined by analysis with BLASTN version 2.0 provided through the NCBI website.
  • Homology with proteins provided by the invention may be determined by analysis with BLASTP version 2.2.2 provided through the NCBI website. This program with aligns the disclosed fragments being compared and determines the extent of identity or similarity between them.
  • sequenced halophilic organisms which can be used with the claimed invention.
  • sequenced halophilic organisms include but are not limited to Chromohalobacter salexigens, Flexistipes sinusarabici strain (MAS10T), Halobacterium sp. NRC-1 , Haloarcula marismortui, Natronomonas pharaonis, Haloquadratum walsbyi, Haloferax volcanii, Halorubrum lacusprofundi, Halobacterium sp.
  • R-1 Halomicrobium mukohataei, Halorhabdus utahensis, Halogeometricum borinquense, Haloterrigena turkmenica, Natronobacterium gregoryi SP2 , Halalkalicoccus jeotgali, Natrialba magadii, Haloarcula hispanica, Halopiger xanaduensis, Halophilic archaeon DL31 , Haloferax mediterranei, Halovivax Tuber, Natronococcus gregoryi , and Natronococcus occultus.
  • suitable moderate halophilic organisms in which homologous enzymes of the invention can be derived from include but are not limited to eukaryotes such as crustaceans (e.g. Artemia salina ), insects (e.g. Ephydra hians ), certain plants from the genera Salicornia spp, algae (e.g. Dunaliella viridis ), fungi, and protozoa (e.g.
  • Fabrea salina phototrophic organisms, such as planktonic and microbial mat-formers cyanobacteria as well as other anaerobic red and green sulphur bacteria from the genera Ectothiorhodospira spp.) and non-sulphur bacteria from the genera Chromatium spp.; gram-negative anaerobic bacteria, for example from the genera Haloanaerobacter spp. some of which are methanogenic, for example from the genera Methanohalophilus spp. and either aerobic or facultative such as species from the genera Halomonas, Chromohalobacter, Salinovibrio, Pseudomonas , for example (e.g.
  • Halomonase elongate gram-positive bacteria from genera such as Halobacillus, Bacillus, Marinococcus , etc. as well as some actinomycetes, for example, Actinopolyspora halophila.
  • halophilic organisms are characterized by low hydrophobicity, over-representation of acidic residues, especially Asp, under-representation of Cys, lower propensities for helix formation and higher propensities for coil structure.
  • halophilic organisms are characterized by the dinucleotide abundance profiles of halophilic genomes bear some common characteristics, which are quite distinct from those of non-halophiles, and hence may be regarded as specific genomic signatures for salt-adaptation.
  • the synonymous codon usage in halophiles also exhibits similar patterns regardless of their long-term evolutionary history.
  • the invention provides for microorganisms comprising a genetic modification that the proteins provided by the invention that are modified for salt tolerance such that they has low hydrophobicity, over-representation of acidic residues, especially Asp, under-representation of Cys, lower propensities for helix formation and higher propensities for coil structure.
  • Suitable salt-tolerant enzymes can include enzymes from salt-tolerant organisms.
  • Salt-tolerant organisms such as, for example, halophiles
  • Suitable salt-tolerant enzymes can include enzymes from salt-tolerant organism that are homologs of the following enzymes: Sucrose-6-phosphate hydrolase (cscA from E. coli ), glucose-6-phosphate isomerase (pgi from E. coli ), fructokinase (cscK from E. coli ), fructose-1,6-bisphosphatase (yggF from E. coli ), fructose 1,6-bisphosphatase (ybhA from E.
  • cscA from E. coli
  • glucose-6-phosphate isomerase pgi from E. coli
  • fructokinase cscK from E. coli
  • fructose-1,6-bisphosphatase yggF from E. coli
  • fructose 1,6-bisphosphatase
  • fructose 1,6-bisphosphatase II glpX from E. coli
  • fructose-1,6-bisphosphatase monomer fbp from E. coli
  • 6-phosphofructokinase-1 monomer pfkA from E. coli
  • 6-phosphofructokinase-2 monomer pfkB from E. coli
  • fructose bisphosphate aldolase monomer fbaB from E. coli
  • fructose bisphosphate aldolase monomer fbaA from E.
  • triose phosphate isomerase monomer tpiA
  • glyceraldehyde 3-phosphate dehydrogenase-A monomer gapA from E. coli
  • phosphoglycerate kinase pgk
  • 2,3-bisphosphoglycerate-independent phosphoglycerate mutase gpmM from E. coli
  • 2,3-bisphosphoglycerate-dependent or tdcE from E. coli
  • phosphoglycerate mutase gpmA
  • enolase eno from E. coli
  • ppc from E.
  • coli malate dehydrogenase (mdh), fumarase A (fum from E. coli ), fumarase B (fumB), fumarase C (fumC from E. coli ), phosphoenolpyruvate synthetase (ppsA from E. coli ), pyruvate kinase I monomer (pykF from E. coli ), pyruvate kinase II monomer (pykA from E. coli ), fumarate reductase (frdABCD from E. coli ), lipoamide dehydrogenase (lpd from E. coli ), pyruvate dehydrogenase (aceE from E.
  • coli pyruvate dehydrogenase
  • aceF from E. coli
  • pyruvate formate-lyase pflB from E. coli
  • acetyl-CoA carboxylase accABCD from E. coli
  • malonyl CoA reductase mcr
  • 3HP dehydrogenase mmsB, NDSD, or ydfG
  • malonate semialdehyde reductase nemA, rutE from E. coli
  • Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%, overall amino acid or nucleotide identity to the above enzymes.
  • Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90% 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%, amino acid or nucleotide to the essential protein function domains of the enzymes above.
  • Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential protein function domain of the enzymes above.
  • suitable salt-tolerant enzyme homologs are enzymes from one of the following organisms: Halomonas elongata, Salinibacter rubur , or Halobacterium species (Archaea).
  • a non-salt-tolerant organism that is genetically modified to make 3-HP, wherein the genetic modification includes a polynucleotide encoding an acetyl-CoA carboxylase from a salt-tolerant organism.
  • the acetyl-CoA carboxylase subunits accA, accB, accC and accD is from Halomonas elongata.
  • any of the microorganisms herein may be genetically modified to introduce a nucleic acid sequence coding for a polypeptide that: (1) facilitates the exportation of the chemical of interest or the export of an inhibitory chemical from within the cell to the extracellular media; and/or (2) facilitates the importation from the extracellular media to within the cell of a reactant, precursor, and/or metabolite used in the organism's production pathway for producing the chemical of interest.
  • this invention relates to the bioproduction of 3-HP using a genetically modified E. coli organism.
  • the present invention contemplates of a host cell genetically modified to express or increase expression of an exporter that can function to transfer 3 HP from the cellular environment extracellularly.
  • Bacterial cells such as E. coli , have at least five different types of exporters: the major facilitator superfamily (MFS); the ATP-binding cassette superfamily (ABC); the small multidrug resistance family (SMR); the resistance-nodulation-cell division superfamily (RND); and the multi antimicrobial extrusion protein family (MATE).
  • MFS major facilitator superfamily
  • ABS ATP-binding cassette superfamily
  • SMR small multidrug resistance family
  • RTD resistance-nodulation-cell division superfamily
  • MATE multi antimicrobial extrusion protein family
  • amino acid exporters which are common to almost all host cells, are likely to export 3-HP.
  • solvent tolerance transporters for example bromoacetate, butanol, isobutanol and the alike may be used to export 3-HP.
  • the invention provides a host cell with a recombinant exporter wherein the exporter is an MFS exporter, ABC exporter, SMR exporter, RND exporter, MATE exporter, amino acid exporter, solvent tolerance transporter or a combination thereof
  • Suitable exporters that can be used with the s herein invention include but are not limited to acrD, bcr, cusA, dedA, eamA, eamB, eamH, emaA, emaB, emrB, emrD, emrKY, emrY, garP, gudP, hsrA, leuE, mdlB, mdtD, mdtG, mdtL, mdtM, mhpT, rhtA, rhtB, rhtC, thtB, yahN, yajR, ybbP, ybiF, ybjJ, ycaP, ydcO, yddG, ydeD, ydgE, yddG, ydhC, ydhP, ydiN, ydiM
  • the invention provides the exporter to be improved for binding to 3-HP. In certain aspects the invention provides the exporters named to be further enhance by genetic modification of the predicted cytoplasmic domain to increase 3-HP binding. In certain aspects the invention provides the exporter to be improved for binding to 3-HP. In certain aspects the invention provides the exporters named to be further enhance by genetic modification of the predicted transmembrane binding domain to increase 3-HP binding or incorporation into the host cell membrane.
  • Suitable exporter homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide identity to the above exporters.
  • Suitable exporter homologs that can be used with the claimed invention can have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% amino acid or nucleotide to the essential protein function domains of the exporters above.
  • Suitable exporter homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential exporter domain of the enzymes above.
  • the invention provides for at least of the exporters provided herein to be expressed in a host cell to increase the chemical production of 3-HP in a host cell. In certain aspects the invention provides for at least of the exporters provided herein to be expressed in a host cell and with a genetic modification of tig to increase the chemical production of 3-HP in a host cell.
  • the invention provides for one exporter to be further modified by on one more genetic modulates so that the expression level and timing of expression of the exporter can be controlled in the host cell.
  • the invention provides for one exporter to be further modified by an inducible promoter, RBS, high, mutlicopy plasmid or combination thereof, as provide herein, in order to control its expression in the host cell.
  • the invention provides exporters provide herein to be expressed in a host cell in equal ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:2 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:3 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:4 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 2:3 ratio.
  • the invention provides for the exporter to maintain the host cell at pH 7.0-7.4 during the continuous production phase.
  • the invention provides for the exporter and the means for importing a base inside the cell in order to maintain the host cell at pH 7.0-7.4 during the continuous production phase.
  • the invention provides for the exporter maintain the host cell at pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0 pH 7.0-7.3 during the continuous production phase.
  • the invention provides for the exporter and the means for importing a base inside the cell in order to maintain the host cell at pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0 pH 7.0-7.3 during the continuous production phase.
  • addition modifications to the host cell may be made to further enhance the transporter's function.
  • deletion of the tig gene from the genome of the host cell may enhance expression and total activity of integral membrane proteins such as exporters and importers.
  • this reaction is catalyzed by the acetyl-CoA carboxylase, and bicarbonate is a reactant needed to drive the reaction.
  • bicarbonate is a reactant needed to drive the reaction.
  • One of the primary sources of bicarbonate to drive this reaction is carbon dioxide within the cell. Carbon dioxide is readily diffusible through a cell's membrane, and a natural equilibrium will be reached between the intracellular and extracellular carbon dioxide. As a cell produces carbon dioxide it migrates through the cell, and since it is not very soluble in the media, it will bubble out of the system and more intracellular carbon dioxide will migrate out of the cell to maintain the equilibrium.
  • an organism in accordance with one aspect of the present invention, includes a heterologous gene encoded therein that acts as a carbon dioxide importer (i.e., it enhances the importation of carbon dioxide into the cell or inhibits the exportation of carbon dioxide from the cell), which results in increased intracellular carbon dioxide.
  • a carbon dioxide importer i.e., it enhances the importation of carbon dioxide into the cell or inhibits the exportation of carbon dioxide from the cell
  • Use of CO2 an importer mitigates against the natural outflow of carbon dioxide.
  • an organism that is genetically modified, wherein the genetic modification includes a polynucleotide encoding a gene capable of importing extracellular carbon dioxide from the media to within the cell membrane or inhibiting the exportation of intracellular carbon dioxide from within the cell membrane to the media.
  • a microorganism is genetically modified to encode one or more of the following heterologous genes: bicA from Synechococcus species, ychM gene product of E. coli , yidE gene product of E. coli , any of the bicarbonate transporters as described in [Felce and Saier, J. Mol. Microbiol. Biotechnol. 8: 169-176, 2004 or any amino acid sequences homologous thereof (e.g., at least 80%, 85%, 90%, 95%, or 99% homologous to the amino acids sequences of the CO2 importer/exporters described herein].
  • the host cell is genetically modified for increased malonyl-CoA flux by at least one heterologous ACCase complex, such as Table 4 to further increase chemical bio-production in host cell.
  • the host cell is genetically modified with heterologous salt tolerant enzymes, such as Table 5 to increase chemical bio-production in a host cell.
  • the host cell is genetically modified with heterologous 3-HP exporters to further increase chemical bio-production in a host cell.
  • the host cell is genetically modified by at least one heterologous gene and/or salt tolerant heterologous gene of FIG. 1 or Table 5 and at least one 3-HP exporter provided herein to further increase chemical bioproduction in a host cell.
  • the host cell is genetically modified with a heterologous gene for increased malonyl-CoA flux, 3-HP export, at least one heterologous and/or salt tolerant heterologous gene, as provided herein, to increase chemical bio-production in a host cell.
  • the host cell is genetically modified for increased malonyl-CoA flux, 3-HP export, at least one heterologous gene and/or salt tolerant heterologous gene and the host cell is genetically modified by at least one gene, as provided herein to increase chemical bioproduction in a host cell.
  • reactions, reactants, intermediates and byproducts created during cell growth can inhibit enzyme induction and/or the organism's ability to produce the desired chemical product.
  • reactions, reactants, intermediates and byproducts created as part of the production pathway can impact cell growth, and even the increased concentration of the chemical product as it is produced can impede cell replication.
  • a method of producing a chemical product from a carbon source through a bioproduction process that comprises a controlled multi-phase production process.
  • the multi-phase production process includes an initiation and/or completion of one or more phases of the production process is controlled by genetic modifications to the organism producing the chemical product and/or is controlled by changes made to the cell environment.
  • the bioproduction process may include two or more of the following phases: (1) growth phase; (2) induction phase; and (3) production phase.
  • growth phase the organism replicates itself and the biocatalyst needed to produce the chemical product is built up.
  • induction phase expression of key enzymes critical to the production of the chemical is induced and the enzymes accumulate within the biocatalyst to carry out the reactions required to produce the product.
  • production phase organism produces the desired chemical product.
  • the initiation and/or completion of the growth, induction and/or production phases are controlled.
  • the growth phase is dependent on the presence of a critical external reactant that will initiate growth.
  • the initiation and completion of the growth phase is controlled by the addition and amount of the initiating reactant added to the reaction vessel.
  • the chemical product is 3-HP and the production organism is E. coli or yeast.
  • the critical external reactant may be phosphate, which is needed for replication of E. coli cells.
  • the growth phase is initiated by the addition of phosphate to a reaction vessel (together with a carbon source such as sugar and the E. coli cells), and the duration of the growth phase is controlled by the amount of phosphate added to the system.
  • the induction phase is controlled by genetic modifications to the producing organism.
  • the key enzymes triggered during this phase are engineered into the organism using promoters that are sensitive to (e.g., activated by) the depletion of the initiating reactant. As a result, once the initiating reactant is depleted, the growth phase ends, the key enzymes are activated and the induction phase begins.
  • the induction phase is controlled by key genes that encode for enzymes in the biosynthetic pathway for the product into the production organism using promoters that are activated by phosphate depletion.
  • the key genetic modifications may include one or more of the following: mcr, mmsB, ydfG, rutE, nemA and NDSD; genes that encode individual or fused subunits of ACCase, such as accA, accB, accC, accD, accDA fusion, and accCB fusion, and the promoters may include one or more of the promoters that direct expression of the following E.
  • coli genes amn, tktB, xasA, yibD, ytfK, pstS, phoH, phnC, or other phosphate-regulated genes as described in [Baek and Lee, FEMS Microbiol Lett 264: 104-109, 2006].
  • expression of the key enzymes is activated by their promoters and the induction phase begins.
  • the production phase may also be controlled by genetic modifications.
  • the organism can be engineered to included mutated forms of enzymes critical to the initiation of production of the chemical product.
  • initiation enzymes may facilitate initiation of production either by: (1) becoming active and serving a key function in the production pathway; and/or (2) becoming inactive and thereby turning off a branch pathway or other competitive pathway that prevents or limits the production pathway leading to the chemical product.
  • initiation enzymes are mutated to form temperature sensitive variants of the enzymes that are either activated by or deactivated at certain temperatures. As a result, the production phase is initiated by changing the changing the temperature within the reaction vessel.
  • the production phase is controlled by genetically modifying the microorganism with a heterologous nucleotide sequence encoding i one or more of the following temperature sensitive enzymes: fabl ts (SEQ ID NO. 27), fabB ts (SEQ ID NO. 28) and fabD ts (SEQ ID NO. 29).
  • fabl ts SEQ ID NO. 27
  • fabB ts SEQ ID NO. 28
  • fabD ts SEQ ID NO. 29
  • the growth phase can last be between 10 to 40 hours, or about 15 to about 35 hours, or about 20 to about 30 hours.
  • the induction phase may be for about 1 to about 6 hours, about 1 to about 5 hours, or about 2 to about 4 hours.
  • the production phase may be greater than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 hours depending on the amount of chemical product that is desired.
  • the growth phase and induction phase are conducted at a temperature of about 25° C. to about 35° C., about 28° C. to about 32° C., or about 30° C.
  • the production phase is conducted at a temperature of about 35° C. to about 45° C., about 35° C. to about 40° C., or about 36° C. to about 38° C.
  • the production phase temperature is higher than the induction phase temperature, and the increase in temperature that initiates the production phase occurs over a period of about 1 to about 5 hours, about 1 to about 3 hours, about 2 hours, or about 1 hour.
  • a method of producing a chemical product from a renewable carbon source through a bioproduction process comprising:
  • a method of producing 3-hydropropionic acid (3-HP) from a renewable carbon source comprising:
  • Depending on the host cell fermentation may be performed under aerobic, microaerobic, or anaerobic conditions, with or without agitation.
  • aerobic, microaerobic and anaerobic conditions are well known to those of ordinary skill in the art.
  • Suitable pH ranges for fermentation depend on the multiple factors such as the host cell. In some applications of the invention fermentation can occur between various pH ranges for example, pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0.
  • the actual pH conditions for a particular application are not meant to be limited by these ranges and can be between the expressed pH ranges if it provides more optimal production of the fermentation process, such as increased 3-HP production.
  • FIG. 1 An overview of the engineered pathways provided by the invention in a host cell is shown in FIG. 1 .
  • Various combinations of the pathways shown can be carried out by various combinations of genetic modifications to key enzymes either in the intrinsic pathways or supplied through the transformation of a heterologous gene.
  • the genetically modified microorganism of the invention may comprise a single genetic modification, or one or more genetic modifications.
  • Various types of genetic modifications that can be used with the invention are disclosed herein.
  • the genetic modified organism of the invention can comprise a genetic modification to the following gene/proteins or a homolog with at least 80% identity to or a functional homolog of: bifunctional malonyl-CoA reductase (MCR from Chloroflexus aurantiacus ), monofunctional malonyl-CoA reductase (caMCR from Chloroflexus aurantiacus ), malonyl-CoA reductase (stMCR from Sulfolobus tokodaii .), Enzyme: malonyl-CoA reductase (cgMCR from Chloroflexus aggregans ), Enzyme: malonyl-CoA reductase (otMCR from Oscillochloris trichoides ), Polypeptide: host restriction; endonuclease R (hsdR from E.
  • Enzyme phosphate acetyltransferase/phosphate propionyltransferase (pta from E. coli ), Enzyme: pyruvate oxidase (poxB from E. coli ), Enzyme: methylglyoxal synthase (mgsA from E. coli ), enzyme: Acetate kinase (ackA from E. coli ), enzymes: phosphotransacetylase-acetate kinase (pta-ack from E. coli ), Enzyme: enoyl-[acyl-carrier-protein] reductase (fabl from E.
  • Enzyme 3-hydroxyisobutyrate/3-HP dehydrogenase (mmsB from Pseudomonas aeruginosa ), Enzyme: lipoamide dehydrogenase (lpd from E. coli ), Enzyme: ⁇ -glutamyl- ⁇ -aminobutyraldehyde dehydrogenase (puuC from E. coli ), Enzyme: malate synthase A (aceB from E. coli ), Enzyme: isocitrate lyase (aceA from E. coli ), Enzyme: isocitrate dehydrogenase phosphatase/kinase (aceK from E.
  • Enzyme 3-hydroxy acid dehydrogenase (ydfG from E. coli ), Enzyme: acetyl CoA carboxylase (accADBC from E. coli ), Polypeptide: predicted transcriptional regulator (yieP from E. coli ), Blastocyin resistance gene (BSD from Schizosaccharomyces pombe ), Enzyme: pyridine nucleotide transhydrogenase (udha from E. coli ), Protein: Cra DNA-binding transcriptional dual regulator (fruR from E. coli ), (SCB from E. coli ), enzyme: aldehyde dehydrogenase B (aldB from E.
  • Enzyme carbonic anhydrase (cynT from E. coli ), Enzyme: cyanase (cynS from E. coli ), DNA gyrase toxin-antitoxin system (ccdAB from E. coli ), Enzyme: phosphoglycerate mutase (pgi from E. coli ), ArcA transcriptional dual regulator or Aerobic respiration control (arcA from E. coli ), Enzyme: 6-phosphofructokinase (pfk from E. coli ), Enzyme: glyceraldehyde 3-phosphate dehydrogenase-A complex (gapA from E.
  • aldehyde dehydrogenase A aldehyde dehydrogenase A (alda from E. coli ), Enzyme: glutamate dehydrogenase (gdhA from E. coli ), Enzyme: NADH-dependent serine dehydrogenase (NDSD from Pseudomonas aeruginosa ), Protein: threonine/homoserine efflux transporter (rhtA from E. coli ), Enzyme: glyceraldehyde 3-phosphate dehydrogenase (gapN from E. coli ), Phosphotransferase system (pts from E.
  • Enzyme 6-phosphofructokinase II (pfkB from E. coli ), Enzyme: 6-phosphofructokinase II (pfkB from E. coli ), Enzyme: methylmalonate-semialdehyde dehydrogenase (mmsA from Pseudomonas aeruginosa ), Oxaloacetate:beta-alanine aminotransferase (OAT-1 from Bacillus cereus ), Enzyme: aspartate 1-decarboxylase (panD from E. coli ), Gene that confers resistance to valine (ValR from E. coli ), Enzyme: glucokinase (glk from E. coli ), Polypeptide: 30 S ribosomal sununit protein S12 (rpsL from E.
  • Enzyme pyruvate kinase (pyk from E. coli ), Enzyme: oxaloacetate 4-decarboxylase (OAD from Leuconostoc mesenteroides ), Enzyme: trigger factor; a molecular chaperone involved in cell division (tig from E. coli ), Transcription Unit (ptsHlcrr from E. coli ), Enzyme: acetyl-CoA acetaldehyde dehydrogenase/alcohol dehydrogenase (adhE from E. coli ), Enzyme: fattyacyl thioesterase I (tesA from E.
  • Enzyme guanosine 3′-diphosphate 5′-triphosphate 3′-diphosphatase (spoT from E. coli ), combination of genes encoding accABCD subunits (from E. coli and Halomonas elongata ), pol (from E. coli ), Enzyme: GDP pyrophosphokinase/GTP pyrophosphokinase (relA from E. coli ), [Enzyme Name] (me from E. coli ), Enzyme: citrate synthase (gltA from E. coli ), Polypeptide: DNA gyrase, subunit A (gyrA from E.
  • Enzyme multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxyglutarate aldolase and oxaloacetate decarboxylase (eda from E. coli ), thiamin biosynthesis (thi from E. coli ), Polypeptide: acetolactate synthase II (ilvG from E. coli ), acetyl CoA carboxylase (accDACB from E.
  • Enzyme acylphosphatase (yccX from E. coli ), acetyl-CoA synthetase (acsA from E. coli ), Polypeptide: restriction of methylated adenine (mrr from E. coli ), Protein: TrpR transcriptional repressor (trpR from E. coli ), Enzymes: glutamate 5-semialdehyde dehydrogenase/gamma-glutamyl kinase (proAB from E. coli ), methylcytosine restriction system (mcrBC from E. coli ), Protein: citrate lyase, citrate-ACP transferase component (citF from E.
  • Enzyme thioesterase II (tesB from E. coli ), Enzyme: DNA-specific endonuclease I (endA from E. coli ), Enzyme: phosphate acetyltransferase (eutD from E. coli ), Enzyme: propionate kinase (tdcD from E. coli ), tRNA: tRNA glnV (supE from E. coli ), Enzyme: DNA-binding, ATP-dependent protease La (lon from E. coli ), Polypeptide: DNA strand exchange and recombination protein with protease and nuclease activity (recA from E.
  • Transcription Unit restriction endonulease component of EcoKI restriction-modification system (hsdRMS from E. coli ), Enzyme: restriction of DNA at 5-methylcytosine residues (mcrA from E. coli ) araD (from E. coli ), araB (from E. coli ), rhaD (from E. coli ), rhaB (from E. coli ), ack (from E. coli ), fruR (from E. coli ), gapA (from E. coli ), lad (from E. coli ), lacZ (from E. coli ), ldhA (from E. coli ), mgsA (from E. coli ), pfkA (from E.
  • the genetic modified organism of the invention uses genetic elements such as siRNA ect, genes, proteins or compounds supplied to the host cell to modulate one or more of the following: bifunctional malonyl-CoA reductase (MCR from Chloroflexus aurantiacus ), monofunctional malonyl-CoA reductase (caMCR from Chloroflexus aurantiacus ),malonyl-CoA reductase (stMCR from Sulfolobus tokodaii .), Enzyme: malonyl-CoA reductase (cgMCR from Chloroflexus aggregans ), Enzyme: malonyl-CoA reductase (otMCR from Oscillochloris trichoides ), Polypeptide: host restriction; endonuclease R (hsdR from E.
  • MCR bifunctional malonyl-CoA reductase
  • caMCR from Chloroflex
  • Enzyme phosphate acetyltransferase/phosphate propionyltransferase (pta from E. coli ), Enzyme: pyruvate oxidase (poxB from E. coli ), Enzyme: methylglyoxal synthase (mgsA from E. coli ), enzyme: Acetate kinase (ackA from E. coli ), enzymes: phosphotransacetylase-acetate kinase (pta-ack from E. coli ), Enzyme: enoyl-[acyl-carrier-protein] reductase (fabl from E.
  • Enzyme 3-hydroxyisobutyrate/3-HP dehydrogenase (mmsB from Pseudomonas aeruginosa ), Enzyme: lipoamide dehydrogenase (lpd from E. coli ), Enzyme: ⁇ -glutamyl- ⁇ -aminobutyraldehyde dehydrogenase (puuC from E. coli ), Enzyme: malate synthase A (aceB from E. coli ), Enzyme: isocitrate lyase (aceA from E. coli ), Enzyme: isocitrate dehydrogenase phosphatase/kinase (aceK from E.
  • Enzyme 3-hydroxy acid dehydrogenase (ydfG from E. coli ), Enzyme: acetyl CoA carboxylase (accADBC from E. coli ), Polypeptide: predicted transcriptional regulator (yieP from E. coli ), Blastocyin resistance gene (BSD from Schizosaccharomyces pombe ), Enzyme: pyridine nucleotide transhydrogenase (udha from E. coli ), Protein: Cra DNA-binding transcriptional dual regulator (fruR from E. coli ), (SCB from E. coli ), enzyme: aldehyde dehydrogenase B (aldB from E.
  • Enzyme carbonic anhydrase (cynT from E. coli ), Enzyme: cyanase (cynS from E. coli ), DNA gyrase toxin-antitoxin system (ccdAB from E. coli ), Enzyme: phosphoglycerate mutase (pgi from E. coli ), ArcA transcriptional dual regulator or Aerobic respiration control (arcA from E. coli ), Enzyme: 6-phosphofructokinase (pfk from E. coli ), Enzyme: glyceraldehyde 3-phosphate dehydrogenase-A complex (gapA from E.
  • aldehyde dehydrogenase A aldehyde dehydrogenase A (alda from E. coli ), Enzyme: glutamate dehydrogenase (gdhA from E. coli ), Enzyme: NADH-dependent serine dehydrogenase (NDSD from Pseudomonas aeruginosa ), Protein: threonine/homoserine efflux transporter (rhtA from E. coli ), Enzyme: glyceraldehyde 3-phosphate dehydrogenase (gapN from E. coli ), Phosphotransferase system (pts from E.
  • Enzyme 6-phosphofructokinase II (pfkB from E. coli ), Enzyme: 6-phosphofructokinase II (pfkB from E. coli ), Enzyme: methylmalonate-semialdehyde dehydrogenase (mmsA from Pseudomonas aeruginosa ), Oxaloacetate:beta-alanine aminotransferase (OAT-1 from Bacillus cereus ), Enzyme: aspartate 1-decarboxylase (panD from E. coli ), Gene that confers resistance to valine (ValR from E. coli ), Enzyme: glucokinase (glk from E. coli ), Polypeptide: 30 S ribosomal sununit protein S12 (rpsL from E.
  • Enzyme pyruvate kinase (pyk from E. coli ), Enzyme: oxaloacetate 4-decarboxylase (OAD from Leuconostoc mesenteroides ), Enzyme: trigger factor; a molecular chaperone involved in cell division (tig from E. coli ), Transcription Unit (ptsHlcrr from E. coli ), Enzyme: acetyl-CoA acetaldehyde dehydrogenase/alcohol dehydrogenase (adhE from E. coli ), Enzyme: fattyacyl thioesterase I (tesA from E.
  • Enzyme guanosine 3′-diphosphate 5′-triphosphate 3′-diphosphatase (spoT from E. coli ), combination of genes encoding accABCD subunits (from E. coli and Halomonas elongata ), pol (from E. coli ), Enzyme: GDP pyrophosphokinase/GTP pyrophosphokinase (relA from E. coli ), [Enzyme Name] (me from E. coli ), Enzyme: citrate synthase (gltA from E. coli ), Polypeptide: DNA gyrase, subunit A (gyrA from E.
  • Enzyme multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxyglutarate aldolase and oxaloacetate decarboxylase (eda from E. coli ), thiamin biosynthesis (thi from E. coli ), Polypeptide: acetolactate synthase II (ilvG from E. coli ), acetyl CoA carboxylase (accDACB from E.
  • Enzyme acylphosphatase (yccX from E. coli ), acetyl-CoA synthetase (acsA from E. coli ), Polypeptide: restriction of methylated adenine (mrr from E. coli ), Protein: TrpR transcriptional repressor (trpR from E. coli ), Enzymes: glutamate 5-semialdehyde dehydrogenase/gamma-glutamyl kinase (proAB from E. coli ), methylcytosine restriction system (mcrBC from E. coli ), Protein: citrate lyase, citrate-ACP transferase component (citF from E.
  • Enzyme thioesterase II (tesB from E. coli ), Enzyme: DNA-specific endonuclease I (endA from E. coli ), Enzyme: phosphate acetyltransferase (eutD from E. coli ), Enzyme: propionate kinase (tdcD from E. coli ), tRNA: tRNA glnV (supE from E. coli ), Enzyme: DNA-binding, ATP-dependent protease La (lon from E. coli ), Polypeptide: DNA strand exchange and recombination protein with protease and nuclease activity (recA from E.
  • Transcription Unit restriction endonulease component of EcoKI restriction-modification system (hsdRMS from E. coli ), Enzyme: restriction of DNA at 5-methylcytosine residues (mcrA from E. coli ).
  • hsdRMS EcoKI restriction-modification system
  • Enzyme restriction of DNA at 5-methylcytosine residues (mcrA from E. coli ).
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the method of bioproduction of various chemicals which can be used to make various consumer products described herein.
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of 1,4-butanediol (1,4-BDO) (U.S. Pub. No. 20110190513).
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of butanol (U.S. application Ser. No. 13/057,359).
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of isobutanol (U.S. application Ser. No. 13/057,359)
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of 3-HP such and its aldehyde metabolites (U.S. application Ser. No. 13/062,917).
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of polyketide chemical products (U.S. application Ser. No. 13/575,581).
  • the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of fatty acid methyl esters (U.S. Pub. No. 20110124063). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of C4-C18 fatty acids (U.S. App No. 61/682,127).
  • Example of genetic modification that can be used by the claimed invention include, but are not limited to, increasing expression of an endogenous genetic element; increasing expression of an exogenous genetic element; decreasing functionality of a repressor gene; increasing functionality of a repressor gene; increasing functionality of a activator gene; decreasing functionality of a activator gene; introducing a genetic change or element integrated in the host genome, introducing a heterologous genetic element permanently, by integration into the genome or transiently by transformation with plasmid; increasing copy number of a nucleic acid sequence encoding a polypeptide catalyzing an enzymatic conversion step; mutating a genetic element to provide a mutated protein to increase specific enzymatic activity; mutating a genetic element to provide a mutated protein to decrease specific enzymatic activity; over-expressing of gene; reduced the expression of a gene; knocking out or deleting a gene; altering or modifying feedback inhibition
  • genetic modules such as multicopy plasmids and various promoters can be used to further modify of the genetic modifications provide herein.
  • compounds such as siRNA technology, anti-sense technology, and small molecule in inhibitors can be used to alter gene expression in the same manner as a genetic modification.
  • Screening methods such as SCALE in combination with random mutagenesis may be practiced to provide genetic modifications that provide a benefit to increased production of 3-HP in a host cell.
  • random mutagenesis can include insertions, deletions and substitutions of one or more nucleic acids in a nucleic acid of interest.
  • a genetic modification results in improved enzymatic specific activity and/or turnover number of an enzyme. Without being limited, changes may be measured by one or more of the following: KM; Kcat, Kavidity, gene expression level, protein expression level, level of a product known to be produced by the enzyme, 3-HP tolerance, or by 3-HP production or by other means.
  • the host cell can be a gram-negative bacterium. In some applications of the invention the host cell can be from the genera Zymomonas, Escherichia, Pseudomonas, Alcaligenes , or Klebsiella . In some applications of the invention the host cell can be Escherichia coli, Cupriavidus necator, Oligotropha carboxidovorans , or Pseudomonas putida . In some applications of the invention the host cell is one or more an E. coli strains.
  • the host cell can be a gram-positive bacterium.
  • the host cell can be from the genera Clostridium, Salmonella, Rhodococcus, Bacillus, Lactobacillus, Enterococcus, Paenibacillus, Arthrobacter, Corynebacterium , or Brevibacterium .
  • the host cell is Bacillus licheniformis, Paenibacillus macerans, Rhodococcus erythropolis, Lactobacillus plantarum, Enterococcus faecium, Enterococcus gallinarium, Enterococcus faecalis , or Bacillus subtilis .
  • the host cell is B. subtilis strain.
  • the host cell is yeast. In some applications of the invention the host cell can be from the genera Pichia, Candida, Hansenula or Saccharomyces . In some applications of the invention the host cell is Saccharomyces cerevisiae . In some applications of the invention the host cell is Saccharomyces pombe.
  • the host cell is an alga. In some applications of the invention the host cell is a halophile. In some applications of the invention the host cell is an alga. In some applications of the invention the host cell is a chemolithotrophic bacterium.
  • the host cell is comprised of multiple host cell types. In some applications of the invention the host cell is comprised of one host cell type. In some applications of the invention the host cell is comprised of one more species or strain of a host cell type.
  • 3-HP purified according to the methods provided in this disclosure may be converted to various other products having industrial uses including, but not limited to, acrylamide, acrylic acid, esters of acrylic acid, 1,3-propanediol, and other chemicals, collectively referred to as “downstream chemical products” or “downstream products.” In some instances the conversion is associated with the separation and/or purification steps. These downstream chemical products are useful for producing a variety of consumer products which are described in more detail below.
  • the methods of the present invention include steps to produce downstream products of 3-HP.
  • 3-HP offers much potential in a variety of chemical conversions to commercially important intermediates, industrial end products, and consumer products.
  • 3-HP may be converted to acrylic acid, acrylates (e.g., acrylic acid salts and esters), 1,3-propanediol, malonic acid, ethyl-3-hydroxypropionate, ethyl ethoxy propionate, propiolactone, acrylamide, or acrylonitrile.
  • 3-HP may be oligomerized or polymerized to form poly(3-hydroxypropionate) homopolymers, or co-polymerized with one or more other monomers to form various co-polymers. Because 3-HP has a single stereoisomer, polymerization of 3-HP is not complicated by the stereo-specificity of monomers during chain growth. This is in contrast to (S)-2-hydroxypropanoic acid (also known as lactic acid), which has two (D, L) stereoisomers that should be considered during its polymerizations.
  • 3-HP can be converted into derivatives starting (i) substantially as the protonated form of 3-hydroxypropionic acid; (ii) substantially as the deprotonated form, 3-hydroxypropionate; or (iii) as mixtures of the protonated and deprotonated forms.
  • the fraction of 3-HP present as the acid versus the salt will depend on the pH, the presence of other ionic species in solution, temperature (which changes the equilibrium constant relating the acid and salt forms), and, to some extent, pressure.
  • Many chemical conversions may be carried out from either of the 3-HP forms, and overall process economics will typically dictate the form of 3-HP for downstream conversion.
  • Acrylic acid obtained from 3-HP purified by the methods described in this disclosure may be further converted to various polymers.
  • the free-radical polymerization of acrylic acid takes place by polymerization methods known to the skilled worker and can be carried out, for example, in an emulsion or suspension in aqueous solution or another solvent.
  • Initiators such as but not limited to organic peroxides, are often added to aid in the polymerization.
  • organic peroxides that may be used as initiators are diacyls, peroxydicarbonates, monoperoxycarbonates, peroxyketals, peroxyesters, dialkyls, and hydroperoxides.
  • azo initiators Another class of initiators is azo initiators, which may be used for acrylate polymerization as well as co-polymerization with other monomers.
  • U.S. Pat. Nos. 5,470,928; 5,510,307; 6,709,919; and 7,678,869 teach various approaches to polymerization using a number of initiators, including organic peroxides, azo compounds, and other chemical types, and are incorporated by reference for such teachings as applicable to the polymers described herein.
  • co-monomers such as crosslinkers
  • co-monomers such as crosslinkers
  • co-monomers such as crosslinkers
  • the free-radical polymerization of the acrylic acid obtained from dehydration of 3-HP, as produced herein, in at least partly neutralized form and in the presence of crosslinkers is practiced in certain embodiments.
  • This polymerization may result in hydrogels which can then be comminuted, ground and, where appropriate, surface-modified, by known techniques.
  • Superabsorbent polymers are primarily used as absorbents for water and aqueous solutions for diapers, adult incontinence products, feminine hygiene products, and similar consumer products. In such consumer products, superabsorbent materials can replace traditional absorbent materials such as cloth, cotton, paper wadding, and cellulose fiber. Superabsorbent polymers absorb, and retain under a slight mechanical pressure, up to 25 times or more their weight in liquid.
  • Superabsorbent polymer particles can be surface-modified to produce a shell structure with the shell being more highly cross-linked than the rest of the particle. This technique improves the balance of absorption, absorption under load, and resistance to gel-blocking. It is recognized that superabsorbent polymers have uses in fields other than consumer products, including agriculture, horticulture, and medicine.
  • Superabsorbent polymers are prepared from acrylic acid (such as acrylic acid derived from 3-HP provided herein) and a crosslinker, by solution or suspension polymerization. Exemplary methods include those provided in U.S. Pat. Nos. 5,145,906; 5,350,799; 5,342,899; 4,857,610; 4,985,518; 4,708, 997; 5,180,798; 4,666,983; 4,734,478; and 5,331,059, each incorporated by reference for their teachings relating to superabsorbent polymers.
  • a diaper, a feminine hygiene product, and an adult incontinence product are made with superabsorbent polymer that itself is made substantially from acrylic acid converted from 3-HP made in accordance with the present invention.
  • Diapers and other personal hygiene products may be produced that incorporate superabsorbent polymers made from acrylic acid made from 3-HP which is produced and purified by the teachings of the present application.
  • the following provides general guidance for making a diaper that incorporates such superabsorbent polymer.
  • the superabsorbent polymer first is molded into an absorbent pad that may be vacuum formed, and in which other materials, such as a fibrous material (e.g., wood pulp) are added.
  • the absorbent pad then is assembled with sheet(s) of fabric, generally a nonwoven fabric (e.g., made from one or more of nylon, polyester, polyethylene, and polypropylene plastics) to form diapers.
  • a nonwoven fabric e.g., made from one or more of nylon, polyester, polyethylene, and polypropylene plastics
  • multiple pressurized nozzles located above a conveyer belt, spray superabsorbent polymer particles (e.g., about 400 micron size or larger), fibrous material, and/or a combination of these onto the conveyer belt at designated spaces/intervals.
  • the conveyor belt is perforated and under vacuum from below, so that the sprayed on materials are pulled toward the belt surface to form a flat pad.
  • fibrous material is applied first on the belt, followed by a mixture of fibrous material and the superabsorbent polymer particles, followed by fibrous material, so that the superabsorbent polymer is concentrated in the middle of the pad.
  • a leveling roller may be used toward the end of the belt path to yield pads of uniform thickness.
  • Each pad thereafter may be further processed, such as to cut it to a proper shape for the diaper, or the pad may be in the form of a long roll sufficient for multiple diapers. Thereafter, the pad is sandwiched between a top sheet and a bottom sheet of fabric (one generally being liquid pervious, the other liquid impervious), for example on a conveyor belt, and these are attached together, for example by gluing, heating or ultrasonic welding, and cut into diaper-sized units (if not previously so cut). Additional features may be provided, such as elastic components, strips of tape, etc., for fit and ease of wearing by a person.
  • the ratio of the fibrous material to polymer particles is known to affect performance characteristics. In some cases, this ratio is between 75:25 and 90:10 (see e.g., U.S. Pat. No. 4,685,915, incorporated by reference for its teachings of diaper manufacture).
  • Other disposable absorbent articles may be constructed in a similar fashion, such as absorbent articles for adult incontinence, feminine hygiene (sanitary napkins), tampons, etc. (see, for example, U.S. Pat. Nos. 5,009,653; 5,558,656; and 5,827,255 incorporated by reference for their teachings of sanitary napkin manufacture).
  • Low molecular weight polyacrylic acid has uses for water treatment, and as a flocculant and thickener for various applications including cosmetics and pharmaceutical preparations.
  • the polymer may be uncrosslinked or lightly cross-linked, depending on the specific application.
  • the molecular weights are typically from about 200 to about 1,000,000 g/mol.
  • Preparation of these low molecular weight polyacrylic acid polymers is described in U.S. Pat. Nos. 3,904,685; 4,301,266; 2,798,053; and 5,093,472, each of which is incorporated by reference for its teachings relating to methods to produce these polymers.
  • Acrylic acid may be co-polymerized with one or more other monomers selected from acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, N,N-dimethylacrylamide, N-isopropylacrylamide, methacrylic acid, and methacrylamide, to name a few.
  • the relative reactivities of the monomers affect the microstructure and thus the physical properties of the polymer.
  • Co-monomers may be derived from 3-HP, or otherwise provided, to produce co-polymers.
  • Ullmann's Encyclopedia of Industrial Chemistry, Polyacrylamides and Poly(Acrylic Acids), WileyVCH Verlag GmbH, Wienham (2005), is incorporated by reference herein for its teachings of polymer and co-polymer processing.
  • Acrylic acid can in principle be copolymerized with almost any free-radically polymerizable monomers including styrene, butadiene, acrylonitrile, acrylic esters, maleic acid, maleic anhydride, vinyl chloride, acrylamide, itaconic acid, and so on. End-use applications typically dictate the co-polymer composition, which influences properties. Acrylic acid also may have a number of optional substitutions and, after such substitutions, may be used as a monomer for polymerization, or co-polymerization reactions.
  • acrylic acid may be substituted by any substituent that does not interfere with the polymerization process, such as alkyl, alkoxy, aryl, heteroaryl, benzyl, vinyl, allyl, hydroxy, epoxy, amide, ethers, esters, ketones, maleimides, succinimides, sulfoxides, glycidyl and silyl (see e.g., U.S. Pat. No. 7,678,869, incorporated by reference above, for further discussion).
  • substituent such as alkyl, alkoxy, aryl, heteroaryl, benzyl, vinyl, allyl, hydroxy, epoxy, amide, ethers, esters, ketones, maleimides, succinimides, sulfoxides, glycidyl and silyl.
  • Paints that comprise polymers and copolymers of acrylic acid and its esters are in wide use as industrial and consumer products. Aspects of the technology for making such paints can be found in e.g., U.S. Pat. Nos. 3,687,885 and 3,891,591, incorporated by reference for their teachings of such paint manufacture.
  • acrylic acid and its esters may form homopolymers or copolymers among themselves or with other monomers, such as amides, methacrylates, acrylonitrile, vinyl, styrene and butadiene.
  • a desired mixture of homopolymers and/or copolymers referred to in the paint industry as “vehicle” (or “binder”) are added to an aqueous solution and agitated sufficiently to form an aqueous dispersion that includes sub-micrometer sized polymer particles.
  • the paint cures by coalescence of these vehicle particles as the water and any other solvent evaporate.
  • Other additives to the aqueous dispersion may include pigment, filler (e.g., calcium carbonate, aluminum silicate), solvent (e.g., acetone, benzol, alcohols, etc., although these are not found in certain no VOC paints), thickener, and additional additives depending on the conditions, applications, intended surfaces, etc.
  • the weight percent of the vehicle portion may range from about nine to about 26 percent, but for other paints the weight percent may vary beyond this range.
  • Acrylic-based polymers are used for many coatings in addition to paints.
  • acrylic acid is used from 0.1-5.0%, along with styrene and butadiene, to enhance binding to the paper and modify rheology, freeze-thaw stability and shear stability.
  • U.S. Pat. Nos. 3,875,101 and 3,872,037 are incorporated by reference for their teachings regarding such latexes.
  • Acrylate-based polymers also are used in many inks, particularly UV curable printing inks
  • acrylamide and/or hydroxy ethyl acrylate are commonly co-polymerized with acrylic acid to produce low molecular-weight linear polymers.
  • co-monomers For thickening agents, a variety of co-monomers can be used, such as those described in U.S. Pat. Nos. 4,268,641 and 3,915,921, incorporated by reference for their description of these co-monomers.
  • U.S. Pat. No. 5,135,677 describes a number of co-monomers that can be used with acrylic acid to produce water-soluble polymers, and is incorporated by reference for such description.
  • conversion to downstream products may be made enzymatically.
  • 3-HP may be converted to 3-HP-CoA, which then may be converted into polymerized 3-HP with an enzyme having polyhydroxy acid synthase activity (EC 2.3.1.-).
  • 1,3-propanediol can be made using polypeptides having oxidoreductase activity or reductase activity (e.g., enzymes in the EC 1.1.1.- class of enzymes).
  • a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme from the 1.1.1.32 class) can be used.
  • Polypeptides having lipase activity may be used to form esters. Enzymatic reactions such as these may be conducted in vitro, such as using cell-free extracts, or in vivo.
  • various embodiments described in this disclosure include conversion steps to any downstream products of microbially produced 3-HP, including but not limited to those chemicals described herein, in the incorporated references, and known in the art.
  • 3-HP is produced and converted to polymerized-3-HP (poly-3-HP) or acrylic acid.
  • 3-HP or acrylic acid can be used to produce polyacrylic acid (polymerized acrylic acid, in various forms), methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, 1,3-propanediol, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate, and acrylic acid or an acrylic acid ester to which an alkyl or aryl addition may be made, and/or to which halogens, aromatic amines or amides, and aromatic hydrocarbons may be added.
  • Stabilizing agents and/or inhibiting agents include, but are not limited to, e.g., phenolic compounds (e.g., dimethoxyphenol (DMP) or alkylated phenolic compounds such as di-tert-butyl phenol), quinones (e.g., t-butyl hydroquinone or the monomethyl ether of hydroquinone (MEHQ)), and/or metallic copper or copper salts (e.g., copper sulfate, copper chloride, or copper acetate)
  • DMP dimethoxyphenol
  • MEHQ monomethyl ether of hydroquinone
  • metallic copper or copper salts e.g., copper sulfate, copper chloride, or copper acetate
  • Inhibitors and/or stabilizers can be used individually or in combinations as will be known by those of skill in the art.
  • the one or more downstream compounds are recovered at a molar yield of up to about 100 percent, or a molar yield in the range from about 70 percent to about 90 percent, or a molar yield in the range from about 80 percent to about 100 percent, or a molar yield in the range from about 90 percent to about 100 percent.
  • Such yields may be the result of single-pass (batch or continuous) or iterative separation and purification steps in a particular process.
  • the methods described in this disclosure can also be used to produce downstream compounds derived from 3-HP, such as but not limited to, polymerized-3-HP (poly-3-HP), acrylic acid, polyacrylic acid (polymerized acrylic acid, in various forms), copolymers of acrylic acid and acrylic esters, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, and 1,3-propanediol.
  • esters that are formed are methyl acrylate, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, and 2-ethylhexyl acrylate.
  • acrylic acid and/or other acrylate esters may be combined, including with other compounds, to form various known acrylic acid-based polymers.
  • Numerous approaches may be employed for such downstream conversions, generally falling into enzymatic, catalytic (chemical conversion process using a catalyst), thermal, and combinations thereof (including some wherein a desired pressure is applied to accelerate a reaction).
  • acrylic acid may be made from 3-HP via a dehydration reaction
  • methyl acrylate may be made from 3-HP via dehydration and esterification, the latter to add a methyl group (such as using methanol)
  • acrylamide may be made from 3-HP via dehydration and amidation reactions
  • acrylonitrile may be made via a dehydration reaction and forming a nitrile moiety
  • propiolactone may be made from 3-HP via a ring-forming internal esterification reaction
  • ethyl-3-HP may be made from 3-HP via esterification with ethanol
  • malonic acid may be made from 3-HP via an oxidation reaction
  • 1,3-propanediol may be made from 3-HP via a reduction reaction.
  • various derivatives of the derivatives of 3-HP and acrylic acid may be made, such as the various known polymers of acrylic acid and its derivatives. Production of such polymers is considered within the scope of the present invention. Copolymers containing acrylic acid and/or esters have been widely used in the pharmaceutical formulation to achieve extended or sustained release of active ingredients, for example as coating material. Downstream compounds may also be converted to consumer products such as diapers, carpet, paint, and adhesives.
  • acrylamide Another important product, acrylamide has been used in a number of industrial applications.
  • Acrylamide may be produced from 3-HP, for example, without being limiting, via an esterification-amidation-dehydration sequence. Refluxing an alcohol solution of 3-HP in the presence of an acid or Lewis acid catalyst described herein would lead to a 3-HP ester. Treatment of the 3-HP ester with either an ammonia gas or an ammonium ion could yield 3-HP amide. Finally, dehydration of the 3-HP amide with dehydration reagents described elsewhere in this disclosure could produce acrylamide. The steps mentioned herein may be rearranged to produce the same final product acrylamide. Polymerization of acrylamide can be achieved, for example, and without being limiting, by radical polymerization. Polyacrylamide polymers have been widely used as additives for treating municipal drinking water and waste water. In addition, they have found applications in gel electrophoresis, oil-drilling, papermaking, ore processing, and the manufacture of permanent press fabrics.
  • cloning vectors or plasmids are maintained at different copy numbers, dependent on the replicon of the plasmid.
  • Most general cloning plasmids can carry a DNA insert up to around 15 kb in size.
  • Multicopy plasmids can be used for the expression of recombinant genes in Escherichia coli .
  • Examples of include multicopy plasmids include high-copy, medium-copy and low-copy plasmids (see FIG. 8 ).
  • the high copy number is generally desired for maximum gene expression.
  • the metabolic burden effects can result from multiple plasmid copies could prove to be detrimental for maximum productivity in certain metabolic engineering applications by adding significant metabolic burden to the system.
  • the low-copy plasmids for example, pBR322 is based on the original ColE1 replicon and thus has a copy number of 15-20.
  • the pACYC series of plasmids are based on the p15A replicon, which has a copy number of 18-22, whereas pSC101 has even a lower copy number around 5, and BACs are maintained at one copy per cell.
  • Such low copy plasmids may be useful in metabolic engineering applications, particularly when one or more of the substrates used in the recombinant pathway are required for normal cellular metabolism and can be toxic to the cell at high levels.
  • the mutant ColE1 replicon as found in the pUC series of plasmids produces a copy number of 500-700 as a result of a point mutation within the RNAII regulatory molecule.
  • Transcription vectors are utilized when the DNA to be cloned has an ATG start codon and a prokaryotic ribosome-binding site.
  • Translation vectors contain an efficient ribosome-binding site and, therefore, it is not necessary for the target DNA to contain one. This is particularly useful in cases where the initial portion of the gene may be cleaved in an effort to improve solubility.
  • Another consideration when choosing a transcription or translation vector is the source of the DNA to be expressed.
  • Prokaryotic genes usually have a ribosome-binding site that is compatible with the host E. coli translation machinery, whereas eukaryotic genes do not. Normal prokaryotic gene expression may be enhanced by use of an engineered promoter and ribosome-binding site.
  • a promoter is a region of DNA that initiates transcription of a particular gene. In bacteria, transcription is initiated by the promoter being recognized by RNA polymerase and an associated sigma factor, which are often brought to the promoter site by an activator protein's binding to its own DNA binding site located by the promoter.
  • Promoter selection is an important factor when designing an expression plasmid system.
  • a promoter is located upstream of the ribosome-binding site. Owing to the fact that many heterologous protein products are toxic to the cell, the promoter can be regulated so that the heterologous protein is expressed at the appropriate amount and time to reduced the burden on the cell host.
  • lac lactose
  • trp tryptophan
  • Other common promoters are the phage lambda promoters, the phage T7 promoter (T7), and the alkaline phosphatase promoter (phoA).
  • Promoters can be constitutive and inducible. Constitutive promoter is active in all circumstances in the cell, while regulated or inducible promoter become active in response to specific stimuli. In addition the strength of the promoter can also differ. A strong promoter has a high frequency of transcription and generates the heterologous protein as 10-30% of the total cellular protein production (for examples see FIG. 8 ).
  • Chemically-inducible promoters that can be used in various aspects of the invention include but are not limited to promoters whose transcriptional activity is regulated by the presence or absence of alcohol, tetracycline, steroids, metal and other compounds.
  • Physically-inducible promoters that can be used in various aspects of the invention include but are not limited to including promoters whose transcriptional activity is regulated by the presence or absence of light and low or high temperatures.
  • an inducible promoter In order to be an inducible promoter, the promoter should be initially be completely repressed to transcription and then transcription induced with the addition of an inducer to allow expression at the time that expression is desired in the host cell.
  • an inducible promoter may be responsive to the lack of a substance, such as inorganic phosphate, such that the absence of inorganic phosphate will allow expression at the time that expression is desired in the host cell (for examples see FIG. 8 ).
  • a Ribosome Binding Sites is an RNA sequence upstream of the start codon that affects the rate at which a particular gene or open reading frame (ORF) is translated.
  • ORF open reading frame
  • Ribosome Binding Sites are typically short sequences, often less than 20 base pairs.
  • Various aspects of RBS design are known to affect the rate at which the gene is translated in the cell.
  • the RBS module can influences the translation rate of a gene largely by two known mechanisms. First, the rate at which ribosomes are recruited to the mRNA and initiate translation is dependent on the sequence of the RBS.
  • the sequence of the RBS can also affect the stability of the mRNA in the cell, which in turn affects the number of proteins.
  • desired genes such as genes encoding enzymes in the biosynthetic pathway for 3-HP, can be tailored activity either at the transcriptional and translational level.
  • the Registry has collections of RBSs that are recommended for general protein expression in E. coli and other prokaryotic hosts.
  • each family of RBSs has multiple members covering a range of translation initiation rates.
  • consensus RBS sequence for E. coli have been described. However, it is important to keep in mind the known RBS functions and mechanisms in a larger context. For example, in certain contexts the RBS can interact with upstream sequences, such as sequence that comprise the promoter or an upstream ORF.
  • the RBS may interact with downstream sequences, for example the ribosome enzyme binds jointly to the RBS and start codon at about the same time. These potential interactions should be considered in the overall RBS sequence design.
  • the degree of secondary structure near the RBS can affect the translation initiation rate. This fact can be used to produce regulated translation initiation rates.
  • the Shine-Dalgarno portion of the RBS is critical to the strength of the RBS.
  • the Shine-Dalgarno is found at the end of the 16s rRNA and is the portion that binds with the mRNA and includes the sequence 5′-ACCUCC-3′.
  • RBSs will commonly include a portion of the Shine-Dalgarno sequence.
  • One of the ribosomal proteins, 51 is known to bind to adenine bases upstream from the Shine-Dalgarno sequence. As a result, the RBS can be made stronger by adding more adenines in the sequence upstream of the RBS.
  • ACCase complex a critical enzyme in the conversion of acetyl-CoA to malonyl-CoA, the immediate precursor for 3-HP
  • salt levels near 0.44M resulted in decreasing the activity of the ACCase enzyme by approximately 80%
  • salts of 3-HP levels near 0.66M decreased the activity of the ACCase enzyme by approximately 80% relative to control ( FIG. 4 ).
  • Levels of greater than 0.66M 60 g/L are expected to be present for commercially viable commercial production of 3-HP.
  • Halophilic organisms such as Halomonas elongata
  • Halomonas elongata are found in environments with high salt concentrations and, in general, have a salt internal concentration >2.5-3M. It is hypothesized that enzymes derived from any salt-tolerant species should be more resistant to enzyme inhibition by salts, such as 3-HP. Further, these enzymes that have greater salt tolerance should in turn have extended production under high salt conditions than enzymes with lower salt tolerance.
  • the genes encoding the accA, accB, accC, accD of H. elongata described in Table 1 were synthesized for expression in E. coli using codons optimized for this organism and supplied individually on pUC57 plasmids without promoters. Synthetic operons comprising the subunits were assembled using the Gibson assembly method.
  • the Gibson Assembly kit was used to construct plasmids expressing the ACCase subunit genes as directed by the manufacturer.
  • the effect of NH 4 -3-HP and NH 4 Cl on H. elongata ACCase was tested and compared to the E. coli ACCase.
  • the ACCase from the halophile is less affected by either NH 4 -3-HP or by NH 4 Cl.
  • Enzyme expression is regulated at transcriptional and translational levels in prokaryotes.
  • Ribosome Binding Sites are 15 nucleotide segments which are known to control the level of protein expression in microorganisms.
  • To enhance H. elongata ACCase expression various customized RBS were constructed and optimized for E. coli translation expression. Table 2 shows the RBS sequences used to increase expression of the individual subunits.
  • H. elongata ACCase 3HP expression plasmid (g/l ⁇ OD) Parent 2-4 0.06 B2 0.81 13A 0.01 14C 0.54 15C 0.14 17C 0.08 35C 0.68 36C 0.31 36C-8 0.31 72B 0.57 105F 0.19
  • ACCase subunit genes from prokaryotes such as E. coli and H. elongata have been shown to have a quaternary structure: accA 2 :accD 2 :accB 4 :accC 2 .
  • the intrinsic levels of the ACCase subunit genes are too low for optimal production. Therefore, for optimal production it is ideal to have overexpression to be coordinated in a similar manner.
  • ACCase subunit genes regulated at transcriptional and translational levels. Coordinated overexpression of the ACCase subunit genes, accA, accB, accC, accD should give better ACCase activity. Examples of fusions of accC-B proteins exist in bacteria. It is hypothesized that coordinated overexpression may be achieved by fusion of subunit genes should ensures equimolar expression of the subunit genes at the optimal time.
  • ACCase subunit gene fusion were constructed and the constructs overexpressed in E. coli : (A) Control ABCD, (B) fusion of accC-B (SEQ ID NO. s 9, 10) subunit genes as seen in bacteria, (C) fusion of accD-A subunit genes using a flexible 15-amino acid linker (Linker sequence LSGGGGSGGGGSGGGGSGGGGSAAA; SEQ ID NO. s 11, 12) as depicted in FIG. 5 .
  • Linker sequence LSGGGGSGGGGSGGGGSGGGGSAAA SEQ ID NO. s 11, 12
  • ACCase activity was determined in cell lysates using an assay for malonyl-CoA production as described in [Kroeger, Zarzycki, and Fuchs, Analytical Biochem. 411:100-105, 2011].
  • Production of 3-HP was determined in cells co-transformed with a plasmid bearing the genes encoding the malonyl-CoA reductase from S. tokadaii and E. coli ydfG providing a 3-HP dehydrogenase to complete the metabolic pathway from malonyl-CoA to 3HP.
  • FIG. 6 shows that the benefit of the accDA fusion were also manifested in 3-HP production in fermentors with environmental controls of nutrient feed, pH, aeration, and temperature.
  • SEQ ID NO. 1 ACCA PROTEIN, HALOMONAS ELONGATA MNPNYLDFEQPIAELQAKIEELRMVGNDSQVNLSDEIGRLEEKSRKLTES IFKDLSAWQVSQLSRHPQRPYTLDYLEHVFTDFDELHGDRRFADDAAIVG GVARLDDKPVMVIGHQKGRDVHEKVRRNFGMPRPEGYRKACRLMEMAERF HMPVLTFIDTPGAYPGIDAEERGQSEAIAYNLGVMSRLKTPIISTVVGEG GSGGALAIGVCDELAMLQYSTYSVISPEGCASILWKSADKASEAAQAMGI TAERLKELGFVDTLIPEPLGGAHRQPSATAERIKTALLESLDRLETMETD ALLERRYERLMSYGAPV SEQ ID NO.
  • NEMA DNA ORGANISM NAME ESCHERICHIA COLI ATGTCATCTG AAAAACTGTA TTCCCCACTG AAAGTGGGCG CGATCACGGC GGCAAACCGT 60 ATTTTTATGG CACCGCTGAC GCGTCTGCGC AGTATTGAAC CGGGTGACAT TCCTACCCCG 120 TTGATGGCGG AATACTATCG CCAACGTGCC AGTGCCGGTT TGATTATTAG TGAAGCCACG 180 CAAATTTCTG CCCAGGCAAA AGGATATGCA GGTGCGCCTG GCATCCATAG TCCGGAGCAA 240 ATTGCCGCAT GGAAAAAAAT CACCGCTGGC GTTCATGCTG AAAATGGTCA TATGGCCGTG 300 CAGCTGTGGC ACACCGGACG CATTTCTCAC GCCTGC AACCTGGCGG TCAGGCACCG 360 GTAGCGCCTT CAGCACTTAG CGCGGGAACA CGTACTTCTC TGCGATGA AAATGGTCAG 420
  • NEMA PROTEIN ORGANISM NAME ESCHERICHIA COLI MSSEKLYSPL KVGAITAANR IFMAPLTRLR SIEPGDIPTP LMAEYYRQRA SAGLIISEAT 60 QISAQAKGYA GAPGIHSPEQ IAAWKKITAG VHAENGHMAV QLWHTGRISH ASLQPGGQAP 120 VAPSALSAGT RTSLRDENGQ AIRVETSMPR ALELEEIPGI VNDFRQAIAN AREAGFDLVE 180 LHSAHGYLLH QFLSPSSNHR TDQYGGSVEN RARLVLEVVD AGIEEWGADR IGIRVSPIGT 240 FQNTDNGPNE EADALYLIEQ LGKRGIAYLH MSEPDWAGGE PYTDAFREKV RARFHGPIIG 300 AGAYTVEKAE TLIGKGLIDA VAFGRDWIAN PDLVARLQRK AELNPQRAES FYGGGAEGYT 360 DYPTL 365 ⁇ 212>TYPE
  • AERUGINOSA NDSD DNA SEQ ID NO. 26: NDSD PROTEIN PSEUDOMONAS AERUGINOSA MGKQIAFIGL GHMGAPMATN LLKAGYLLNV FDLVQSAVDG LVAAGASAAR SARDAVQGAD 60 VVISMLPASQ HVEGLYLDDD GLLAHIAPGT LVLECSTIAP TSARKIHAAA RERGLAMLDA 120 PVSGGTAGAA AGTLTFMVGG DAEALEKARP LFEAMGRNIF HAGPDGAGQV AKVCNNQLLA 180 VLMIGTAEAM ALGVANGLEA KVLAEIMRRS SGGNWALEVY NPWPGVMENA PASRDYSGGF 240 MAQLMAKDLG LAQEAAQASA SSTPMGSLAL SLYRLLLKQG YAERDFSVVQ KLFDPTQGQ 299 ⁇ 212>TYPE: PRT ⁇ 211>LENGTH: 299 SEQUENCENAME: P.
  • AERUGINOSA NDSD PROTEIN SEQ ID NO. 27 FABI(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI MGFLSGKRIL VTGVASKLSI AYGIAQAMHR EGAELAFTYQ NDKLKGRVEE FAAQLGSDIV 60 LQCDVAEDAS IDTMFAELGK VWPKFDGFVH SIGFAPGDQL DGDYVNAVTR EGFKIAHDIS 120 SYSFVAMAKA CRSMLNPGSA LLTLSYLGAE RAIPNYNVMG LAKASLEANV RYMANAMGPE 180 GVRVNAISAG PIRTLAASGI KDFRKMLAHC EAVTPIRRTV TIEDVGNSAA FLCSDLSAGI 240 FGEVVHVDGG FSIAAMNELE LK 262 ⁇ 212>TYPE: PRT ⁇ 211>LENGTH: 262 SEQUENCENAME: ESCHERICHIA COLI FABI(TS) PROTEIN SEQ ID NO.
  • EAMA ORGANISM NAME ESCHERICHIA COLI MSRKDGVLAL LVVVVWGLNF VVIKVGLHNM PPLMLAGLRF MLVAFPAIFF VARPKVPLNL LLGYGLTISF AQFAFLFCAI NFGMPAGLAS LVLQAQAFFT IMLGAFTFGE RLHGKQLAGI ALAIFGVLVL IEDSLNGQHV AMLGFMLTLA AAFSWACGNI FNKKIMSHST RPAVMSLVIW SALIPIIPFF VASLILDGSA TMIHSLVTID MTTILSLMYL AFVATIVGYG IWGTLLGRYE TWRVAPLSLL VPVVGLASAA LLLDERLTGL QFLGAVLIMT GLYINVFGLR WRKAVKVGS SEQ ID NO.
  • EAMB ORGANISM NAME ESCHERICHIA COLI MTPTLLSAFW TYTLITAMTP GPNNILALSS ATSHGFRQST RVLAGMSLGF LIVMLLCAGI SFSLAVIDPA AVHLLSWAGA AYIVWLAWKI ATSPTKEDGL QAKPISFWAS FALQFVNVKI ILYGVTALST FVLPQTQALS WVVGVSVLLA MIGTFGNVCW ALAGHLFQRL FRQYGRQLNI VLALLLVYCA VRIFY SEQ ID NO.
  • EMRKY ORGANISM NAME ESCHERICHIA COLI MAITKSTPAP LTGGTLWCVT IALSLATFMQ MLDSTISNVA IPTISGFLGA STDEGTWVIT SFGVANAIAI PVTGRLAQRI GELRLFLLSV TFFSLSSLMC SLSTNLDVLI FFRVVQGLMA GPLIPLSQSL LLRNYPPEKR TFALALWSMT VIIAPICGPI LGGYICDNFS WGWIFLINVP MGIIVLTLCL TLLKGRETET SPVKMNLPGL TLLVLGVGGL QIMLDKGRDL DWFNSSTIII LTVVSVISLI SLVIWESTSE NPILDLSLFK SRNFTIGIVS ITCAYLFYSG AIVLMPQLLQ ETMGYNAIWA GLAYAPIGIM PLLISPLIGR YGNKIDMRLL VTFSFLMYAV CYYWRSVTFM PTIDFTGIIL PQFFQGFAVA CFFLPLTTIS FSGL
  • HSRA ORGANISM NAME ESCHERICHIA COLI MSDKKKRSMA GLPWIAAMAF FMQALDATIL NTALPAIAHS LNRSPLAMQS AIISYTLTVA MLIPVSGWLA DRFGTRRIFT LAVSLFTLGS LACALSNSLP QLVVFRVIQG IGGAMMMPVA RLALLRAYPR NELLPVLNFV AMPGLVGPIL GPVLGGVLVT WATWHWIFLI NIPIGIAGLL YARKHMPNFT TARRRFDITG FLLFGLSLVL FSSGIELFGE KIVASWIALT VIVTSIGLLL LYILHARRTP NPLISLDLFK TRTFSIGIVG NIATRLGTGC VPFLMPLMLQ VGFGYQAFIA GCMMAPTALG SIIAKSMVTQ VLRRLGYRHT LVGITVIIGL MIAQFSLQSP AMAIWMLILP LFILGMAMST QFTAMNTITL ADLTDDNASS GN
  • MDLB ORGANISM NAME ESCHERICHIA COLI MRSFSQLWPT LKRLLAYGSP WRKPLGIAVL MMWVAAAAEV SGPLLISYFI DNMVAKNNLP LKVVAGLAAA YVGLQLFAAG LHYAQSLLFN RAAVGVVQQL RTDVMDAALR QPLSEFDTQP VGQVISRVTN DTEVIRDLYV TVVATVLRSA ALVGAMLVAM FSLDWRMALV AIMIFPVVLV VMVIYQRYST PIVRRVRAYL ADINDGFNEI INGMSVIQQF RQQARFGERM GEASRSHYMA RMQTLRLDGF LLRPLLSLFS SLILCGLLML FGFSASGTIE VGVLYAFISY LGRLNEPLIE LTTQQAMLQQ AVVAGERVFE LMDGPRQQYG NDDRPLQSGT IEVDNVSFAY RDDNLVLKNI NLSVPSRNFV ALV
  • RHTA ORGANISM NAME ESCHERICHIA COLI MPGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTFGT LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN SEQ ID NO.
  • RHTB ORGANISM NAME ESCHERICHIA COLI MTLEWWFAYL LTSIILSLSP GSGAINTMTT SLNHGYRGAV ASIAGLQTGL AIHIVLVGVG LGTLFSRSVI AFEVLKWAGA AYLIWLGIQQ WRAAGAIDLK SLASTQSRRH LFQRAVFVNL TNPKSIVFLA ALFPQFIMPQ QPQLMQYIVL GVTTIVVDII VMIGYATLAQ RIALWIKGPK QMKALNKIFG SLFMLVGALL ASARHA SEQ ID NO.
  • RHTC ORGANISM NAME ESCHERICHIA COLI MLMLFLTVAM VHIVALMSPG PDFFFVSQTA VSRSRKEAMM GVLGITCGVM VWAGIALLGL HLIIEKMAWL HTLIMVGGGL YLCWMGYQML RGALKKEAVS APAPQVELAK SGRSFLKGLL TNLANPKAII YFGSVFSLFV GDNVGTTARW GIFALIIVET LAWFTVVASL FALPQMRRGY QRLAKWIDGF AGALFAGFGI HLIISR SEQ ID NO.
  • YAHN ORGANISM NAME ESCHERICHIA COLI MMQLVHLFMD EITMDPLHAV YLTVGLFVIT FFNPGANLFV VVQTSLASGR RAGVLTGLGV ALGDAFYSGL GLFGLATLIT QCEEIFSLIR IVGGAYLLWF AWCSMRRQST PQMSTLQQPI SAPWYVFFRR GLITDLSNPQ TVLFFISIFS VTLNAETPTW ARLMAWAGIV LASIIWRVFL SQAFSLPAVR RAYGRMQRVA SRVIGAIIGV FALRLIYEGV TQR SEQ ID NO.
  • YBBP ORGANISM NAME ESCHERICHIA COLI MIARWFWREW RSPSLLIVWL ALSLAVACVL ALGNISDRME KGLSQQSREF MAGDRALRSS REVPQAWLEE AQKRGLKVGK QLTFATMTFA GDTPQLANVK AVDDIYPMYG DLQTNPPGLK PQAGSVLLAP RLMALLNLKT GDTIDVGDAT LRIAGEVIQE PDSGFNPFQM APRLMMNLAD VDKTGAVQPG SRVTWRYKFG GNENQLDGYE KWLLPQLKPE QRWYGLEQDE GALGRSMERS QQFLLLSALL TLLLAVAAVA VAMNHYCRSR YDLVAILKTL GAGRAQLRKL IVGQWLMVLT LSAVTGGAIG LLFENVLMVL LKPVLPAALP PASLWPWLWA LGTMTVISLL VGLRPYRLLL ATQPLRVLRN
  • YCAP ORGANISM NAME ESCHERICHIA COLI MKAFDLHRMA FDKVPFDFLG EVALRSLYTF VLVFLFLKMT GRRGVRQMSL FEVLIILTLG SAAGDVAFYD DVPMVPVLIV FITLALLYRL VMWLMAHSEK LEDLLEGKPV VIIEDGELAW SKLNNSNMTE FEFFMELRLR GVEQLGQVRL AILETNGQIS VYFFEDDKVK PGLLILPSDC TQRYKVVPES ADYACIRCSE IIHMKAGEKQ LCPRCANPEW TKASRAKRVT SEQ ID NO.
  • YDDG ORGANISM NAME ESCHERICHIA COLI MTRQKATLIG LIAIVLWSTM VGLIRGVSEG LGPVGGAAAI YSLSGLLLIF TVGFPRIRQI PKGYLLAGSL LFVSYEICLA LSLGYAATHH QAIEVGMVNY LWPSLTILFA ILFNGQKTNW LIVPGLLLAL VGVCWVLGGD NGLHYDEIIN NITTSPLSYF LAFIGAFIWA AYCTVTNKYA RGFNGITVFV LLTGASLWVY YFLTPQPEMI FSTPVMIKLI SAAFTLGFAY AAWNVGILHG NVTIMAVGSY FTPVLSSALA AVLLSAPLSF SFWQGALMVC GGSLLCWLAT RRG SEQ ID NO.
  • YDHC ORGANISM NAME ESCHERICHIA COLI MQPGKRFLVW LAGLSVLGFL ATDMYLPAFA AIQADLQTPA SAVSASLSLF LAGFAAAQLL WGPLSDRYGR KPVLLIGLTI FALGSLGMLW VENAATLLVL RFVQAVGVCA AAVIWQALVT DYYPSQKVNR IFAAIMPLVG LSPALAPLLG SWLLVHFSWQ AIFATLFAIT VVLILPIFWL KPTTKARNNS QDGLTFTDLL RSKTYRGNVL IYAACSASFF AWLTGSPFIL SEMGYSPAVI GLSYVPQTIA FLIGGYGCRA ALQKWQGKQL LPWLLVLFAV SVIATWAAGF ISHVSLVEIL IPFCVMAIAN GAIYPIVVAQ ALRPFPHATG RAAALQNTLQ LGLCFLASLV VSWLISISTP LLTTTSVMLS TVVLVALGYM MQRCEEVGCQ
  • YDIM ORGANISM NAME ESCHERICHIA COLI MKNPYFPTAL GLYFNYLVHG MGVLLMSLNM ASLETLWQTN AAGVSIVISS LGIGRLSVLL FAGLLSDRFG RRPFIMLGMC CYMAFFFGIL QTNNIIIAYV FGFLAGMANS FLDAGTYPSL MEAFPRSPGT ANILIKAFVS SGQFLLPLII SLLVWAELWF GWSFMIAAGI MFINALFLYR CTFPPHPGRR LPVIKKTTSS TEHRCSIIDL ASYTLYGYIS MATFYLVSQW LAQYGQFVAG MSYTMSIKLL SIYTVGSLLC VFITAPLIRN TVRPTTLLML YTFISFIALF TVCLHPTFYV VIIFAFVIGF TSAGGVVQIG LTLMAERFPY AKGKATGIYY SAGSIATFTI PLITAHLSQR SIADIMWFDT AIAAIGFLLA LFIGLRSRKK TR
  • 74 YDJF ORGANISM NAME: ESCHERICHIA COLI MAAKDRIQAI KQMVANDKKV TVSNLSGIFQ VTEETIRRDL EKLEDEGFLT RTYGGAVLNT AMLTENIHFY KRASSFYEEK QLIARKALPF IDNKTTMAAD SSSTVMELLK LLQDRSGLTL LTNSAEAIHV LAQSEIKVVS TGGELNKNTL SLQGRITKEI IRRYHVDIMV MSCKGLDINS GALDSNEAEA EIKKTMIRQA TEVALLVDHS KFDRKAFVQL ADFSHINYII TDKSPGAEWI AFCKDNNIQL VW SEQ ID NO.
  • YEAN ORGANISM NAME ESCHERICHIA COLI MTCSTSLSGK NRIVLIAGIL MIATTLRVTF TGAAPLLDTI RSAYSLTTAQ TGLLTTLPLL AFALISPLAA PVARRFGMER SLFAALLLIC AGIAIRSLPS PYLLFGGTAV IGGGIALGNV LLPGLIKRDF PHSVARLTGA YSLTMGAAAA LGSAMVVPLA LNGFGWQGAL LMLMCFPLLA LFLWLPQWRS QQHANLSTSR ALHTRGIWRS PLAWQVTLFL GINSLVYYVI IGWLPAILIS HGYSEAQAGS LHGLLQLATA APGLLIPLFL HHVKDQRGIA AFVALMCAVG AVGLCFMPAH AITWTLLFGF GSGATMILGL TFIGLRASSA HQAAALSGMA QSVGYLLAAC GPPLMGKIHD ANGNWSVPLM GVAILSLLMA IFGLCAGRDK E
  • YEDA ORGANISM NAME ESCHERICHIA COLI MRFRQLLPLF GALFALYIIW GSTYFVIRIG VESWPPLMMA GVRFLAAGIL LLAFLLLRGH KLPPLRPLLN AALIGLLLLA VGNGMVTVAE HQNVPSGIAA VVVATVPLFT LCFSRLFGIK TRKLEWVGIA IGLAGIIMLN SGGNLSGNPW GAILILIGSI SWAFGSVYGS RITLPVGMMA GAIEMLAAGV VLMIASMIAG EKLTALPSLS GFLAVGYLAL FGSIIAINAY MYLIRNVSPA LATSYAYVNP VVAVLLGTGL GGETLSKIEW LALGVIVFAV VLVTLGKYLF PAKPVVAPVI QDASSE SEQ ID NO.
  • YIGK (RHTB) ORGANISM NAME: ESCHERICHIA COLI MTLEWWFAYL LTSIILSLSP GSGAINTMTT SLNHGYRGAV ASIAGLQTGL AIHIVLVGVG LGTLFSRSVI AFEVLKWAGA AYLIWLGIQQ WRAAGAIDLK SLASTQSRRH LFQRAVFVNL TNPKSIVFLA ALFPQFIMPQ QPQLMQYIVL GVTTIVVDII VMIGYATLAQ RIALWIKGPK QMKALNKIFG SLFMLVGALL ASARHA SEQ ID NO.
  • 103 YKGH ORGANISM NAME: ESCHERICHIA COLI MREQIKQDID LIEILFYLKK KIRVILFIMA ICMAMVLLFL YINKDNIKVI YSLKINQTTP GILVSCDSNN NFACQTTMTE DVIQRITTFF HTSPDVKNRE IRLEWSGDKR ALPTAEEEIS RVQASIIKWY ASEYHNGRQV LDEIQTPSAI NSELYTKMIY LTRNWSLYPN GDGCVTISSP EIKNKYPAAI CLALGFFLSI VISVMFCLVK KMVDEYQQNS GQ SEQ ID NO.
  • 104 YPJD ORGANISM NAME: ESCHERICHIA COLI MQRLEQRSPD AILLLFLIAQ TVDITMPVFA LLALVAYSVS LALIVPGLLQ KNGGWRRMAI ISAVIALVCH AIALEARILP DGDSGQNLSL LNVGSLVSLM ICTVMTIVAS RNRGWLLLPI VYAFALINLA LATFMPNEYI THLEATPGML VHIGLSLFSY ATLIIAALYA LQLAWIDYQL KNKKLAFNQE MPPLMSIERK MFHITQIGVV LLTLTLCTGL FYMHNLFSME NIDKAVLSIV AWFVYIVLLW GHYHEGWRGR RVVWFNVAGA VILTLAYFGS RIVQQLIS SEQ ID NO.
  • YTFF ORGANISM NAME ESCHERICHIA COLI MPVMISGVLY ALLAGLMWGL IFVGPLIVPE YPAMLQSMGR YLALGLIALP IAWLGRVRLR QLARRDWLTA LMLTMMGNLI YYFCLASAIQ RTGAPVSTMI IGTLPVVIPV FANLLYSQRD GKLAWGKLAP
  • YTFL ORGANISM NAME ESCHERICHIA COLI MLNSILVILC LIAVSAFFSM SEISLAASRK IKLKLLADEG NINAQRVLNM QENPGMFFTV VQIGLNAVAI LGGIVGDAAF SPAFHSLFSR YMSAELSEQL SFILSFSLVT GMFILFADLT PKRIGMIAPE AVALRIINPM RFCLYVCTPL VWFFNGLANI IFRIFKLPMV RKDDITSDDI YAVVEAGALA GVLRKQEHEL IENVFELESR TVPSSMTPRE NVIWFDLHED EQSLKNKVAE HPHSKFLVCN EDIDHIIGYV DSKDLLNRVL ANQSLALNSG VQIRNTLIVP DTLTLSEALE SFKTAGEDFA VIMNEYALVV GIITLNDVMT TLMGDLVGQG LEEQIVARDE NSWLIDGGTP IDDVMRVLDI DEFPQSGNYE TI

Abstract

The present invention provides various combinations of genetic modifications to a transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.

Description

  • This application claims priority to U.S. Provisional Patent Application No. 61/852,387, filed on Mar. 15, 2013; which is hereby incorporated herein by reference in its entirety.
  • BACKGROUND OF THE INVENTION
  • There is a need for alternative production methods of industrial chemicals used for various consumer products and fuels that are currently made from petroleum. One alternative method is the use of engineered microorganisms to produce industrial chemicals. Currently, in the field of bioproduced chemicals there is a need to improve microbial enzyme performance, enhanced production rate in order to reach the goal of becoming an at-cost replacement basis for petro-based chemicals.
  • A common challenge faced in field of bio-produced chemicals in microorganisms is that any one modification to a host cell may require coordination with other modifications in order to successfully enhance chemical bioproduction.
  • The current invention provides methods, systems of fermentation, genetically modified microorganisms, modified enhanced enzymes for chemical production, all of which may be used in various combinations to increase chemical production of a desired chemical product.
  • INCORPORATION BY REFERENCE
  • All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
  • SUMMARY OF THE INVENTION
  • The present invention relates to genetically modified organisms capable of producing an industrial chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding one or more of the following: (1) an acetyl-CoA carboxylase gene with one or more of its subunits fused together in the genetic structure of the organism; (2) an acetyl-CoA carboxylase gene having a predefined stoichiometric ratio of each of the four ACCase subunits relative to one another; (3) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde and one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD, rutE, and nemA; (4) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde and one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP, and one or more genes encoding one or more enzymes capable of converting either the malonate semialdehyde enol form or the malonate semialdehyde hydrated form to 3-HP; (5) a monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is either: (a) primarily not NADPH-dependent, (b) primarily NADH-dependent, (c) primarily flavin-dependent, (d) less susceptible to 3-HP inhibition at high concentration, and/or (e) catalyzes a reaction pathway to 3-HP that is substantially irreversible; (6) a monofunctional malonyl-CoA reductase enzyme fused to one or more malonate semialdehyde dehydrogenase enzymes; (7) a malonyl-CoA reductase gene that is mutated to enhance its activity at lower temperatures; (8) salt-tolerant enzymes; (9) a gene that facilitates the exportation of a chemical product of interest or the export of an inhibitory chemical from within the cell to the extracellular media; and/or (10) a gene that facilitates the importation from the extracellular media to within the cell of a reactant, precursor, and/or metabolite used in the organism's production pathway for producing a chemical product of interest.
  • The present invention further relates to methods of producing a chemical product using the genetically modified organisms of the invention. The present invention further includes products made from these methods. In accordance with certain embodiments that product is acetyl-CoA, malonyl-CoA, malonate semialdehyde, 3-hydroxypropionic acid (3-HP), acrylic acid, 1,3 propanediol, malonic acid, ethyl 3-HP, propiolactone, acrylonitrile, acrylamide, methyl acrylate, a polymer including super absorbent polymers and polyacrylic acid, or a consumer product.
  • The present invention further relates to a method of producing a chemical product from a renewable carbon source through a bioproduction process that comprises a controlled multi-phase production process wherein the initiation and/or completion of one or more phases of the production process is controlled by genetic modifications to the organism producing the chemical product and/or is controlled by changes made to the cell environment. In accordance with this aspect of the invention, the bioproduction process may include two or more of the following phases: (1) growth phase; (2) induction phase; and (3) production phase. The present invention further includes products made from these methods.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
  • FIG. 1 Depicts some embodiments of the metabolic pathways to produce 3-hydroxypropionic acid.
  • FIG. 2 Depicts some embodiments of the of various equilibrium states in the malonate semialdehyde to 3-HP reaction in a cell environment.
  • FIG. 3 Depicts some embodiments of the reaction catalyzed by acetyl-CoA carboxylase (ACCase)
  • FIG. 4 Shows the inhibition of ACCase enzyme activity by high salt concentration
  • FIG. 5 Depicts some embodiments of the fusion ACCase subunit gene constructs overexpressed in E. coli.
  • FIG. 6 Show improved production of 3-HP by genetically modified organism with DA fusion ACCase
  • FIG. 7 Shows improved production of 3-HP by genetically modified organism with overexpression of rhtA exporter.
  • FIG. 8 Shows various embodiments of the genetic modules used for optimizing expression in host cells.
  • FIG. 9 Shows various chemical products that can made from various embodiments of the invention.
  • Table 1 Lists the accession numbers for genes encoding ACCase subunits from Halomonas elongate.
  • Table 2 Depicts some embodiments of the RBS sequences used to enhance expression of H. elongate ACCase subunits.
  • Table 3 Shows the improvement in 3-HP production by RBS-optimized expression of H. elongata ACCase subunits.
  • Table 4 Shows some embodiments of the ACCase subunit fusions that increase and ACCase enzyme complex activity.
  • Table 5 Shows some of the genetic modifications of a host cell for increase chemical production.
  • DETAILED DESCRIPTION OF THE INVENTION Definitions
  • The term “homology” refers to the optimal alignment of sequences (either nucleotides or amino acids), which may be conducted by computerized implementations of algorithms. “Homology”, with regard to polynucleotides, for example, may be determined by analysis with BLASTN version 2.0 using the default parameters. “Homology”, with respect to polypeptides (i.e., amino acids), may be determined using a program, such as BLASTP version 2.2.2 with the default parameters, which aligns the polypeptide or fragments (and can also align nucleotide fragments) being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid “homology” includes conservative substitutions, i.e. those that substitute a given amino acid in a polypeptide by another amino acid of similar characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, VaI, Leu and He with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa; replacement of an acidic residue such as Asp or GIu with another acidic residue; replacement of a residue bearing an amide group, such as Asn or GIn, with another residue bearing an amide group; exchange of a basic residue such as Lys or Arg with another basic residue; and replacement of an aromatic residue such as Phe or Tyr with another aromatic residue. For example, homologs can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide identity to the gene or proteins of the invention; or can have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% amino acid or nucleotide to the essential protein functional domains of the gene or proteins of the invention; or at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential functional domain of the gene or proteins of the invention.
  • The above descriptions and methods for sequence homology are intended to be exemplary and it is recognized that this concept is well-understood in the art. Further, it is appreciated that nucleic acid sequences may be varied and still provide a functional enzyme, and such variations are within the scope of the present invention. The term “enzyme homolog” can also mean a functional variant.
  • The term “Functional homolog” means a polypeptide that is determined to possess an enzymatic activity and specificity of an enzyme of interest but which has an amino acid sequence different from such enzyme of interest. A corresponding “homolog nucleic acid sequence” may be constructed that is determined to encode such an identified enzymatic functional variant.
  • The term “3-HP” means 3-hydroxypropionic acid.
  • The term “heterologous DNA,” “heterologous nucleic acid sequence,” and the like as used herein refers to a nucleic acid sequence wherein at least one of the following is true: (a) the sequence of nucleic acids is foreign to (i.e., not naturally found in) a given host microorganism; (b) the sequence may be naturally found in a given host microorganism, but in an unnatural (e.g., greater than expected) amount; or (c) the sequence of nucleic acids comprises two or more subsequences that are not found in the same relationship to each other in nature. For example, regarding instance (c), a heterologous nucleic acid sequence that is recombinantly produced will have two or more sequences from unrelated genes arranged to make a new functional nucleic acid. Embodiments of the present invention may result from introduction of an expression vector into a host microorganism, wherein the expression vector contains a nucleic acid sequence coding for an enzyme that is, or is not, normally found in a host microorganism. With reference to the host microorganism's genome prior to the introduction of the heterologous nucleic acid sequence, then, the nucleic acid sequence that codes for the enzyme is heterologous (whether or not the heterologous nucleic acid sequence is introduced into that genome). The term “heterologous” is intended to include the term “exogenous” as the latter term is generally used in the art as well as “endogenous”.
  • As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an “expression vector” includes a single expression vector as well as a plurality of expression vectors, either the same (e.g., the same operon) or different; reference to “microorganism” includes a single microorganism as well as a plurality of microorganisms; and the like.
  • I. Introduction
  • The present invention relates to various genetically modified microorganisms, methods for making the same, and use of the same in making industrial products. Any and all of the microorganisms herein may include a combination of genetic alterations as described herein. The present invention contemplates, for example, a genetically modified microorganism having one or more of the following genetic modifications (i) an alteration that affects the stoichiometric ratio, expression or production of one or more ACCase enzyme genes (ii) a recombinant ACCase gene having at least 80% sequence homology to an ACCase gene from a salt tolerant organism (iii) a genetic alteration in one or more non-ACCase genes (iv) one or more genetic alterations that encodes for one or more exporters capable of exporting 3-HP out of a cell (v) new hybrid molecules or co-expressed of a mono-functional malonyl-CoA reductase enzyme with various 3-HP dehydrogenase proteins that: (a) exhibit less inhibition by high 3-HP concentrations (b) that is less reversible or irreversible (c) enzymes that utilized NADH (d) enzymes that utilized flavin (vi) one or more genetic alterations that can be used to switch the carbon in the standard metabolic pathways of the cells to a pathway engineered to produce a chemical. More details about each of the above modifications and how the modification are used together to increase chemical production in a host cell is described below.
  • The present invention also relates to methods of fermentation. The genetically modified microorganisms are cultured under conditions that optimized a host cell for increase chemical production. The bio-production process may include two or more of the following phases of fermentation: (1) growth phase where the culture organism replicates itself and the carbon intermediate product is built up; (2) the induction phase, where the expression of key enzymes critical to the chemical production is induced and the enzymes accumulate within the organism to carry out the engineered pathway reactions required to further produce the chemical product (3) production phase is where the organism expresses proteins that provide for continuously production the desired chemical product. The above phases are further controlled by (1) addition and amount of the initiating reactant added to the reaction vessel (2) key enzymes engineered into the organism using promoters that are sensitive to (e.g., activated by) the depletion of the initiating reactant. Addition details about the fermentation process of the invention are disclosed below.
  • II. Acetyl-CoA Carboxylase
  • Malonyl-CoA Flux
  • One of the steps in the biosynthesis of 3-HP involves the reaction catalyzed by acetyl-CoA carboxylase (ACCase) enzyme. ACCase is a primary control point in the 3-HP pathway shown in FIG. 1 (previously described in) for the converting acetyl-CoA to malonyl-CoA and hence to malonate semialdehyde and 3-HP. The present invention contemplates the use of genetic modifications that increase activity of ACCase complex enzymes to thereby increase 3-HP production in a host cell.
  • Fused Subunits
  • The acetyl-CoA carboxylase complex (ACCase) is a multi-subunit protein. Prokaryotes and plants have multi-subunit ACCs composed of several polypeptides encoded by distinct genes. However, humans and most other eukaryotes, such as yeast, have evolved an ACC with CT and BC catalytic domains and biotin carboxyl carrier domains on a single polypeptide. The biotin carboxylase (BC) activity, biotin carboxyl carrier protein (BCCP), and carboxyl transferase (CT) activity are each contained on a different subunit. In E. coli the ACCase complex is derived from multi polypeptide transcribed by distinct, separable protein components known as accA, accB, accC, and accD.
  • Acetyl-CoA carboxylase is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT). The first reaction is carried out by BC and involves the ATP-dependent carboxylation of biotin with bicarbonate. The carboxyl group is transferred from biotin to acetyl-CoA to form malonyl-CoA in the second reaction, which is catalyzed by CT. The main function of ACCase complex in the cell is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.
  • The conversion of acetyl-CoA to malonyl-CoA is an important step in the bioconversion of a renewable carbon source (such as, for example, sugar or natural gas) to a useful industrial chemical (such as, for example, 3-hydroxypropionic acid (3-HP)). In certain organisms, such as E. coli or yeast, the native ACCase expression from the chromosome alone is insufficient to enable the organism to produce chemicals such as 3-HP at a rate to support a commercial scale operation. Overexpression of the ACCase complex has been shown to provide some advantage [U.S. Ser. No. 12/891,760 U.S. Ser. No. 12/891,790 U.S. Ser. No. 13/055,138].
  • Applicants have discovered that the introduction of an acetyl-CoA carboxylase gene with one or more of its subunits fused is beneifical to the production of a chemical product in a host cell. In certain aspects of the invention, fusion is the two gene products produced from a single polypeptide controlled by a single promoter, will further enhance an organism's bioproduction of an industrial chemical. In certain aspects of the invention, fusion is the two gene products produced by at least one promoter, will further enhance an organism's bioproduction of an industrial chemical. In certain aspects of the invention, fusion is the two gene products produced from a single polypeptide controlled by at least one inducible promoter, will further enhance an organism's bioproduction of an industrial chemical. Keeping components of the ACCase complex fused together in the genetic structure of an organism can be advantageous because it enhances the stability of the non-native ACCase genetic modification and it facilitates equimolar expression of the fused acc subunits.
  • In particular, the subunit-fused ACCase may be an accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD or accA-accB-accC-accD fused subunit that have having at least 80% sequence homology to E. coli accA, accB, accC and accD or is a functional homolog thereof. In addition, the organism may include any combination of these fused subunits, or any combination of these fused subunits together with one or more of the four non-fused subunits. When such combinations are used, the subunits (fused and non-fused) may be expressed on the same plasmid or on different plasmids or on the chromosome of the organism.
  • In accordance with a preferred embodiment, an accA-accD fused subunit is introduced into an organism either alone or in combination with the accB-accC fused subunit, the accB gene, and/or the accC gene. In accordance with a preferred embodiment, the organism is a bacteria, and preferably E. coli or Cupriavidus necator.
  • Composition Stoichiometry
  • Composition stoichiometry is the quantitative relationships among elements that comprise a compound. A stoichiometric ratio of a reagent is the optimum amount or ratio where, assuming that the reaction proceeds to completion. Although stoichiometric terms are traditionally reserved for chemical compounds, theses theoretical consideration of stoichiometry are relevant when considering the optimal function of heterologous multi-subunit protein in a host cell.
  • In accordance with another aspect of the invention, the stoichiometric ratio of each of the four ACCase subunits relative to one another is important, and each such ratio can be between 0 and about 10, and preferably between about 0.5 to about 2 or about 7 to about 9. In accordance with a preferred embodiment the ratios for the protein subunits are accA:accB:accC:accD are 1:2:1:1. In accordance with a preferred embodiment, an organism is genetically modified to include an accA-accD fused subunit, an accB non-fused subunit, and an accC non-fused subunit, with the molar ratios of the accDA fusion:accB:accC being about 1:2:1, which is close to the optimum for enzymatic activity.
  • In certain embodiments where an organism is engineered to make 3-HP, in order to get optimal function in a host cell of a heterologous ACCase enzyme complex it is important to engineer the stoichiometry of these subunits in such a way that provides maximal production of 3-HP such that the subunit can make a more stable enzyme complex when overexpressed in the cell.
  • In certain aspects the invention provides for the controlled expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD. In certain aspects the invention provides for the inducible expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD. In certain aspects the invention provides for the low, medium, high and/or inducible expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD.
  • In certain aspects the invention provides for the expression of the natural accC and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accB and accA subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accC and accD subunits with the accA subunit of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accC and accD subunits with the accB subunit of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression.
  • In certain aspects the invention provides for the expression of a fusion of two, three, or all of the four ACCase subunits in one polypeptide in low, medium, high or inducible expression. Such fusion may include any of the following combinations of the ACCase subunits: accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD, and accA-accB-accC-accD have having at least 80% sequence homology to E. coli accA, accB, accC and accD or is a functional homolog thereof.
  • In certain aspects the invention provides for ACC complex in the stoichiometry of these subunits of the accCB and accDA in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for ACC complex in the stoichiometry of these subunits of the accDA and accCB in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • In certain aspects the invention provides for the stoichiometry of the accD-A subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for the stoichiometry of the accC-B subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for the stoichiometry of the accC-A subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for the stoichiometry of the accC-B subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.
  • III. Conversion of Malonyl-CoA to Malonate Semialdehyde
  • One of the steps in the biosynthesis of 3-HP involves the conversion of malonyl-CoA (MCA) to malonate semialdehyde (MSA) and the conversion of malonate semialdehyde (MSA) to 3-HP (WO2011/038364). In accordance with another aspect of the present invention, the present invention contemplates the use of novel enzymes and/or combinations of enzymes to catalyze the reaction in a microorganism from MCA to MSA, which results in enhanced cellular bioproduction of 3-HP in the host cell.
  • In certain aspects the invention provides novel enzyme compositions or co-expression of a combinations of enzyme compositions to catalyze the conversion of malonyl-CoA to 3-HP. A general overview of the enzymes and the relevant reaction pathways methods are shown in FIG. 1.
  • In accordance with this aspect of the invention, malonyl-CoA is converted to malonate semialdehyde by a malonyl-CoA reductase and malonate semialdehyde is converted to 3-HP through either or both of two alternative pathways.
  • In accordance with one aspect of the invention, malonyl-CoA is converted to malonate semialdehyde by a monofunctional malonyl-CoA reductase that catalyzes the malonyl-CoA conversion, but does not catalyze the malonate semialdehyde conversion.
  • In one embodiment, the microorganism herein comprise a genetic modification that include the monofunctional malonyl-CoA reductase may be derived from Sulfolobus tokodaii (stMCR) (SEQ ID NO. 15 nucleic acid, SEQ ID NO. 16 protein sequence) or a functional homolog of stMCR or a homolog with at least 80% identity.
  • In some embodiments, the microorganism herein comprise a genetic modification that include the bi-functional malonyl-CoA reductase comprised of two protein fragments with one fragment having malonyl-CoA reductase activity and the other fragment having malonate semialdehyde dehydrogenase activity may be derived from Chloroflexus aurantiacus (caMCR).
  • MCR-Dehydrogenase Enzymes for Conversion of 3-HP Ions
  • Following the conversion of the malonyl-CoA to malonate semialdehyde, the malonate semialdehyde is converted to 3-HP through either or both of two alternative pathways. Malonate semialdehyde may exist in at least three states; the keto form, the enol form, and hydrate form, as shown in FIG. 2. Malonate semialdehyde in the enol form, which will stabilize this form when compared to other aldehydes where the enol form is highly unfavored in the equilibrium among the three forms.
  • The malonate semialdehyde keto form is converted to 3-HP utilizing a 3-hydroxy acid dehydrogenase enzyme (ydfG SEQ ID NO. 21 nucleic acid, SEQ ID NO. 22 protein), a 3-hydroxyisobutyrate dehydrogenase enzyme (Pseudomonas aeruginosa mmsB, SEQ ID No 23 nucleic acid, SEQ ID NO. 24 protein), and/or NAD+-dependent serine dehydrogenase (Pseudomonas NDSD, SEQ ID NO. 25 nucleic acid, SEQ ID NO. 26 protein). In accordance with a preferred embodiment, Pseudomonas mmsB, Pseudomonas NDSD, and E. coli ydfG are used. The gene, ydfG from E. coli is largely NADPH dependent, whereas mmsB and NDSD from Pseudomonas can utilize either NADPH or NADH.
  • The malonate semialdehyde enol form is converted to 3-HP utilizing an N-ethylmaleimide reductase (nemA, SEQ ID NO. 17 nucleic acid, SEQ ID NO. 18 protein), and/or a malonic semialdehyde reductase (rutE, SEQ ID NO. 19 nucleic acid, SEQ ID NO. 20 protein) from E. coli. These enzymes does not directly utilize NADPH or NADH. Instead, these enzymes utilize a flavin mononucleotide that is cycled between oxidized and reduced states by NADPH or NADH. The enol pathway also has advantages over the keto pathway in that equilibrium between the malonate semialdehyde enol form and 3-HP significantly favors 3-HP, making the reaction much less reversible, and essentially irreversible.
  • The malonate semialdehyde hydrated form may also be converted to 3-HP by either the 3-HP dehydrogenase or malonate semialdehyde reductase enzymes, although the hydrated form is more likely to be converted to the enol form as the equilibrium continuously readjusts.
  • In one embodiment, the microorganism herein comprise a genetic modification that include (i.e., microorganism) includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; and (2) one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD, rutE, and nemA or a functional homolog or a homolog with at least 80% identity.
  • In accordance with another aspect of the invention, there is provided an organism that is genetically modified to make 3-HP, wherein the genetic modification includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; (2) one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP; and (3) one or more genes encoding one or more enzymes capable of converting either the malonate semialdehyde enol form or the malonate semialdehyde hydrated form to 3-HP.
  • In certain aspects the invention provides monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is either: (1) primarily not NADPH-dependent; (2) primarily NADH-dependent; (3) primarily flavin-dependent; (4) less susceptible to 3-HP inhibition at high concentration; and/or (5) catalyzes a reaction pathway to 3-HP that is substantially irreversible.
  • In certain aspects the invention also provides monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is NADPH-dependent.
  • Suitable 3-HP dehydrogenase enzymes that are largely NADH-dependent that can be used with the claimed invention include, but are not limited to, mmsB or NDSD. Suitable malonate reductase enzymes that are flavin-dependent include, but are not limited to, rutE and nemA. Suitable 3-HP dehydrogenase enzymes that are less susceptible 3-HP inhibition at high concentration that can be used with the claimed invention include, but are not limited to, ydfG and NDSD. Suitable 3-HP dehydrogenase or malonate semialdehyde dehydrogenase enzymes that catalyze a reaction pathway to 3-HP that is substantially irreversible are rutE and nemA.
  • In certain aspects the invention provides monofunctional malonyl-CoA reductase enzyme fused to one or more dehydrogenase enzymes. Malonate semialdehyde, which is the intermediate product in the conversion of malonyl-CoA to 3-HP can be very reactive. Therefore, it is advantageous to have a reaction pathway wherein the residence time of malonate semialdehyde within the cell is minimized, and its conversion to 3-HP occurs quickly. By fusing the malonyl-CoA reductase with the malonate semialdehyde dehydrogenase to create a multi-domain protein (e.g., two domain protein) and having the MCR and dehydrogenase domains adjacent in the sequence, when the themalonate semialdehyde is quicklyis quickly converted to 3-HP.
  • In certain aspects the invention provides first monofunctional malonyl-CoA reductase enzyme fused to a first dehydrogenase enzyme of one type and second monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme of a different type than the first dehydrogenase enzyme. Suitable different dehydrogenase enzymes include, but are not limited to, enzymes that function on the different forms of malonate semialdehyde.
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from S. tokadaii is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). The fused enzyme may include any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof.
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from C. aggregans is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). The fused enzyme may include any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof.
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from O. trichoides is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). The fused enzyme may include but are not limited to any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof
  • Enhanced Mutated Monofunctional MCR for Bioproduction
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that include mutated form of stMCR that has enhanced activity at about 20° C. to about 44° C., about 30° C. to about 37° C., or about 32° C. to about 38° C. Such mutate forms may be designed based on the crystal structure now available for stMCR [Demmer et al., J. Biol. Chem. 288:6363-6370, 2013].
  • It is also contemplated the carboxylase domains of the malonyl-CoA reductase derived from Chloroflexus aggregans, Oscillochloris trichoides can be enhanced by mutations in the carboxylase binding domain to provide increased 3-HP production over the natural occurring enzyme.
  • The carboxylase activity of the malonyl-CoA reductase derived from Chloroflexus aurantiacus can be enhanced activity. In certain aspects the invention provides for mutated form of it carboxylase domain to provide increased 3-HP production over the natural occurring enzyme.
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that include carboxylase domains of the malonyl-CoA reductase derived from C. aggregans is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). It is contemplated that the any of the enhanced MCR by mutation, as provide above, may be fused in any of the following configurations including but not limited to mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof
  • IV. Salt-Tolerant Enzymes
  • The growth of engineered microorganism for enhanced production of a chemical product, such as E. coli is severely inhibited by high salt concentrations accumulated when the chemical product is produced at high rate within the organism.
  • Dose-dependent studies with increasing amounts of NaCl and Na-3-HP show that salt has inhibitory effects on ACCase activity which is essential to fatty acid biosynthesis of membranes required for growth and propagation and for the production of 3-HP (see EXAMPLE 1). Thus, the use of salt-tolerant enzymes in 3-HP production should increase 3-HP production in a host cell.
  • A. Enzymes from Halophilic Organisms
  • Halophiles are characterized as organisms with a great affinity for salt. In some instances a halophilic organism is one that requires at least 0.05M, 0.1M, 0.2M, 0.3M or 0.4M concentrations of salt (NaCl) for growth. Halophiles live in hypersaline environments that are generally defined occurring to their salt concentration of their habitats. Halophilic organisms that are defined as “Slight salt affinity” have optimal growth at 2-5% NaCl, moderate halophiles have optimal growth at 5-20% NaCl and extreme halophiles have optimal growth at 20-30% NaCl.
  • Depending on the conditions of that the genetically engineered microorganism is under one might use homologous enzymes of the invention specifically, for example, from a moderate halophiles or an extreme halophiles depending on the engineered cell's environment.
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that includes enzymes of the invention provided herein from slight halophiles organisms. In certain aspects the invention provides for microorganisms comprising a genetic modification that includes enzymes of the invention provided herein from moderate halophiles organisms. In certain aspects the invention provides for microorganisms comprising a genetic modification that includes homologous enzymes of the invention provided herein from extreme halophiles organisms.
  • Homology with genes provided by the invention may be determined by analysis with BLASTN version 2.0 provided through the NCBI website. Homology with proteins provided by the invention may be determined by analysis with BLASTP version 2.2.2 provided through the NCBI website. This program with aligns the disclosed fragments being compared and determines the extent of identity or similarity between them.
  • To date there are many sequenced halophilic organisms which can be used with the claimed invention. Examples of some sequenced halophilic organisms include but are not limited to Chromohalobacter salexigens, Flexistipes sinusarabici strain (MAS10T), Halobacterium sp. NRC-1, Haloarcula marismortui, Natronomonas pharaonis, Haloquadratum walsbyi, Haloferax volcanii, Halorubrum lacusprofundi, Halobacterium sp. R-1, Halomicrobium mukohataei, Halorhabdus utahensis, Halogeometricum borinquense, Haloterrigena turkmenica, Natronobacterium gregoryi SP2, Halalkalicoccus jeotgali, Natrialba magadii, Haloarcula hispanica, Halopiger xanaduensis, Halophilic archaeon DL31, Haloferax mediterranei, Halovivax Tuber, Natronococcus gregoryi, and Natronococcus occultus.
  • Examples of suitable moderate halophilic organisms in which homologous enzymes of the invention can be derived from include but are not limited to eukaryotes such as crustaceans (e.g. Artemia salina), insects (e.g. Ephydra hians), certain plants from the genera Salicornia spp, algae (e.g. Dunaliella viridis), fungi, and protozoa (e.g. Fabrea salina), phototrophic organisms, such as planktonic and microbial mat-formers cyanobacteria as well as other anaerobic red and green sulphur bacteria from the genera Ectothiorhodospira spp.) and non-sulphur bacteria from the genera Chromatium spp.; gram-negative anaerobic bacteria, for example from the genera Haloanaerobacter spp. some of which are methanogenic, for example from the genera Methanohalophilus spp. and either aerobic or facultative such as species from the genera Halomonas, Chromohalobacter, Salinovibrio, Pseudomonas, for example (e.g. Halomonase elongate); gram-positive bacteria from genera such as Halobacillus, Bacillus, Marinococcus, etc. as well as some actinomycetes, for example, Actinopolyspora halophila.
  • Genomic and Proteomic Hallmarks of Halophilic Organisms
  • Comparative genomic and proteomic studies of halophiles and non-halophiles reveal some common trends in the genomes and proteomes of halophiles. At the protein level, halophilic organisms are characterized by low hydrophobicity, over-representation of acidic residues, especially Asp, under-representation of Cys, lower propensities for helix formation and higher propensities for coil structure.
  • At the DNA level, halophilic organisms are characterized by the dinucleotide abundance profiles of halophilic genomes bear some common characteristics, which are quite distinct from those of non-halophiles, and hence may be regarded as specific genomic signatures for salt-adaptation. The synonymous codon usage in halophiles also exhibits similar patterns regardless of their long-term evolutionary history.
  • In certain aspects the invention provides for microorganisms comprising a genetic modification that the proteins provided by the invention that are modified for salt tolerance such that they has low hydrophobicity, over-representation of acidic residues, especially Asp, under-representation of Cys, lower propensities for helix formation and higher propensities for coil structure.
  • Suitable salt-tolerant enzymes can include enzymes from salt-tolerant organisms. Salt-tolerant organisms (such as, for example, halophiles) include any living organism that are adapted to living in conditions of high salinity. Suitable salt-tolerant enzymes can include enzymes from salt-tolerant organism that are homologs of the following enzymes: Sucrose-6-phosphate hydrolase (cscA from E. coli), glucose-6-phosphate isomerase (pgi from E. coli), fructokinase (cscK from E. coli), fructose-1,6-bisphosphatase (yggF from E. coli), fructose 1,6-bisphosphatase (ybhA from E. coli), fructose 1,6-bisphosphatase II (glpX from E. coli), fructose-1,6-bisphosphatase monomer (fbp from E. coli), 6-phosphofructokinase-1 monomer (pfkA from E. coli), 6-phosphofructokinase-2 monomer (pfkB from E. coli), fructose bisphosphate aldolase monomer (fbaB from E. coli), fructose bisphosphate aldolase monomer (fbaA from E. coli), triose phosphate isomerase monomer (tpiA), glyceraldehyde 3-phosphate dehydrogenase-A monomer (gapA from E. coli), phosphoglycerate kinase (pgk), 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (gpmM from E. coli), 2,3-bisphosphoglycerate-dependent or tdcE (from E. coli), phosphoglycerate mutase (gpmA), enolase (eno from E. coli), phosphoenolpyruvate carboxylase (ppc from E. coli), malate dehydrogenase (mdh), fumarase A (fum from E. coli), fumarase B (fumB), fumarase C (fumC from E. coli), phosphoenolpyruvate synthetase (ppsA from E. coli), pyruvate kinase I monomer (pykF from E. coli), pyruvate kinase II monomer (pykA from E. coli), fumarate reductase (frdABCD from E. coli), lipoamide dehydrogenase (lpd from E. coli), pyruvate dehydrogenase (aceE from E. coli), pyruvate dehydrogenase (aceF from E. coli), pyruvate formate-lyase (pflB from E. coli), acetyl-CoA carboxylase (accABCD from E. coli), malonyl CoA reductase (mcr), 3HP dehydrogenase (mmsB, NDSD, or ydfG), malonate semialdehyde reductase (nemA, rutE from E. coli), or a combination thereof.
  • Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%, overall amino acid or nucleotide identity to the above enzymes. Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90% 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%, amino acid or nucleotide to the essential protein function domains of the enzymes above. Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential protein function domain of the enzymes above.
  • In accordance with a preferred embodiment of the invention, suitable salt-tolerant enzyme homologs are enzymes from one of the following organisms: Halomonas elongata, Salinibacter rubur, or Halobacterium species (Archaea).
  • In accordance with a preferred embodiment of the present invention, there is provided a non-salt-tolerant organism that is genetically modified to make 3-HP, wherein the genetic modification includes a polynucleotide encoding an acetyl-CoA carboxylase from a salt-tolerant organism. In accordance with a preferred embodiment, the acetyl-CoA carboxylase subunits accA, accB, accC and accD is from Halomonas elongata.
  • V. Chemical Transporter
  • In accordance with another aspect of the present invention, any of the microorganisms herein may be genetically modified to introduce a nucleic acid sequence coding for a polypeptide that: (1) facilitates the exportation of the chemical of interest or the export of an inhibitory chemical from within the cell to the extracellular media; and/or (2) facilitates the importation from the extracellular media to within the cell of a reactant, precursor, and/or metabolite used in the organism's production pathway for producing the chemical of interest.
  • 3-HP Exporter
  • In accordance with a preferred embodiment, this invention relates to the bioproduction of 3-HP using a genetically modified E. coli organism. Thus, the present invention contemplates of a host cell genetically modified to express or increase expression of an exporter that can function to transfer 3 HP from the cellular environment extracellularly.
  • Bacterial cells, such as E. coli, have at least five different types of exporters: the major facilitator superfamily (MFS); the ATP-binding cassette superfamily (ABC); the small multidrug resistance family (SMR); the resistance-nodulation-cell division superfamily (RND); and the multi antimicrobial extrusion protein family (MATE). In addition, amino acid exporters, which are common to almost all host cells, are likely to export 3-HP. Additionally, solvent tolerance transporters, for example bromoacetate, butanol, isobutanol and the alike may be used to export 3-HP.
  • In certain aspects the invention provides a host cell with a recombinant exporter wherein the exporter is an MFS exporter, ABC exporter, SMR exporter, RND exporter, MATE exporter, amino acid exporter, solvent tolerance transporter or a combination thereof
  • Suitable exporters that can be used with the s herein invention include but are not limited to acrD, bcr, cusA, dedA, eamA, eamB, eamH, emaA, emaB, emrB, emrD, emrKY, emrY, garP, gudP, hsrA, leuE, mdlB, mdtD, mdtG, mdtL, mdtM, mhpT, rhtA, rhtB, rhtC, thtB, yahN, yajR, ybbP, ybiF, ybjJ, ycaP, ydcO, yddG, ydeD, ydgE, yddG, ydhC, ydhP, ydiN, ydiM, ydjE, ydjI, ydjK, yeaS, yedA, yeeO, yegH, yggA, yfcJ, yfiK, yhjE, yidE, yigK, yigJ, yijE, yjil, yjiJ, yjiO, ykgH, ypjD, ytfF, ytfL or functional homolog or homolog with 80% sequence identity thereof. Other potential transporter proteins may be identified using topology analysis as illustrated in [Daley et al., Science 308: 1321-1323, 2005].
  • In certain aspects the invention provides the exporter to be improved for binding to 3-HP. In certain aspects the invention provides the exporters named to be further enhance by genetic modification of the predicted cytoplasmic domain to increase 3-HP binding. In certain aspects the invention provides the exporter to be improved for binding to 3-HP. In certain aspects the invention provides the exporters named to be further enhance by genetic modification of the predicted transmembrane binding domain to increase 3-HP binding or incorporation into the host cell membrane.
  • Suitable exporter homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide identity to the above exporters. Suitable exporter homologs that can be used with the claimed invention can have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% amino acid or nucleotide to the essential protein function domains of the exporters above. Suitable exporter homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential exporter domain of the enzymes above.
  • In certain aspects the invention provides for at least of the exporters provided herein to be expressed in a host cell to increase the chemical production of 3-HP in a host cell. In certain aspects the invention provides for at least of the exporters provided herein to be expressed in a host cell and with a genetic modification of tig to increase the chemical production of 3-HP in a host cell.
  • In certain aspects the invention provides for one exporter to be further modified by on one more genetic modulates so that the expression level and timing of expression of the exporter can be controlled in the host cell. In certain aspects the invention provides for one exporter to be further modified by an inducible promoter, RBS, high, mutlicopy plasmid or combination thereof, as provide herein, in order to control its expression in the host cell.
  • In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:2 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:3 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:4 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 2:3 ratio.
  • In certain aspects the invention provides for the exporter to maintain the host cell at pH 7.0-7.4 during the continuous production phase. In certain aspects the invention provides for the exporter and the means for importing a base inside the cell in order to maintain the host cell at pH 7.0-7.4 during the continuous production phase. In certain aspects the invention provides for the exporter maintain the host cell at pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0 pH 7.0-7.3 during the continuous production phase. In certain aspects the invention provides for the exporter and the means for importing a base inside the cell in order to maintain the host cell at pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0 pH 7.0-7.3 during the continuous production phase.
  • In accordance with this aspect of the present invention, addition modifications to the host cell may be made to further enhance the transporter's function. In particular, deletion of the tig gene from the genome of the host cell may enhance expression and total activity of integral membrane proteins such as exporters and importers.
  • Bicarbonate Importer
  • One of the key steps in the conversion of biomass to 3-HP is the conversion of acetyl-CoA to malonyl-CoA, which is illustrated in FIG. 3.
  • As shown in FIG. 3, this reaction is catalyzed by the acetyl-CoA carboxylase, and bicarbonate is a reactant needed to drive the reaction. One of the primary sources of bicarbonate to drive this reaction is carbon dioxide within the cell. Carbon dioxide is readily diffusible through a cell's membrane, and a natural equilibrium will be reached between the intracellular and extracellular carbon dioxide. As a cell produces carbon dioxide it migrates through the cell, and since it is not very soluble in the media, it will bubble out of the system and more intracellular carbon dioxide will migrate out of the cell to maintain the equilibrium. This process impedes the production of 3-HP since bicarbonate (which is in equilibrium with the dissolved carbon dioxide in the form of carbonic acid) is needed to drive the acetyl-CoA→malonyl-CoA reaction, and the intracellular carbon dioxide is the primary source for intracellular bicarbonate.
  • In accordance with one aspect of the present invention, an organism is provided that includes a heterologous gene encoded therein that acts as a carbon dioxide importer (i.e., it enhances the importation of carbon dioxide into the cell or inhibits the exportation of carbon dioxide from the cell), which results in increased intracellular carbon dioxide. Use of CO2 an importer mitigates against the natural outflow of carbon dioxide.
  • In accordance with this aspect of the invention, there is provided an organism that is genetically modified, wherein the genetic modification includes a polynucleotide encoding a gene capable of importing extracellular carbon dioxide from the media to within the cell membrane or inhibiting the exportation of intracellular carbon dioxide from within the cell membrane to the media. In accordance with a preferred embodiment of the present invention, a microorganism is genetically modified to encode one or more of the following heterologous genes: bicA from Synechococcus species, ychM gene product of E. coli, yidE gene product of E. coli, any of the bicarbonate transporters as described in [Felce and Saier, J. Mol. Microbiol. Biotechnol. 8: 169-176, 2004 or any amino acid sequences homologous thereof (e.g., at least 80%, 85%, 90%, 95%, or 99% homologous to the amino acids sequences of the CO2 importer/exporters described herein].
  • Bioproduction Methods
  • In some applications of the invention the host cell is genetically modified for increased malonyl-CoA flux by at least one heterologous ACCase complex, such as Table 4 to further increase chemical bio-production in host cell. In some applications of the invention the host cell is genetically modified with heterologous salt tolerant enzymes, such as Table 5 to increase chemical bio-production in a host cell. In some applications of the invention the host cell is genetically modified with heterologous 3-HP exporters to further increase chemical bio-production in a host cell.
  • In some applications of the invention the host cell is genetically modified by at least one heterologous gene and/or salt tolerant heterologous gene of FIG. 1 or Table 5 and at least one 3-HP exporter provided herein to further increase chemical bioproduction in a host cell.
  • In some applications of the invention the host cell is genetically modified with a heterologous gene for increased malonyl-CoA flux, 3-HP export, at least one heterologous and/or salt tolerant heterologous gene, as provided herein, to increase chemical bio-production in a host cell. In some applications of the invention the host cell is genetically modified for increased malonyl-CoA flux, 3-HP export, at least one heterologous gene and/or salt tolerant heterologous gene and the host cell is genetically modified by at least one gene, as provided herein to increase chemical bioproduction in a host cell.
  • When utilizing certain organisms to create certain products, it may be advantageous to control each phase discretely. For example, depending on the pathway involved, reactions, reactants, intermediates and byproducts created during cell growth can inhibit enzyme induction and/or the organism's ability to produce the desired chemical product. Similarly, reactions, reactants, intermediates and byproducts created as part of the production pathway can impact cell growth, and even the increased concentration of the chemical product as it is produced can impede cell replication.
  • Table. 5
  • VI. Multi-Phase Fermentation
  • In accordance with another aspect of the present invention, there is provided a method of producing a chemical product from a carbon source through a bioproduction process that comprises a controlled multi-phase production process. The multi-phase production process includes an initiation and/or completion of one or more phases of the production process is controlled by genetic modifications to the organism producing the chemical product and/or is controlled by changes made to the cell environment.
  • In accordance with this aspect of the invention, the bioproduction process may include two or more of the following phases: (1) growth phase; (2) induction phase; and (3) production phase. During the growth phase, the organism replicates itself and the biocatalyst needed to produce the chemical product is built up. During the induction phase, expression of key enzymes critical to the production of the chemical is induced and the enzymes accumulate within the biocatalyst to carry out the reactions required to produce the product. During the production phase organism produces the desired chemical product.
  • The initiation and/or completion of the growth, induction and/or production phases are controlled. In accordance with the present invention, the growth phase is dependent on the presence of a critical external reactant that will initiate growth. The initiation and completion of the growth phase is controlled by the addition and amount of the initiating reactant added to the reaction vessel.
  • In accordance with certain preferred embodiments of the present invention, the chemical product is 3-HP and the production organism is E. coli or yeast. The critical external reactant may be phosphate, which is needed for replication of E. coli cells. In accordance with a preferred embodiment, the growth phase is initiated by the addition of phosphate to a reaction vessel (together with a carbon source such as sugar and the E. coli cells), and the duration of the growth phase is controlled by the amount of phosphate added to the system.
  • The induction phase is controlled by genetic modifications to the producing organism. The key enzymes triggered during this phase are engineered into the organism using promoters that are sensitive to (e.g., activated by) the depletion of the initiating reactant. As a result, once the initiating reactant is depleted, the growth phase ends, the key enzymes are activated and the induction phase begins.
  • In accordance with a preferred embodiment, the induction phase is controlled by key genes that encode for enzymes in the biosynthetic pathway for the product into the production organism using promoters that are activated by phosphate depletion. In one embodiment where the chemical product is 3-HP and the production organism is E. coli, the key genetic modifications may include one or more of the following: mcr, mmsB, ydfG, rutE, nemA and NDSD; genes that encode individual or fused subunits of ACCase, such as accA, accB, accC, accD, accDA fusion, and accCB fusion, and the promoters may include one or more of the promoters that direct expression of the following E. coli genes: amn, tktB, xasA, yibD, ytfK, pstS, phoH, phnC, or other phosphate-regulated genes as described in [Baek and Lee, FEMS Microbiol Lett 264: 104-109, 2006]. In accordance with this embodiment, once the phosphate is depleted, expression of the key enzymes is activated by their promoters and the induction phase begins.
  • The production phase may also be controlled by genetic modifications. For example, the organism can be engineered to included mutated forms of enzymes critical to the initiation of production of the chemical product. These initiation enzymes may facilitate initiation of production either by: (1) becoming active and serving a key function in the production pathway; and/or (2) becoming inactive and thereby turning off a branch pathway or other competitive pathway that prevents or limits the production pathway leading to the chemical product. In accordance with a preferred embodiment, initiation enzymes are mutated to form temperature sensitive variants of the enzymes that are either activated by or deactivated at certain temperatures. As a result, the production phase is initiated by changing the changing the temperature within the reaction vessel.
  • In one embodiment, the production phase is controlled by genetically modifying the microorganism with a heterologous nucleotide sequence encoding i one or more of the following temperature sensitive enzymes: fablts (SEQ ID NO. 27), fabBts (SEQ ID NO. 28) and fabDts (SEQ ID NO. 29). These enzymes are deactivated or shut-off at the desired temperature for production of the chemical product. These enzymes play a key role shuttling carbon atoms into the fatty acid synthesis pathway. Although fatty acid synthesis pathway is critical during the growth phase, it inhibits production of the chemical product. Once the reaction vessel temperature is changed, the temperature sensitive enzymes are deactivated and the fatty acid synthesis pathway shuts down thereby allowing the production pathway of the chemical product to ramp up.
  • In accordance with the present invention, the growth phase can last be between 10 to 40 hours, or about 15 to about 35 hours, or about 20 to about 30 hours. The induction phase may be for about 1 to about 6 hours, about 1 to about 5 hours, or about 2 to about 4 hours. The production phase may be greater than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 hours depending on the amount of chemical product that is desired.
  • In accordance with the present invention, the growth phase and induction phase are conducted at a temperature of about 25° C. to about 35° C., about 28° C. to about 32° C., or about 30° C. The production phase is conducted at a temperature of about 35° C. to about 45° C., about 35° C. to about 40° C., or about 36° C. to about 38° C. Preferably, the production phase temperature is higher than the induction phase temperature, and the increase in temperature that initiates the production phase occurs over a period of about 1 to about 5 hours, about 1 to about 3 hours, about 2 hours, or about 1 hour.
  • In accordance with the present invention, there is provided a method of producing a chemical product from a renewable carbon source through a bioproduction process comprising:
      • (1) constructing a genetically modified organism capable of converting said renewable carbon source to said chemical product, wherein said genetically modified organism requires inorganic phosphate for growth and comprises: (a) at least one heterologous gene whose expression is regulated by a promoter sensitive to inorganic phosphate levels within a culture system, wherein said gene provides a critical function in converting said carbon source to said chemical product and is not required for the genetically modified organism to replicate; and (b) a gene encoding a temperature-sensitive enzyme;
      • (2) forming a culture system comprising said carbon source in an aqueous medium and said genetically modified microorganism;
      • (3) maintaining the culture system under conditions that allow the genetically modified microorganism to replicate comprising maintaining a sufficient level of inorganic phosphate within said culture system;
      • (4) allowing the inorganic phosphate to deplete thereby triggering the expression of the gene regulated by a promoter sensitive to inorganic phosphate levels; and
      • (5) changing the temperature of the culture system thereby activating or deactivating said temperature-sensitive enzyme and initiating the production of said chemical product.
  • In accordance with the present invention, there is provided a method of producing 3-hydropropionic acid (3-HP) from a renewable carbon source, comprising:
      • (1) constructing a genetically modified organism capable of converting said renewable carbon source to 3-HP, wherein said genetically modified organism requires inorganic phosphate for growth and comprises: (a) at least one heterologous gene whose expression is regulated by a promoter sensitive to inorganic phosphate levels within a culture system, wherein said gene is selected from the group consisting of mcr, mmsB, ydfG, rutE, nemA, NDSD, accA, accB, accC, accD, accDA fusion, and accCB fusion; and (b) a gene encoding a temperature-sensitive enzyme selected from the group consisting of fabl, fabB and fabD;
      • (2) forming a culture system comprising said carbon source in an aqueous medium, phosphate and said genetically modified microorganism, and thereby initiating a growth phase during which the genetically modified microorganism replicates;
      • (3) maintaining a sufficient level of inorganic phosphate within said culture system until the desired level of cell growth is achieved;
      • (4) allowing the inorganic phosphate to deplete thereby initiating an induction phase which begins the expression of said gene regulated by a promoter sensitive to inorganic phosphate levels; and
      • (5) changing the temperature of the culture system thereby activating or deactivating said temperature-sensitive enzyme and initiating a growth phase during which said genetically modified microorganism produces 3-HP.
    Fermentation Conditions
  • Depending on the host cell fermentation may be performed under aerobic, microaerobic, or anaerobic conditions, with or without agitation. The operation of culture systems to achieve aerobic, microaerobic and anaerobic conditions are well known to those of ordinary skill in the art.
  • Suitable pH ranges for fermentation depend on the multiple factors such as the host cell. In some applications of the invention fermentation can occur between various pH ranges for example, pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0. However, the actual pH conditions for a particular application are not meant to be limited by these ranges and can be between the expressed pH ranges if it provides more optimal production of the fermentation process, such as increased 3-HP production.
  • VII. Genes and Proteins for the Bioproduction of Chemicals
  • An overview of the engineered pathways provided by the invention in a host cell is shown in FIG. 1. Various combinations of the pathways shown can be carried out by various combinations of genetic modifications to key enzymes either in the intrinsic pathways or supplied through the transformation of a heterologous gene.
  • In some applications of the genetically modified microorganism of the invention may comprise a single genetic modification, or one or more genetic modifications. Various types of genetic modifications that can be used with the invention are disclosed herein.
  • In some embodiments the genetic modified organism of the invention can comprise a genetic modification to the following gene/proteins or a homolog with at least 80% identity to or a functional homolog of: bifunctional malonyl-CoA reductase (MCR from Chloroflexus aurantiacus), monofunctional malonyl-CoA reductase (caMCR from Chloroflexus aurantiacus), malonyl-CoA reductase (stMCR from Sulfolobus tokodaii.), Enzyme: malonyl-CoA reductase (cgMCR from Chloroflexus aggregans), Enzyme: malonyl-CoA reductase (otMCR from Oscillochloris trichoides), Polypeptide: host restriction; endonuclease R (hsdR from E. coli), lactose metabolism (lac from E. coli), L-rhamnulose kinase (rhaB from E. coli), rhamnulose-1-phosphate aldolase (rhaD from E. coli), Enzyme: β-galactosidase (lacZ from E. coli), L-ribulose 5-phosphate 4-epimerase (araD from E. coli), L-ribulokinase (araB from E. coli), Enzyme: D-lactate dehydrogenase-fermentative (ldhA from E. coli), enzyme: pyruvate formate-lyase (pflB from E. coli), Enzyme: phosphate acetyltransferase/phosphate propionyltransferase (pta from E. coli), Enzyme: pyruvate oxidase (poxB from E. coli), Enzyme: methylglyoxal synthase (mgsA from E. coli), enzyme: Acetate kinase (ackA from E. coli), enzymes: phosphotransacetylase-acetate kinase (pta-ack from E. coli), Enzyme: enoyl-[acyl-carrier-protein] reductase (fabl from E. coli), Protein: zeocin binding protein (zeoR from Streptoalloteichus Hindustanus), Enzyme: carboxytransferase moiety of acetyl-CoA carboxylase (accAD from E. coli), Enzyme: triose phosphate isomerase (tpiA from E. coli), Enzyme: biotoin carboxylase moiety of acetyl-CoA carboxylase (accBC from E. coli), Enzyme: transhydrogenase (pntAB from E. coli), Polypeptide: Lad DNA-binding transcriptional repressor (lad from E. coli), Enzyme: f3-ketoacyl-ACP synthases I (fabB from E. coli), Enzyme: f3-ketoacyl-ACP synthases II (fabF from E. coli), Enzyme: malonyl-CoA-ACP transacylase (fabD from E. coli), Enzyme: pantothenate kinase (coaA from E. coli), Enzyme: pyruvate dehydrogenase complex (aceEF from E. coli), Enzyme: 3-hydroxyisobutyrate/3-HP dehydrogenase (mmsB from Pseudomonas aeruginosa), Enzyme: lipoamide dehydrogenase (lpd from E. coli), Enzyme: γ-glutamyl-γ-aminobutyraldehyde dehydrogenase (puuC from E. coli), Enzyme: malate synthase A (aceB from E. coli), Enzyme: isocitrate lyase (aceA from E. coli), Enzyme: isocitrate dehydrogenase phosphatase/kinase (aceK from E. coli), Enzyme: 3-hydroxy acid dehydrogenase (ydfG from E. coli), Enzyme: acetyl CoA carboxylase (accADBC from E. coli), Polypeptide: predicted transcriptional regulator (yieP from E. coli), Blastocyin resistance gene (BSD from Schizosaccharomyces pombe), Enzyme: pyridine nucleotide transhydrogenase (udha from E. coli), Protein: Cra DNA-binding transcriptional dual regulator (fruR from E. coli), (SCB from E. coli), enzyme: aldehyde dehydrogenase B (aldB from E. coli), Enzyme: carbonic anhydrase (cynT from E. coli), Enzyme: cyanase (cynS from E. coli), DNA gyrase toxin-antitoxin system (ccdAB from E. coli), Enzyme: phosphoglycerate mutase (pgi from E. coli), ArcA transcriptional dual regulator or Aerobic respiration control (arcA from E. coli), Enzyme: 6-phosphofructokinase (pfk from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase-A complex (gapA from E. coli), aldehyde dehydrogenase A (alda from E. coli), Enzyme: glutamate dehydrogenase (gdhA from E. coli), Enzyme: NADH-dependent serine dehydrogenase (NDSD from Pseudomonas aeruginosa), Protein: threonine/homoserine efflux transporter (rhtA from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase (gapN from E. coli), Phosphotransferase system (pts from E. coli), Enzyme: 6-phosphofructokinase II (pfkB from E. coli), Enzyme: methylmalonate-semialdehyde dehydrogenase (mmsA from Pseudomonas aeruginosa), Oxaloacetate:beta-alanine aminotransferase (OAT-1 from Bacillus cereus), Enzyme: aspartate 1-decarboxylase (panD from E. coli), Gene that confers resistance to valine (ValR from E. coli), Enzyme: glucokinase (glk from E. coli), Polypeptide: 30 S ribosomal sununit protein S12 (rpsL from E. coli), Polypeptide: CynR DNA-binding transcriptional repressor (cynR from E. coli), Transporter: galactose:H+ symporter (galP from E. coli), aspartate aminotransferase (aspC from E. coli), Enzyme: alpha-ketoglutarate reductase (serA from E. coli), Enzyme: 6-phosphofructokinase I (pfkA from E. coli), Enzyme: phosphoenolpyruvate carboxylase (ppc from E. coli), Enzyme: succinate-semialdehyde dehydrogenase (NADP+) (gabD from E. coli), Enzyme: pyruvate kinase (pyk from E. coli), Enzyme: oxaloacetate 4-decarboxylase (OAD from Leuconostoc mesenteroides), Enzyme: trigger factor; a molecular chaperone involved in cell division (tig from E. coli), Transcription Unit (ptsHlcrr from E. coli), Enzyme: acetyl-CoA acetaldehyde dehydrogenase/alcohol dehydrogenase (adhE from E. coli), Enzyme: fattyacyl thioesterase I (tesA from E. coli), Enzyme: guanosine 3′-diphosphate 5′-triphosphate 3′-diphosphatase (spoT from E. coli), combination of genes encoding accABCD subunits (from E. coli and Halomonas elongata), pol (from E. coli), Enzyme: GDP pyrophosphokinase/GTP pyrophosphokinase (relA from E. coli), [Enzyme Name] (me from E. coli), Enzyme: citrate synthase (gltA from E. coli), Polypeptide: DNA gyrase, subunit A (gyrA from E. coli), Enzyme: multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxyglutarate aldolase and oxaloacetate decarboxylase (eda from E. coli), thiamin biosynthesis (thi from E. coli), Polypeptide: acetolactate synthase II (ilvG from E. coli), acetyl CoA carboxylase (accDACB from E. coli), Citrate synthase (ArCS from Arthrobacter aurescens), Acetyl-CoA carboxylase from Corynebacter glutamicum (CgACC from Corynebacter glutamicum), Polypeptide: ferrichrome/phage/antibiotic outer membrane porin FhuA (fhuA from E. coli), Transporter: phosphate:H+ symporter PitA (pitA from E. coli), Transporter: uracil:H+ symporter (uraA from E. coli), Enzyme: uracil phosphoribosyltransferase (upp from E. coli), Enzyme: acylphosphatase (yccX from E. coli), acetyl-CoA synthetase (acsA from E. coli), Polypeptide: restriction of methylated adenine (mrr from E. coli), Protein: TrpR transcriptional repressor (trpR from E. coli), Enzymes: glutamate 5-semialdehyde dehydrogenase/gamma-glutamyl kinase (proAB from E. coli), methylcytosine restriction system (mcrBC from E. coli), Protein: citrate lyase, citrate-ACP transferase component (citF from E. coli), Enzyme: thioesterase II (tesB from E. coli), Enzyme: DNA-specific endonuclease I (endA from E. coli), Enzyme: phosphate acetyltransferase (eutD from E. coli), Enzyme: propionate kinase (tdcD from E. coli), tRNA: tRNA glnV (supE from E. coli), Enzyme: DNA-binding, ATP-dependent protease La (lon from E. coli), Polypeptide: DNA strand exchange and recombination protein with protease and nuclease activity (recA from E. coli), Transcription Unit: restriction endonulease component of EcoKI restriction-modification system (hsdRMS from E. coli), Enzyme: restriction of DNA at 5-methylcytosine residues (mcrA from E. coli) araD (from E. coli), araB (from E. coli), rhaD (from E. coli), rhaB (from E. coli), ack (from E. coli), fruR (from E. coli), gapA (from E. coli), lad (from E. coli), lacZ (from E. coli), ldhA (from E. coli), mgsA (from E. coli), pfkA (from E. coli), pflB (from E. coli), pgi (from E. coli), poxB (from E. coli), pta-ack (from E. coli), ptsH (from E. coli), glut1 (from E. coli) and/or ack (from E. coli) or any combination thereof.
  • The use of genetic modifications in genetic elements, genes, proteins or the use of compounds, such as siRNA technology, anti-sense technology, and small molecule inhibitors supplied to the host cell that modulate the expression of gene and proteins provided by the present invention are also contemplated.
  • In some embodiments the genetic modified organism of the invention uses genetic elements such as siRNA ect, genes, proteins or compounds supplied to the host cell to modulate one or more of the following: bifunctional malonyl-CoA reductase (MCR from Chloroflexus aurantiacus), monofunctional malonyl-CoA reductase (caMCR from Chloroflexus aurantiacus),malonyl-CoA reductase (stMCR from Sulfolobus tokodaii.), Enzyme: malonyl-CoA reductase (cgMCR from Chloroflexus aggregans), Enzyme: malonyl-CoA reductase (otMCR from Oscillochloris trichoides), Polypeptide: host restriction; endonuclease R (hsdR from E. coli), lactose metabolism (lac from E. coli), L-rhamnulose kinase (rhaB from E. coli), rhamnulose-1-phosphate aldolase (rhaD from E. coli), Enzyme: β-galactosidase (lacZ from E. coli), L-ribulose 5-phosphate 4-epimerase (araD from E. coli), L-ribulokinase (araB from E. coli), Enzyme: D-lactate dehydrogenase-fermentative (ldhA from E. coli), enzyme: pyruvate formate-lyase (pflB from E. coli), Enzyme: phosphate acetyltransferase/phosphate propionyltransferase (pta from E. coli), Enzyme: pyruvate oxidase (poxB from E. coli), Enzyme: methylglyoxal synthase (mgsA from E. coli), enzyme: Acetate kinase (ackA from E. coli), enzymes: phosphotransacetylase-acetate kinase (pta-ack from E. coli), Enzyme: enoyl-[acyl-carrier-protein] reductase (fabl from E. coli), Protein: zeocin binding protein (zeoR from Streptoalloteichus Hindustanus), Enzyme: carboxytransferase moiety of acetyl-CoA carboxylase (accAD from E. coli), Enzyme: triose phosphate isomerase (tpiA from E. coli), Enzyme: biotoin carboxylase moiety of acetyl-CoA carboxylase (accBC from E. coli), Enzyme: transhydrogenase (pntAB from E. coli), Polypeptide: Lad DNA-binding transcriptional repressor (lad from E. coli), Enzyme: f3-ketoacyl-ACP synthases I (fabB from E. coli), Enzyme: f3-ketoacyl-ACP synthases II (fabF from E. coli), Enzyme: malonyl-CoA-ACP transacylase (fabD from E. coli), Enzyme: pantothenate kinase (coaA from E. coli), Enzyme: pyruvate dehydrogenase complex (aceEF from E. coli), Enzyme: 3-hydroxyisobutyrate/3-HP dehydrogenase (mmsB from Pseudomonas aeruginosa), Enzyme: lipoamide dehydrogenase (lpd from E. coli), Enzyme: γ-glutamyl-γ-aminobutyraldehyde dehydrogenase (puuC from E. coli), Enzyme: malate synthase A (aceB from E. coli), Enzyme: isocitrate lyase (aceA from E. coli), Enzyme: isocitrate dehydrogenase phosphatase/kinase (aceK from E. coli), Enzyme: 3-hydroxy acid dehydrogenase (ydfG from E. coli), Enzyme: acetyl CoA carboxylase (accADBC from E. coli), Polypeptide: predicted transcriptional regulator (yieP from E. coli), Blastocyin resistance gene (BSD from Schizosaccharomyces pombe), Enzyme: pyridine nucleotide transhydrogenase (udha from E. coli), Protein: Cra DNA-binding transcriptional dual regulator (fruR from E. coli), (SCB from E. coli), enzyme: aldehyde dehydrogenase B (aldB from E. coli), Enzyme: carbonic anhydrase (cynT from E. coli), Enzyme: cyanase (cynS from E. coli), DNA gyrase toxin-antitoxin system (ccdAB from E. coli), Enzyme: phosphoglycerate mutase (pgi from E. coli), ArcA transcriptional dual regulator or Aerobic respiration control (arcA from E. coli), Enzyme: 6-phosphofructokinase (pfk from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase-A complex (gapA from E. coli), aldehyde dehydrogenase A (alda from E. coli), Enzyme: glutamate dehydrogenase (gdhA from E. coli), Enzyme: NADH-dependent serine dehydrogenase (NDSD from Pseudomonas aeruginosa), Protein: threonine/homoserine efflux transporter (rhtA from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase (gapN from E. coli), Phosphotransferase system (pts from E. coli), Enzyme: 6-phosphofructokinase II (pfkB from E. coli), Enzyme: methylmalonate-semialdehyde dehydrogenase (mmsA from Pseudomonas aeruginosa), Oxaloacetate:beta-alanine aminotransferase (OAT-1 from Bacillus cereus), Enzyme: aspartate 1-decarboxylase (panD from E. coli), Gene that confers resistance to valine (ValR from E. coli), Enzyme: glucokinase (glk from E. coli), Polypeptide: 30 S ribosomal sununit protein S12 (rpsL from E. coli), Polypeptide: CynR DNA-binding transcriptional repressor (cynR from E. coli), Transporter: galactose:H+ symporter (galP from E. coli), aspartate aminotransferase (aspC from E. coli), Enzyme: alpha-ketoglutarate reductase (serA from E. coli), Enzyme: 6-phosphofructokinase I (pfkA from E. coli), Enzyme: phosphoenolpyruvate carboxylase (ppc from E. coli), Enzyme: succinate-semialdehyde dehydrogenase (NADP+) (gabD from E. coli), Enzyme: pyruvate kinase (pyk from E. coli), Enzyme: oxaloacetate 4-decarboxylase (OAD from Leuconostoc mesenteroides), Enzyme: trigger factor; a molecular chaperone involved in cell division (tig from E. coli), Transcription Unit (ptsHlcrr from E. coli), Enzyme: acetyl-CoA acetaldehyde dehydrogenase/alcohol dehydrogenase (adhE from E. coli), Enzyme: fattyacyl thioesterase I (tesA from E. coli), Enzyme: guanosine 3′-diphosphate 5′-triphosphate 3′-diphosphatase (spoT from E. coli), combination of genes encoding accABCD subunits (from E. coli and Halomonas elongata), pol (from E. coli), Enzyme: GDP pyrophosphokinase/GTP pyrophosphokinase (relA from E. coli), [Enzyme Name] (me from E. coli), Enzyme: citrate synthase (gltA from E. coli), Polypeptide: DNA gyrase, subunit A (gyrA from E. coli), Enzyme: multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxyglutarate aldolase and oxaloacetate decarboxylase (eda from E. coli), thiamin biosynthesis (thi from E. coli), Polypeptide: acetolactate synthase II (ilvG from E. coli), acetyl CoA carboxylase (accDACB from E. coli), Citrate synthase (ArCS from Arthrobacter aurescens), Acetyl-CoA carboxylase from Corynebacter glutamicum (CgACC from Corynebacter glutamicum), Polypeptide: ferrichrome/phage/antibiotic outer membrane porin FhuA (fhuA from E. coli), Transporter: phosphate:H+ symporter PitA (pitA from E. coli), Transporter: uracil:H+ symporter (uraA from E. coli), Enzyme: uracil phosphoribosyltransferase (upp from E. coli), Enzyme: acylphosphatase (yccX from E. coli), acetyl-CoA synthetase (acsA from E. coli), Polypeptide: restriction of methylated adenine (mrr from E. coli), Protein: TrpR transcriptional repressor (trpR from E. coli), Enzymes: glutamate 5-semialdehyde dehydrogenase/gamma-glutamyl kinase (proAB from E. coli), methylcytosine restriction system (mcrBC from E. coli), Protein: citrate lyase, citrate-ACP transferase component (citF from E. coli), Enzyme: thioesterase II (tesB from E. coli), Enzyme: DNA-specific endonuclease I (endA from E. coli), Enzyme: phosphate acetyltransferase (eutD from E. coli), Enzyme: propionate kinase (tdcD from E. coli), tRNA: tRNA glnV (supE from E. coli), Enzyme: DNA-binding, ATP-dependent protease La (lon from E. coli), Polypeptide: DNA strand exchange and recombination protein with protease and nuclease activity (recA from E. coli), Transcription Unit: restriction endonulease component of EcoKI restriction-modification system (hsdRMS from E. coli), Enzyme: restriction of DNA at 5-methylcytosine residues (mcrA from E. coli). In some embodiment the genetic modifications listed above are modified further with the genetic modules provided herein.
  • In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the method of bioproduction of various chemicals which can be used to make various consumer products described herein.
  • In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of 1,4-butanediol (1,4-BDO) (U.S. Pub. No. 20110190513). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of butanol (U.S. application Ser. No. 13/057,359). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of isobutanol (U.S. application Ser. No. 13/057,359)
  • In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of 3-HP such and its aldehyde metabolites (U.S. application Ser. No. 13/062,917).
  • In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of polyketide chemical products (U.S. application Ser. No. 13/575,581).
  • In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of fatty acid methyl esters (U.S. Pub. No. 20110124063). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of C4-C18 fatty acids (U.S. App No. 61/682,127).
  • Genetic Modifications
  • Various methods to achieve such genetic modification in a host strain are well known to one skilled in the art. Example of genetic modification that can be used by the claimed invention include, but are not limited to, increasing expression of an endogenous genetic element; increasing expression of an exogenous genetic element; decreasing functionality of a repressor gene; increasing functionality of a repressor gene; increasing functionality of a activator gene; decreasing functionality of a activator gene; introducing a genetic change or element integrated in the host genome, introducing a heterologous genetic element permanently, by integration into the genome or transiently by transformation with plasmid; increasing copy number of a nucleic acid sequence encoding a polypeptide catalyzing an enzymatic conversion step; mutating a genetic element to provide a mutated protein to increase specific enzymatic activity; mutating a genetic element to provide a mutated protein to decrease specific enzymatic activity; over-expressing of gene; reduced the expression of a gene; knocking out or deleting a gene; altering or modifying feedback inhibition; providing an enzyme variant comprising one or more of an impaired binding sites or active sites; increasing functionality of a siRNA, decreasing functionality of a siRNA, increasing functionality of a antisense molecule, decreasing functionality of a antisense molecule, addition of genetic modules such as RBS, ‘3 UTR elements to increase mRNA stability or translation; deletion of genetic modules such as RBS, ‘3 UTR elements to decrease mRNA stability or translation; addition or modification of genetic modules such as ‘5 UTR elements to increase transcription; deletion or modification of genetic modules such as ‘5 UTR and elements to increase transcription. In addition other genetic modules, provide herein, such a multicopy plasmids and various promoters can be used to further modify of the genetic modifications provide herein. Additionally, as known to those of ordinarily skill in the art compounds such as siRNA technology, anti-sense technology, and small molecule in inhibitors can be used to alter gene expression in the same manner as a genetic modification.
  • Screening methods, such as SCALE in combination with random mutagenesis may be practiced to provide genetic modifications that provide a benefit to increased production of 3-HP in a host cell. Examples of random mutagenesis can include insertions, deletions and substitutions of one or more nucleic acids in a nucleic acid of interest. In various embodiments a genetic modification results in improved enzymatic specific activity and/or turnover number of an enzyme. Without being limited, changes may be measured by one or more of the following: KM; Kcat, Kavidity, gene expression level, protein expression level, level of a product known to be produced by the enzyme, 3-HP tolerance, or by 3-HP production or by other means.
  • Host Cells
  • In some applications of the invention the host cell can be a gram-negative bacterium. In some applications of the invention the host cell can be from the genera Zymomonas, Escherichia, Pseudomonas, Alcaligenes, or Klebsiella. In some applications of the invention the host cell can be Escherichia coli, Cupriavidus necator, Oligotropha carboxidovorans, or Pseudomonas putida. In some applications of the invention the host cell is one or more an E. coli strains.
  • In some applications of the invention the host cell can be a gram-positive bacterium. In some applications of the invention the host cell can be from the genera Clostridium, Salmonella, Rhodococcus, Bacillus, Lactobacillus, Enterococcus, Paenibacillus, Arthrobacter, Corynebacterium, or Brevibacterium. In some applications of the invention the host cell is Bacillus licheniformis, Paenibacillus macerans, Rhodococcus erythropolis, Lactobacillus plantarum, Enterococcus faecium, Enterococcus gallinarium, Enterococcus faecalis, or Bacillus subtilis. In some applications of the invention the host cell is B. subtilis strain.
  • In some applications of the invention the host cell is yeast. In some applications of the invention the host cell can be from the genera Pichia, Candida, Hansenula or Saccharomyces. In some applications of the invention the host cell is Saccharomyces cerevisiae. In some applications of the invention the host cell is Saccharomyces pombe.
  • In some applications of the invention the host cell is an alga. In some applications of the invention the host cell is a halophile. In some applications of the invention the host cell is an alga. In some applications of the invention the host cell is a chemolithotrophic bacterium.
  • In some applications of the invention the host cell is comprised of multiple host cell types. In some applications of the invention the host cell is comprised of one host cell type. In some applications of the invention the host cell is comprised of one more species or strain of a host cell type.
  • Downstream Consumer Products Chemicals
  • 3-HP purified according to the methods provided in this disclosure may be converted to various other products having industrial uses including, but not limited to, acrylamide, acrylic acid, esters of acrylic acid, 1,3-propanediol, and other chemicals, collectively referred to as “downstream chemical products” or “downstream products.” In some instances the conversion is associated with the separation and/or purification steps. These downstream chemical products are useful for producing a variety of consumer products which are described in more detail below. The methods of the present invention include steps to produce downstream products of 3-HP.
  • As a C3 building block, 3-HP offers much potential in a variety of chemical conversions to commercially important intermediates, industrial end products, and consumer products. For example, 3-HP may be converted to acrylic acid, acrylates (e.g., acrylic acid salts and esters), 1,3-propanediol, malonic acid, ethyl-3-hydroxypropionate, ethyl ethoxy propionate, propiolactone, acrylamide, or acrylonitrile.
  • Additionally, 3-HP may be oligomerized or polymerized to form poly(3-hydroxypropionate) homopolymers, or co-polymerized with one or more other monomers to form various co-polymers. Because 3-HP has a single stereoisomer, polymerization of 3-HP is not complicated by the stereo-specificity of monomers during chain growth. This is in contrast to (S)-2-hydroxypropanoic acid (also known as lactic acid), which has two (D, L) stereoisomers that should be considered during its polymerizations.
  • As will be further described, 3-HP can be converted into derivatives starting (i) substantially as the protonated form of 3-hydroxypropionic acid; (ii) substantially as the deprotonated form, 3-hydroxypropionate; or (iii) as mixtures of the protonated and deprotonated forms. Generally, the fraction of 3-HP present as the acid versus the salt will depend on the pH, the presence of other ionic species in solution, temperature (which changes the equilibrium constant relating the acid and salt forms), and, to some extent, pressure. Many chemical conversions may be carried out from either of the 3-HP forms, and overall process economics will typically dictate the form of 3-HP for downstream conversion.
  • Acrylic acid obtained from 3-HP purified by the methods described in this disclosure may be further converted to various polymers. For example, the free-radical polymerization of acrylic acid takes place by polymerization methods known to the skilled worker and can be carried out, for example, in an emulsion or suspension in aqueous solution or another solvent. Initiators, such as but not limited to organic peroxides, are often added to aid in the polymerization. Among the classes of organic peroxides that may be used as initiators are diacyls, peroxydicarbonates, monoperoxycarbonates, peroxyketals, peroxyesters, dialkyls, and hydroperoxides. Another class of initiators is azo initiators, which may be used for acrylate polymerization as well as co-polymerization with other monomers. U.S. Pat. Nos. 5,470,928; 5,510,307; 6,709,919; and 7,678,869 teach various approaches to polymerization using a number of initiators, including organic peroxides, azo compounds, and other chemical types, and are incorporated by reference for such teachings as applicable to the polymers described herein.
  • Accordingly, it is further possible for co-monomers, such as crosslinkers, to be present during the polymerization. The free-radical polymerization of the acrylic acid obtained from dehydration of 3-HP, as produced herein, in at least partly neutralized form and in the presence of crosslinkers is practiced in certain embodiments. This polymerization may result in hydrogels which can then be comminuted, ground and, where appropriate, surface-modified, by known techniques.
  • An important commercial use of polyacrylic acid is for superabsorbent polymers. This specification hereby incorporates by reference Modern Superabsorbent Polymer Technology, Buchholz and Graham (Editors), Wiley-VCH, 1997, in its entirety for its teachings regarding superabsorbent polymers components, manufacture, properties and uses. Superabsorbent polymers are primarily used as absorbents for water and aqueous solutions for diapers, adult incontinence products, feminine hygiene products, and similar consumer products. In such consumer products, superabsorbent materials can replace traditional absorbent materials such as cloth, cotton, paper wadding, and cellulose fiber. Superabsorbent polymers absorb, and retain under a slight mechanical pressure, up to 25 times or more their weight in liquid. The swollen gel holds the liquid in a solid, rubbery state and prevents the liquid from leaking Superabsorbent polymer particles can be surface-modified to produce a shell structure with the shell being more highly cross-linked than the rest of the particle. This technique improves the balance of absorption, absorption under load, and resistance to gel-blocking. It is recognized that superabsorbent polymers have uses in fields other than consumer products, including agriculture, horticulture, and medicine.
  • Superabsorbent polymers are prepared from acrylic acid (such as acrylic acid derived from 3-HP provided herein) and a crosslinker, by solution or suspension polymerization. Exemplary methods include those provided in U.S. Pat. Nos. 5,145,906; 5,350,799; 5,342,899; 4,857,610; 4,985,518; 4,708, 997; 5,180,798; 4,666,983; 4,734,478; and 5,331,059, each incorporated by reference for their teachings relating to superabsorbent polymers.
  • Among consumer products, a diaper, a feminine hygiene product, and an adult incontinence product are made with superabsorbent polymer that itself is made substantially from acrylic acid converted from 3-HP made in accordance with the present invention.
  • Diapers and other personal hygiene products may be produced that incorporate superabsorbent polymers made from acrylic acid made from 3-HP which is produced and purified by the teachings of the present application. The following provides general guidance for making a diaper that incorporates such superabsorbent polymer. The superabsorbent polymer first is molded into an absorbent pad that may be vacuum formed, and in which other materials, such as a fibrous material (e.g., wood pulp) are added. The absorbent pad then is assembled with sheet(s) of fabric, generally a nonwoven fabric (e.g., made from one or more of nylon, polyester, polyethylene, and polypropylene plastics) to form diapers.
  • More particularly, in one non-limiting process, multiple pressurized nozzles, located above a conveyer belt, spray superabsorbent polymer particles (e.g., about 400 micron size or larger), fibrous material, and/or a combination of these onto the conveyer belt at designated spaces/intervals. The conveyor belt is perforated and under vacuum from below, so that the sprayed on materials are pulled toward the belt surface to form a flat pad. In various embodiments, fibrous material is applied first on the belt, followed by a mixture of fibrous material and the superabsorbent polymer particles, followed by fibrous material, so that the superabsorbent polymer is concentrated in the middle of the pad. A leveling roller may be used toward the end of the belt path to yield pads of uniform thickness. Each pad thereafter may be further processed, such as to cut it to a proper shape for the diaper, or the pad may be in the form of a long roll sufficient for multiple diapers. Thereafter, the pad is sandwiched between a top sheet and a bottom sheet of fabric (one generally being liquid pervious, the other liquid impervious), for example on a conveyor belt, and these are attached together, for example by gluing, heating or ultrasonic welding, and cut into diaper-sized units (if not previously so cut). Additional features may be provided, such as elastic components, strips of tape, etc., for fit and ease of wearing by a person.
  • The ratio of the fibrous material to polymer particles is known to affect performance characteristics. In some cases, this ratio is between 75:25 and 90:10 (see e.g., U.S. Pat. No. 4,685,915, incorporated by reference for its teachings of diaper manufacture). Other disposable absorbent articles may be constructed in a similar fashion, such as absorbent articles for adult incontinence, feminine hygiene (sanitary napkins), tampons, etc. (see, for example, U.S. Pat. Nos. 5,009,653; 5,558,656; and 5,827,255 incorporated by reference for their teachings of sanitary napkin manufacture).
  • Low molecular weight polyacrylic acid has uses for water treatment, and as a flocculant and thickener for various applications including cosmetics and pharmaceutical preparations. For these applications, the polymer may be uncrosslinked or lightly cross-linked, depending on the specific application. The molecular weights are typically from about 200 to about 1,000,000 g/mol. Preparation of these low molecular weight polyacrylic acid polymers is described in U.S. Pat. Nos. 3,904,685; 4,301,266; 2,798,053; and 5,093,472, each of which is incorporated by reference for its teachings relating to methods to produce these polymers.
  • Acrylic acid may be co-polymerized with one or more other monomers selected from acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, N,N-dimethylacrylamide, N-isopropylacrylamide, methacrylic acid, and methacrylamide, to name a few. The relative reactivities of the monomers affect the microstructure and thus the physical properties of the polymer. Co-monomers may be derived from 3-HP, or otherwise provided, to produce co-polymers. Ullmann's Encyclopedia of Industrial Chemistry, Polyacrylamides and Poly(Acrylic Acids), WileyVCH Verlag GmbH, Wienham (2005), is incorporated by reference herein for its teachings of polymer and co-polymer processing.
  • Acrylic acid can in principle be copolymerized with almost any free-radically polymerizable monomers including styrene, butadiene, acrylonitrile, acrylic esters, maleic acid, maleic anhydride, vinyl chloride, acrylamide, itaconic acid, and so on. End-use applications typically dictate the co-polymer composition, which influences properties. Acrylic acid also may have a number of optional substitutions and, after such substitutions, may be used as a monomer for polymerization, or co-polymerization reactions. As a general rule, acrylic acid (or one of its co-polymerization monomers) may be substituted by any substituent that does not interfere with the polymerization process, such as alkyl, alkoxy, aryl, heteroaryl, benzyl, vinyl, allyl, hydroxy, epoxy, amide, ethers, esters, ketones, maleimides, succinimides, sulfoxides, glycidyl and silyl (see e.g., U.S. Pat. No. 7,678,869, incorporated by reference above, for further discussion). The following paragraphs provide a few non-limiting examples of copolymerization applications.
  • Paints that comprise polymers and copolymers of acrylic acid and its esters are in wide use as industrial and consumer products. Aspects of the technology for making such paints can be found in e.g., U.S. Pat. Nos. 3,687,885 and 3,891,591, incorporated by reference for their teachings of such paint manufacture. Generally, acrylic acid and its esters may form homopolymers or copolymers among themselves or with other monomers, such as amides, methacrylates, acrylonitrile, vinyl, styrene and butadiene. A desired mixture of homopolymers and/or copolymers, referred to in the paint industry as “vehicle” (or “binder”) are added to an aqueous solution and agitated sufficiently to form an aqueous dispersion that includes sub-micrometer sized polymer particles. The paint cures by coalescence of these vehicle particles as the water and any other solvent evaporate. Other additives to the aqueous dispersion may include pigment, filler (e.g., calcium carbonate, aluminum silicate), solvent (e.g., acetone, benzol, alcohols, etc., although these are not found in certain no VOC paints), thickener, and additional additives depending on the conditions, applications, intended surfaces, etc. In many paints, the weight percent of the vehicle portion may range from about nine to about 26 percent, but for other paints the weight percent may vary beyond this range.
  • Acrylic-based polymers are used for many coatings in addition to paints. For example, for paper coating latexes, acrylic acid is used from 0.1-5.0%, along with styrene and butadiene, to enhance binding to the paper and modify rheology, freeze-thaw stability and shear stability. In this context, U.S. Pat. Nos. 3,875,101 and 3,872,037 are incorporated by reference for their teachings regarding such latexes. Acrylate-based polymers also are used in many inks, particularly UV curable printing inks For water treatment, acrylamide and/or hydroxy ethyl acrylate are commonly co-polymerized with acrylic acid to produce low molecular-weight linear polymers. In this context, U.S. Pat. Nos. 4,431,547 and 4,029,577 are incorporated by reference for their teachings of such polymers. Co-polymers of acrylic acid with maleic acid or itaconic acid are also produced for water-treatment applications, as described in U.S. Pat. No. 5,135,677, incorporated by reference for that teaching. Sodium acrylate (the sodium salt of glacial acrylic acid) can be co-polymerized with acrylamide (which may be derived from acrylic acid via amidation chemistry) to make an anionic co-polymer that is used as a flocculant in water treatment.
  • For thickening agents, a variety of co-monomers can be used, such as those described in U.S. Pat. Nos. 4,268,641 and 3,915,921, incorporated by reference for their description of these co-monomers. U.S. Pat. No. 5,135,677 describes a number of co-monomers that can be used with acrylic acid to produce water-soluble polymers, and is incorporated by reference for such description.
  • In some cases, conversion to downstream products may be made enzymatically. For example, 3-HP may be converted to 3-HP-CoA, which then may be converted into polymerized 3-HP with an enzyme having polyhydroxy acid synthase activity (EC 2.3.1.-). Also, 1,3-propanediol can be made using polypeptides having oxidoreductase activity or reductase activity (e.g., enzymes in the EC 1.1.1.- class of enzymes). Alternatively, when creating 1,3-propanediol from 3-HP, a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme from the 1.1.1.32 class) can be used. Polypeptides having lipase activity may be used to form esters. Enzymatic reactions such as these may be conducted in vitro, such as using cell-free extracts, or in vivo.
  • Thus, various embodiments described in this disclosure, such as methods of making a chemical, include conversion steps to any downstream products of microbially produced 3-HP, including but not limited to those chemicals described herein, in the incorporated references, and known in the art. For example, in some cases, 3-HP is produced and converted to polymerized-3-HP (poly-3-HP) or acrylic acid. In some cases, 3-HP or acrylic acid can be used to produce polyacrylic acid (polymerized acrylic acid, in various forms), methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, 1,3-propanediol, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate, and acrylic acid or an acrylic acid ester to which an alkyl or aryl addition may be made, and/or to which halogens, aromatic amines or amides, and aromatic hydrocarbons may be added.
  • a) Reactions that form downstream compounds such as acrylates or acrylamides can be conducted in conjunction with use of suitable stabilizing agents or inhibiting agents reducing the likelihood of polymer formation. See, for example, U.S. Publication No. 2007/0219390, incorporated by reference in its entirety. Stabilizing agents and/or inhibiting agents include, but are not limited to, e.g., phenolic compounds (e.g., dimethoxyphenol (DMP) or alkylated phenolic compounds such as di-tert-butyl phenol), quinones (e.g., t-butyl hydroquinone or the monomethyl ether of hydroquinone (MEHQ)), and/or metallic copper or copper salts (e.g., copper sulfate, copper chloride, or copper acetate) Inhibitors and/or stabilizers can be used individually or in combinations as will be known by those of skill in the art.
  • In some cases, the one or more downstream compounds are recovered at a molar yield of up to about 100 percent, or a molar yield in the range from about 70 percent to about 90 percent, or a molar yield in the range from about 80 percent to about 100 percent, or a molar yield in the range from about 90 percent to about 100 percent. Such yields may be the result of single-pass (batch or continuous) or iterative separation and purification steps in a particular process.
  • The methods described in this disclosure can also be used to produce downstream compounds derived from 3-HP, such as but not limited to, polymerized-3-HP (poly-3-HP), acrylic acid, polyacrylic acid (polymerized acrylic acid, in various forms), copolymers of acrylic acid and acrylic esters, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, and 1,3-propanediol. Also, among esters that are formed are methyl acrylate, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, and 2-ethylhexyl acrylate. These and/or other acrylic acid and/or other acrylate esters may be combined, including with other compounds, to form various known acrylic acid-based polymers. Numerous approaches may be employed for such downstream conversions, generally falling into enzymatic, catalytic (chemical conversion process using a catalyst), thermal, and combinations thereof (including some wherein a desired pressure is applied to accelerate a reaction). For example, without being limiting, acrylic acid may be made from 3-HP via a dehydration reaction, methyl acrylate may be made from 3-HP via dehydration and esterification, the latter to add a methyl group (such as using methanol), acrylamide may be made from 3-HP via dehydration and amidation reactions, acrylonitrile may be made via a dehydration reaction and forming a nitrile moiety, propiolactone may be made from 3-HP via a ring-forming internal esterification reaction, ethyl-3-HP may be made from 3-HP via esterification with ethanol, malonic acid may be made from 3-HP via an oxidation reaction, and 1,3-propanediol may be made from 3-HP via a reduction reaction. Additionally, it is appreciated that various derivatives of the derivatives of 3-HP and acrylic acid may be made, such as the various known polymers of acrylic acid and its derivatives. Production of such polymers is considered within the scope of the present invention. Copolymers containing acrylic acid and/or esters have been widely used in the pharmaceutical formulation to achieve extended or sustained release of active ingredients, for example as coating material. Downstream compounds may also be converted to consumer products such as diapers, carpet, paint, and adhesives.
  • Another important product, acrylamide, has been used in a number of industrial applications. Acrylamide may be produced from 3-HP, for example, without being limiting, via an esterification-amidation-dehydration sequence. Refluxing an alcohol solution of 3-HP in the presence of an acid or Lewis acid catalyst described herein would lead to a 3-HP ester. Treatment of the 3-HP ester with either an ammonia gas or an ammonium ion could yield 3-HP amide. Finally, dehydration of the 3-HP amide with dehydration reagents described elsewhere in this disclosure could produce acrylamide. The steps mentioned herein may be rearranged to produce the same final product acrylamide. Polymerization of acrylamide can be achieved, for example, and without being limiting, by radical polymerization. Polyacrylamide polymers have been widely used as additives for treating municipal drinking water and waste water. In addition, they have found applications in gel electrophoresis, oil-drilling, papermaking, ore processing, and the manufacture of permanent press fabrics.
  • VIII. Expression Systems General Concepts
  • The following general concepts are applicable to embodiments of the invention described above.
  • Multicopy Plasmids
  • The researcher is faced with a myriad of genetic module options when designing a plasmid for expression of a heterologous protein in a host cell. How to optimize an expression plasmid system often depends on the downstream use of the expressed protein.
  • Different cloning vectors or plasmids are maintained at different copy numbers, dependent on the replicon of the plasmid. Most general cloning plasmids can carry a DNA insert up to around 15 kb in size.
  • Multicopy plasmids can be used for the expression of recombinant genes in Escherichia coli. Examples of include multicopy plasmids include high-copy, medium-copy and low-copy plasmids (see FIG. 8). The high copy number is generally desired for maximum gene expression. However, the metabolic burden effects can result from multiple plasmid copies could prove to be detrimental for maximum productivity in certain metabolic engineering applications by adding significant metabolic burden to the system.
  • The low-copy plasmids for example, pBR322 is based on the original ColE1 replicon and thus has a copy number of 15-20. The pACYC series of plasmids are based on the p15A replicon, which has a copy number of 18-22, whereas pSC101 has even a lower copy number around 5, and BACs are maintained at one copy per cell. Such low copy plasmids may be useful in metabolic engineering applications, particularly when one or more of the substrates used in the recombinant pathway are required for normal cellular metabolism and can be toxic to the cell at high levels.
  • However, the used of high-copy plasmids may be useful in enhanced cellular metabolism contexts. The mutant ColE1 replicon, as found in the pUC series of plasmids produces a copy number of 500-700 as a result of a point mutation within the RNAII regulatory molecule.
  • There are transcription and translation vectors. Transcription vectors are utilized when the DNA to be cloned has an ATG start codon and a prokaryotic ribosome-binding site. Translation vectors contain an efficient ribosome-binding site and, therefore, it is not necessary for the target DNA to contain one. This is particularly useful in cases where the initial portion of the gene may be cleaved in an effort to improve solubility. Another consideration when choosing a transcription or translation vector is the source of the DNA to be expressed. Prokaryotic genes usually have a ribosome-binding site that is compatible with the host E. coli translation machinery, whereas eukaryotic genes do not. Normal prokaryotic gene expression may be enhanced by use of an engineered promoter and ribosome-binding site.
  • Promoters
  • A promoter is a region of DNA that initiates transcription of a particular gene. In bacteria, transcription is initiated by the promoter being recognized by RNA polymerase and an associated sigma factor, which are often brought to the promoter site by an activator protein's binding to its own DNA binding site located by the promoter.
  • Promoter selection is an important factor when designing an expression plasmid system. A promoter is located upstream of the ribosome-binding site. Owing to the fact that many heterologous protein products are toxic to the cell, the promoter can be regulated so that the heterologous protein is expressed at the appropriate amount and time to reduced the burden on the cell host.
  • Historically, the most commonly used promoters have been the lactose (lac) and tryptophan (trp) promoters. These two promoters were combined to create the hybrid promoters tac and trc that are also commonly used. Other common promoters are the phage lambda promoters, the phage T7 promoter (T7), and the alkaline phosphatase promoter (phoA).
  • Promoters can be constitutive and inducible. Constitutive promoter is active in all circumstances in the cell, while regulated or inducible promoter become active in response to specific stimuli. In addition the strength of the promoter can also differ. A strong promoter has a high frequency of transcription and generates the heterologous protein as 10-30% of the total cellular protein production (for examples see FIG. 8). Chemically-inducible promoters that can be used in various aspects of the invention include but are not limited to promoters whose transcriptional activity is regulated by the presence or absence of alcohol, tetracycline, steroids, metal and other compounds. Physically-inducible promoters that can be used in various aspects of the invention include but are not limited to including promoters whose transcriptional activity is regulated by the presence or absence of light and low or high temperatures.
  • In order to be an inducible promoter, the promoter should be initially be completely repressed to transcription and then transcription induced with the addition of an inducer to allow expression at the time that expression is desired in the host cell. Alternatively, an inducible promoter may be responsive to the lack of a substance, such as inorganic phosphate, such that the absence of inorganic phosphate will allow expression at the time that expression is desired in the host cell (for examples see FIG. 8).
  • Ribosome Binding Sites
  • A Ribosome Binding Sites (RBS) is an RNA sequence upstream of the start codon that affects the rate at which a particular gene or open reading frame (ORF) is translated. One can tailor an RBS site to a particular gene. Ribosome Binding Sites (RBSs) are typically short sequences, often less than 20 base pairs. Various aspects of RBS design are known to affect the rate at which the gene is translated in the cell. The RBS module can influences the translation rate of a gene largely by two known mechanisms. First, the rate at which ribosomes are recruited to the mRNA and initiate translation is dependent on the sequence of the RBS. Secondly, the sequence of the RBS can also affect the stability of the mRNA in the cell, which in turn affects the number of proteins. Through the use of genetic expression modules the expression of desired genes, such as genes encoding enzymes in the biosynthetic pathway for 3-HP, can be tailored activity either at the transcriptional and translational level.
  • One can access the registry RBS collection as a starting point for designing an RBS <<http://partsregistry.org/Ribosome_Binding_Sites/Catalog>>. The Registry has collections of RBSs that are recommended for general protein expression in E. coli and other prokaryotic hosts. In addition, each family of RBSs has multiple members covering a range of translation initiation rates. There are also several consensus RBS sequence for E. coli have been described. However, it is important to keep in mind the known RBS functions and mechanisms in a larger context. For example, in certain contexts the RBS can interact with upstream sequences, such as sequence that comprise the promoter or an upstream ORF. In other contexts, the RBS may interact with downstream sequences, for example the ribosome enzyme binds jointly to the RBS and start codon at about the same time. These potential interactions should be considered in the overall RBS sequence design. The degree of secondary structure near the RBS can affect the translation initiation rate. This fact can be used to produce regulated translation initiation rates.
  • The Shine-Dalgarno portion of the RBS is critical to the strength of the RBS. The Shine-Dalgarno is found at the end of the 16s rRNA and is the portion that binds with the mRNA and includes the sequence 5′-ACCUCC-3′. RBSs will commonly include a portion of the Shine-Dalgarno sequence. One of the ribosomal proteins, 51, is known to bind to adenine bases upstream from the Shine-Dalgarno sequence. As a result, the RBS can be made stronger by adding more adenines in the sequence upstream of the RBS.
  • When considering the design of the spacing between the RBS and the start codon, it is important to think of the aligned spacing rather than just the absolute spacing. While the Shine-Dalgarno portion of the RBS is critical to the strength of the RBS, the sequence upstream of the Shine-Dalgarno sequence is also important. Note that the promoter may add some bases onto the start of the mRNA that may affect the strength of the RBS by affecting Si binding. Computer programs that design RBS sequence to match protein coding sequences, desired upstream sequences including regulatory mRNA sequences, and account of secondary structure are known [Salis, Mirsky, and Voight, Nature Biotechnology 27: 946-950, 2009] and were used to optimize RBSs for the ACCase subunit genes as described in (see EXAMPLE 3).
  • While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
  • EXAMPLES Example 1 Salt Inhibition Studies in E. coli
  • The activity of ACCase complex, a critical enzyme in the conversion of acetyl-CoA to malonyl-CoA, the immediate precursor for 3-HP, is severely inhibited by salt. Dose-dependent effects on ACCase activity was observed in the presence of NaCl, NH4Cl, Na-3-HP, or NH4-3-HP such that salt levels near 0.44M resulted in decreasing the activity of the ACCase enzyme by approximately 80%, while salts of 3-HP levels near 0.66M decreased the activity of the ACCase enzyme by approximately 80% relative to control (FIG. 4). Levels of greater than 0.66M (60 g/L) are expected to be present for commercially viable commercial production of 3-HP.
  • Example 2 ACCase from Halophilic Organism
  • Halophilic organisms, such as Halomonas elongata, are found in environments with high salt concentrations and, in general, have a salt internal concentration >2.5-3M. It is hypothesized that enzymes derived from any salt-tolerant species should be more resistant to enzyme inhibition by salts, such as 3-HP. Further, these enzymes that have greater salt tolerance should in turn have extended production under high salt conditions than enzymes with lower salt tolerance.
  • Accordingly, the genes encoding the accA, accB, accC, accD of H. elongata described in Table 1 were synthesized for expression in E. coli using codons optimized for this organism and supplied individually on pUC57 plasmids without promoters. Synthetic operons comprising the subunits were assembled using the Gibson assembly method.
  • TABLE 1
    Accession numbers for genes encoding ACCase
    subunits from Halomonas elongata
    Gene Accession number SEQ ID NO.
    accA YP_003898857.1 SEQ ID NO. 1, 2
    accB YP_003897250.1 SEQ ID NO. 3, 4
    accC YP_003897249.1 SEQ ID NO. 5, 6
    accD YP_003897309.1 SEQ ID NO. 7, 8

    Each gene was amplified by PCRs with Pfu Ultra II HS using the manufacturer's instructions, and the PCR products were purified using the Zymo PCR Cleanup kit. Concentrations of products were measured using the Nanodrop spectophotometer. The Gibson Assembly kit (NEB) was used to construct plasmids expressing the ACCase subunit genes as directed by the manufacturer. The effect of NH4-3-HP and NH4Cl on H. elongata ACCase was tested and compared to the E. coli ACCase. As shown in FIG. 4, whereas the E. coli ACCase is significantly inhibited by the salts, the ACCase from the halophile is less affected by either NH4-3-HP or by NH4Cl. This result indicated that use of the H. elongata ACCase in 3-HP production strains would in beneficial in relieving 3-HP inhibition of the conversion of acetyl-CoA to malonyl-CoA, a critical step in the pathway.
  • Example 3 RBS-Optimized Genes
  • Enzyme expression is regulated at transcriptional and translational levels in prokaryotes. Ribosome Binding Sites (RBS) are 15 nucleotide segments which are known to control the level of protein expression in microorganisms. To enhance H. elongata ACCase expression various customized RBS were constructed and optimized for E. coli translation expression. Table 2 shows the RBS sequences used to increase expression of the individual subunits.
  • TABLE 2
    H. elongata
    ACC Modified RBS sequences 
    expression preceeding ATG (underlined)
    plasmid He_accD He_accA He_accC He_accB
    Parent 2-4 5′- 5′- 5′- 5′-
    GCGTAGTAAAGGA CAATTTATTTAAGGA GAAATTTCATACC GGAAGAACAAGGG
    GGTAACATATG GGACTCTTAAGATG ACAGGCGAAGGAG GTGTACATG
    GAAAAACCATG
    B2 Same as 2-4 Same as 2-4 Same as 2-4 5′-
    ggaagaattaagg
    gggacaaggggga
    ataATG
    13A 5′- Same as 2-4 Same as 2-4
    gcgtagtagccggg
    tgataaggagccgt
    aacATG
    14C 5′- Same as 2-4 Same as 2-4 Same as 2-4
    gcgtagtagctgat
    ataaaaggaggtaa
    cggATG
    15C Same as 2-4 5′- Same as 2-4 Same as 2-4
    caatttatttttgtt
    cacccaaggagtatt
    gctaATG
    17C Same as 2-4 5′- Same as 2-4 Same as 2-4
    caatttatttaccga
    aataaaaggagggat
    gcgaATG
    35C 5′- 5′- Same as 2-4 Same as 2-4
    gcgtagtagccggg caatttatttttgtt
    tgataaggagccgt cacccaaggagtatt
    aacATG gctaATG
    36C 5′- 5′- Same as 2-4 Same as 2-4
    gcgtagtagccggg caatttatttaccga
    tgataaggagccgt aataaaaggagggat
    aacATG gcgaATG
    36C-8 5′- 5′- Same as 2-4 5′-
    gcgtagtagccggg caatttatttaccga ggaagaattaagg
    tgataaggagccgt aataaaaggagggat gggacaaggggga
    aacATG gcgaATG ataATG
    72B 5′- 5′- 5′- 5′-
    gcgtagtagccggg caatttatttaccga TCTTCCCACAACA GAAATTTCATACC
    tgataaggagccgt aataaaaggagggat CTGGCGGACTCCA ACAGGCGAAGGAG
    aacATG gcgaATG TCATG GAAAAACCATG
    105F 5′- 5′- 5′- 5′-
    gcgtagtagccggg caatttatttttgtt TCTTCCCACAACA GAAATTTCATACC
    tgataaggagccgt cacccaaggagtatt CTGGCGGACTCCA ACAGGCGAAGGAG
    aacATG gctaATG TCATG GAAAAACCATG
    RBS sequences used to enhance expression ofH. elongate ACCase subunits.
  • The expression performance of the RBS-optimized H. elongata ACCases was evaluated by 3-HP production in a 96-well format, each in triplicate wells, and the averaged results shown in Table 3. Specific 3HP production is shown as g/L per OD600. As may be seen in Table 3, enhancing the efficiency of the RBS in strains B2, 35C, and 72 B clearly resulted in increased malonyl-CoA production leading to increased 3-HP production. It is evident from these results that combinations of enhanced RBS's before each of the individual genes accA, accB, accC, and accD may result in strains with even higher ACCase expression and activity.
  • TABLE 3
    Improvement in 3-HP production by RBS-optimized
    expression of H. elongata ACCase subunits.
    H. elongata ACCase 3HP
    expression plasmid (g/l · OD)
    Parent 2-4 0.06
    B2 0.81
    13A 0.01
    14C 0.54
    15C 0.14
    17C 0.08
    35C 0.68
    36C 0.31
    36C-8 0.31
    72B 0.57
    105F 0.19
  • Example 4 Coordinated Expression by Subunit Fusions
  • In nature ACCase subunit genes from prokaryotes such as E. coli and H. elongata have been shown to have a quaternary structure: accA2:accD2:accB4:accC2. However, the intrinsic levels of the ACCase subunit genes are too low for optimal production. Therefore, for optimal production it is ideal to have overexpression to be coordinated in a similar manner.
  • Expression of the genes encoding each ACCase subunit is regulated at transcriptional and translational levels. Coordinated overexpression of the ACCase subunit genes, accA, accB, accC, accD should give better ACCase activity. Examples of fusions of accC-B proteins exist in bacteria. It is hypothesized that coordinated overexpression may be achieved by fusion of subunit genes should ensures equimolar expression of the subunit genes at the optimal time.
  • The following ACCase subunit gene fusion were constructed and the constructs overexpressed in E. coli: (A) Control ABCD, (B) fusion of accC-B (SEQ ID NO. s 9, 10) subunit genes as seen in bacteria, (C) fusion of accD-A subunit genes using a flexible 15-amino acid linker (Linker sequence LSGGGGSGGGGSGGGGSGGGGSAAA; SEQ ID NO. s 11, 12) as depicted in FIG. 5.
  • The performance of the ACC fusions were tested for their ACCase activity and for various 3-HP production metrics in Table 4. ACCase activity was determined in cell lysates using an assay for malonyl-CoA production as described in [Kroeger, Zarzycki, and Fuchs, Analytical Biochem. 411:100-105, 2011]. Production of 3-HP was determined in cells co-transformed with a plasmid bearing the genes encoding the malonyl-CoA reductase from S. tokadaii and E. coli ydfG providing a 3-HP dehydrogenase to complete the metabolic pathway from malonyl-CoA to 3HP. These results show that the strain with the fused accDA genes had higher average specific productivity of 3-HP compared to the parental strain in which the overexpressed ACCase is not fused. FIG. 6 shows that the benefit of the accDA fusion were also manifested in 3-HP production in fermentors with environmental controls of nutrient feed, pH, aeration, and temperature.
  • Table 4:
  • TABLE 4
    ACC Fusions and ACCase activity
    ACCase
    Avg specific Avg specific specific
    prodn rate prodn rate activity
    Strain (g/gDCW · h) (g/gDCW · hr) at TS + 6
    designation Plasmid at TS + 6 at TS + 20 (U/mg)
    BX3_783 Parent 0.160 0.146 0.057
    (unfused
    ACCase)
    BX3_829 No ACC 0.069 0.062 0.000
    BX3_837 EC ACC 0.209 0.201 0.054
    DA fusion

  • Example 5 3-HP Exporter
  • Growth inhibition has been demonstrated for E. coli strains grown in the presence of 3-HP at levels as low as 20 g/L. To produce high titers of 3-HP the production host is required to balance production with overcoming inhibition. A known chemical exporter from E. coli that has been previously characterized for homoserine transport, rhtA, was evaluated for increased production of 3-HP. A mutant version of the exporter, rhtA(P2S) (SEQ ID NO. 30 nucleic acid, SEQ ID NO. 31 protein) was synthesized behind the PtpiA promoter and inserted into the pTRC-PyibD-MCR plasmid behind a terminator using the Gibson Assemply kit (NEB) according to manufacturer's instructions. The effects of overexpression of rhtA were evaluated in 1 L fermentation compared to the control plasmid without rhtA. As shown in FIG. 7, overexpression of rhtA resulted in a significant improvement in 3HP titer compared to the control production strain. Construction of plasmids expressing another putative transporter, ydcO (SEQ ID NO. 32 nucleic acid, SEQ ID NO. 33 protein) is carried out in the same manner.
  • Example 6 Bicarbonate Importer (Prophetic)
  • Increased import of bicarbonate to increase availability of bicarbonate for the ACCase reaction will increase production of malonyl-CoA and hence products derived metabolically from malonyl-CoA, such as 3-HP. The gene encoding the bicA bicarbonate transporter (SEQ ID NO. 13) of Synechococcus sp. was synthesized using codons optimized for expression in E. coli (SEQ ID NO. 14) and expressed using the E. coli tal promoter in a strain cotransformed with plasmids encoding ACCase and MCR functions. Production of 3-HP by this strain is compared to that achieved by a control strain without overexpressed bicA.
  • SEQUENCE LISTING
    SEQ ID NO. 1: ACCA PROTEIN, HALOMONAS ELONGATA
    MNPNYLDFEQPIAELQAKIEELRMVGNDSQVNLSDEIGRLEEKSRKLTES
    IFKDLSAWQVSQLSRHPQRPYTLDYLEHVFTDFDELHGDRRFADDAAIVG
    GVARLDDKPVMVIGHQKGRDVHEKVRRNFGMPRPEGYRKACRLMEMAERF
    HMPVLTFIDTPGAYPGIDAEERGQSEAIAYNLGVMSRLKTPIISTVVGEG
    GSGGALAIGVCDELAMLQYSTYSVISPEGCASILWKSADKASEAAQAMGI
    TAERLKELGFVDTLIPEPLGGAHRQPSATAERIKTALLESLDRLETMETD
    ALLERRYERLMSYGAPV
    SEQ ID NO. 2: ACCA NUCLEIC ACID, HALOMONAS ELONGATA 
    (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION)
    ATGAATCCGAACTATCTGGACTTTGAACAACCGATCGCTGAACTGCAAGCCAAAATCGAA
    GAACTGCGTATGGTGGGCAACGACTCACAGGTGAACCTGTCTGATGAAATTGGCCGTCTG
    GAAGAAAAAAGTCGCAAACTGACCGAATCCATCTTTAAAGACCTGTCAGCGTGGCAAGTT
    AGCCAACTGTCTCGTCATCCGCAACGCCCGTATACCCTGGATTACCTGGAACATGTCTTT
    ACGGATTTCGACGAACTGCACGGTGACCGTCGCTTTGCAGATGACGCGGCCATTGTTGGC
    GGTGTCGCTCGTCTGGATGACAAACCGGTCATGGTGATCGGCCATCAGAAAGGTCGTGAT
    GTGCACGAAAAAGTTCGTCGCAACTTCGGCATGCCGCGCCCGGAAGGTTATCGTAAAGCG
    TGCCGCCTGATGGAAATGGCCGAACGCTTTCACATGCCGGTGCTGACCTTCATTGATACG
    CCGGGCGCATATCCGGGTATCGACGCTGAAGAACGTGGCCAAAGCGAAGCGATTGCCTAC
    AATCTGGGTGTTATGTCGCGCCTGAAAACCCCGATTATCAGCACGGTGGTTGGCGAAGGC
    GGTTCTGGCGGTGCACTGGCTATCGGTGTCTGCGATGAACTGGCGATGCTGCAATATAGT
    ACCTACTCCGTGATTTCACCGGAAGGCTGTGCCTCGATCCTGTGGAAAAGCGCAGATAAA
    GCTTCTGAAGCAGCTCAAGCGATGGGCATTACCGCCGAACGTCTGAAAGAACTGGGTTTC
    GTTGACACGCTGATCCCGGAACCGCTGGGCGGTGCACATCGTCAGCCGAGTGCGACCGCC
    GAACGCATTAAAACGGCCCTGCTGGAAAGCCTGGATCGCCTGGAAACGATGGAAACGGAT
    GCCCTGCTGGAACGCCGCTATGAACGCCTGATGTCTTACGGTGCCCCGGTCTGA
    SEQ ID NO. 3: ACCB PROTEIN, HALOMONAS ELONGATA
    MDIRKVKKLIELLEESNISEIEIQEGEESVRISRHPNGTEHPQPAAPAWP
    ATAAAPAPQPAAAPVESPAEVDEGPAYQGQPIVSPMVGTFYRAPAPGAKA
    FVELGQSVKKGETVCIVEAMKMMNQIEADRDGVVEA1LVEDGEPVEFEQP
    MVVIS
    SEQ ID NO. 4: ACCB NUCLEIC ACID HALOMONAS ELONGATA 
    (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION)
    ATGGACATCCGCAAAGTGAAAAAACTGATCGAACTGCTGGAAGAAAGTAACATCTCTGAA
    ATTGAAATCCAAGAAGGCGAAGAAAGCGTGCGTATTAGTCGCCATCCGAACGGCACCGAA
    CACCCGCAGCCGGCGGCACCGGCATGGCCGGCCACGGCAGCTGCGCCGGCGCCGCAACCG
    GCCGCAGCTCCGGTGGAAAGCCCGGCAGAAGTTGATGAAGGCCCGGCTTATCAGGGTCAA
    CCGATCGTTTCTCCGATGGTCGGCACCTTTTACCGTGCGCCGGCACCGGGTGCAAAAGCT
    TTCGTCGAACTGGGCCAGAGCGTTAAAAAAGGTGAAACGGTCTGCATTGTGGAAGCCATG
    AAAATGATGAATCAAATCGAAGCCGATCGCGACGGTGTGGTTGAAGCAATCCTGGTGGAA
    GATGGTGAACCGGTGGAATTTGAACAGCCGATGGTGGTGATTAGTTAA
    SEQ ID NO. 5: ACCC PROTEIN, HALOMONAS ELONGATA
    MLDKVLIANRGEIALRILRACKELGIRTVAVHSKADRELMHVRLADEAVC
    IGPASSAQSYLNIPALISAAEVTDTSAIHPGYGFLSENADFAEQVERSGF
    TFIGPSAETIRLMGDKVSAINAMKEAGVPTVPGSNGPLGDDEGElLATAR
    RIGYPVIIKAAAGGGGRGMRVVHAEGHLLSAVNVTRTEAHSSFGDGTVYM
    EKFLENPRHVEVQVLADGQGNAIHLYDRDCSLQRRHQKVLEEAPAPGLDQ
    QAREQVFKACRDACVKIGYRGAGTFEFLYENGEFFFIEMNTRVQVEHPVT
    EMVTGVDIVREQLRIASGLPLSIRQEDVELSGHAFECRINAEDSRTFMPS
    PGRVTLYHPPGGLGVRMDSHVYTGYTVPPHYDSLIGKLITWGDDRETALI
    RMRNALDELLVEGIKTNTDLHKDLVRDGYFQQGGVNIHYLEKKLGL
    SEQ ID NO. 6: ACCC NUCLEIC ACID, HALOMONAS ELONGATA
    (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION)
    ATGCTGGACAAAGTGCTGATTGCGAATCGTGGCGAAATTGCGCTGCGTATCCTGCGTGCG
    TGTAAAGAACTGGGTATCCGTACCGTCGCTGTTCATTCAAAAGCGGACCGTGAACTGATG
    CACGTCCGCCTGGCCGATGAAGCAGTGTGCATTGGTCCGGCTAGCTCTGCGCAGTCGTAT
    CTGAACATTCCGGCACTGATCAGTGCGGCCGAAGTGACCGACACGTCCGCGATCCATCCG
    GGCTACGGTTTCCTGAGCGAAAATGCCGATTTTGCAGAACAAGTCGAACGTTCAGGTTTC
    ACCTTTATTGGCCCGTCGGCCGAAACGATCCGCCTGATGGGTGATAAAGTTAGTGCTATT
    AACGCGATGAAAGAAGCAGGCGTGCCGACCGTTCCGGGTTCCAATGGTCCGCTGGGTGAT
    GACGAAGGTGAAATTCTGGCCACCGCACGTCGCATCGGCTATCCGGTTATTATCAAAGCA
    GCTGCGGGCGGTGGCGGTCGTGGTATGCGTGTGGTTCATGCTGAAGGCCACCTGCTGAGC
    GCGGTCAACGTGACCCGTACGGAAGCGCATAGTTCCTTCGGCGATGGCACCGTTTATATG
    GAAAAATTTCTGGAAAACCCGCGTCACGTTGAAGTCCAGGTGCTGGCCGATGGCCAGGGT
    AATGCAATTCATCTGTACGATCGCGACTGCTCTCTGCAACGTCGCCACCAAAAAGTGCTG
    GAAGAAGCTCCGGCACCGGGTCTGGACCAGCAAGCACGTGAACAGGTTTTTAAAGCCTGC
    CGCGATGCATGTGTCAAAATTGGTTATCGTGGCGCGGGCACCTTCGAATTTCTGTACGAA
    AACGGCGAATTTTTCTTTATCGAAATGAATACGCGCGTTCAGGTCGAACATCCGGTGACC
    GAAATGGTCACGGGTGTGGATATTGTTCGTGAACAGCTGCGTATCGCATCAGGTCTGCCG
    CTGTCGATTCGCCAAGAAGACGTTGAACTGAGCGGTCATGCCTTCGAATGTCGTATCAAT
    GCAGAAGATAGCCGCACCTTTATGCCGTCTCCGGGTCGTGTCACGCTGTATCACCCGCCG
    GGCGGTCTGGGTGTCCGTATGGACAGCCATGTGTATACCGGCTACACGGTTCCGCCGCAC
    TACGATTCTCTGATTGGTAAACTGATCACCTGGGGCGATGACCGTGAAACGGCTCTGATT
    CGTATGCGCAACGCCCTGGATGAACTGCTGGTTGAAGGCATCAAAACCAATACGGATCTG
    CACAAAGACCTGGTTCGCGATGGCTACTTTCAGCAAGGCGGTGTCAACATTCACTACCTG
    GAAAAAAAACTGGGTCTGTAA
    SEQ ID NO. 7: ACCD PROTEIN, HALOMONAS ELONGATA
    MSWLDKIVPSVGRIQRKERRTSVPDGLWRKCPKCESVLYLPELEKHHNVC
    PKCDHHLRLTARKRLDWFLDKEGREEIAADLEPVDRLKFRDSKKYKDRLS
    AAQKATGEKDGLVAMRGTLEGLPVVAVAFEFTFMGGSMGAVVGEKFVRAA
    TQALDEGVPLVCFSASGGARMQEALFSLMQMAKTSAALEKLKQAGVPYIS
    VLTDPVFGGVSASLAMLGDLNIAEPNALIGFAGPRVIEQTVREQLPEGFQ
    RSEFLLEHGAVDMIVHRQQIRERLGGVLRKLTHQPASGPAVVENDEPDLV
    DAAEQAEPQPEAPEAVETSESEAPTEKGVEADSEETDESPRSGDNR
    SEQ ID NO. 8: ACCD NUCLEIC ACID, HALOMONAS ELONGATA 
    (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION)
    ATGTCTTGGTTAGATAAAATCGTCCCGTCAGTGGGTCGCATTCAACGCAAAGAACGTCGC
    ACCTCGGTCCCGGATGGTCTGTGGCGTAAATGCCCGAAATGTGAATCAGTTCTGTATCTG
    CCGGAACTGGAAAAACATCACAACGTCTGCCCGAAATGTGATCATCACCTGCGTCTGACC
    GCGCGTAAACGCCTGGACTGGTTCCTGGATAAAGAAGGCCGCGAAGAAATTGCGGCCGAC
    CTGGAACCGGTGGATCGTCTGAAATTTCGCGACAGCAAAAAATACAAAGATCGTCTGAGC
    GCGGCGCAGAAAGCAACCGGTGAAAAAGACGGTCTGGTGGCCATGCGTGGCACGCTGGAA
    GGTCTGCCGGTGGTTGCAGTTGCTTTTGAATTTACCTTTATGGGCGGTAGCATGGGCGCA
    GTCGTGGGTGAAAAATTCGTTCGTGCGGCCACGCAGGCTCTGGATGAAGGTGTGCCGCTG
    GTTTGCTTCAGCGCATCTGGCGGTGCCCGCATGCAGGAAGCACTGTTTAGTCTGATGCAA
    ATGGCTAAAACCTCCGCAGCTCTGGAAAAACTGAAACAGGCGGGCGTGCCGTATATTTCT
    GTTCTGACGGACCCGGTCTTCGGCGGTGTGAGTGCGTCCCTGGCCATGCTGGGTGATCTG
    AACATTGCAGAACCGAATGCTCTGATCGGCTTTGCGGGTCCGCGTGTCATCGAACAGACC
    GTGCGCGAACAACTGCCGGAAGGCTTCCAGCGTTCAGAATTTCTGCTGGAACATGGTGCC
    GTTGATATGATTGTCCACCGTCAGCAAATCCGTGAACGCCTGGGCGGTGTGCTGCGCAAA
    CTGACGCATCAACCGGCATCGGGTCCGGCCGTTGTCGAAAATGATGAACCGGACCTGGTC
    GATGCGGCCGAACAGGCAGAACCGCAACCGGAAGCACCGGAAGCTGTTGAAACCTCAGAA
    TCGGAAGCACCGACGGAAAAAGGCGTGGAAGCAGACTCGGAAGAAACGGATGAATCACCG
    CGCTCAGGCGACAACCGCTAA
    SEQ ID NO. 9: FUSION ACCCB PROTEIN, E. COLI
    MLDKIVIANRGEIALRILRACKELGIKTVAVHSSADRDLKHVLLADETVC
    IGPAPSVKSYLNIPAIISAAEITGAVAIHPGYGFLSENANFAEQVERSGF
    IFIGPKAETIRLMGDKVSAIAAMKKAGVPCVPGSDGPLGDDMDKNRAIAK
    RIGYPVIIKASGGGGGRGMRVVRGDAELAQSISMTRAEAKAAFSNDMVYM
    EKYLENPRHVEIQVLADGQGNAIYLAERDCSMQRRHQKVVEEAPAPGITP
    ELRRYIGERCAKACVDIGYRGAGTFEFLFENGEFYFIEMNTRIQVEHPVT
    EMITGVDLIKEQLRIAAGQPLSIKQEEVHVRGHAVECRINAEDPNTFLPS
    PGKITRFHAPGGFGVRWESHIYAGYTVPPYYDSMIGKLICYGENRDVAIA
    RMKNALQELIIDGIKTNVDLQIRIMNDENFQHGGTNIHYLEKKLGLQEKD
    IRKIKKLIELVEESGISELEISEGEESVRISRAAPAASFPVMQQAYAAPM
    MQQPAQSNAAAPATVPSMEAPAAAEISGHIVRSPMVGTFYRTPSPDAKAF
    IEVGQKVNVGDTLCIVEAMKMMNQIEADKSGTVKAILVESGQPVEFDEPL
    VVIE
    SEQ ID NO. 10: FUSION ACCCB NUCLEIC ACID, E. COLI
    ATGCTGGACAAGATCGTCATCGCCAACCGCGGCGAAATCGCCCTGCGCATCTTGCGCGCG
    TGTAAAGAGCTGGGCATTAAGACTGTTGCCGTGCATTCCAGCGCAGACCGCGACCTGAAG
    CATGTTCTGCTGGCCGACGAAACGGTTTGCATCGGTCCGGCACCGAGCGTGAAAAGCTAT
    CTGAACATCCCGGCCATCATCTCTGCGGCAGAGATCACCGGTGCAGTGGCGATTCATCCG
    GGCTACGGTTTCCTGAGCGAGAACGCTAACTTTGCTGAACAAGTGGAGCGTAGCGGTTTC
    ATCTTCATTGGCCCTAAGGCGGAGACGATTCGCCTGATGGGCGACAAAGTGAGCGCCATT
    GCAGCGATGAAAAAGGCCGGTGTGCCGTGTGTTCCGGGCAGCGATGGTCCGCTGGGTGAC
    GATATGGACAAGAACCGTGCCATCGCTAAACGTATTGGCTACCCGGTCATTATCAAAGCC
    TCTGGTGGTGGCGGTGGCCGTGGTATGCGTGTCGTCCGTGGTGATGCGGAACTGGCGCAA
    AGCATCAGCATGACCCGTGCGGAAGCCAAAGCGGCGTTCTCTAACGATATGGTGTATATG
    GAGAAGTATCTGGAGAATCCGCGCCACGTTGAAATCCAAGTTCTGGCGGATGGTCAGGGC
    AATGCGATCTACTTGGCAGAACGTGATTGCTCCATGCAACGCCGTCATCAGAAGGTGGTG
    GAAGAGGCACCGGCTCCGGGTATTACGCCGGAACTGCGTCGCTACATCGGTGAGCGCTGT
    GCGAAAGCGTGTGTGGACATTGGTTACCGTGGTGCGGGTACGTTTGAGTTCCTGTTCGAA
    AATGGTGAGTTTTACTTCATTGAAATGAATACCCGCATCCAGGTTGAGCACCCGGTGACC
    GAGATGATTACTGGCGTTGATCTGATCAAAGAGCAACTGCGCATTGCGGCTGGTCAGCCG
    CTGTCGATCAAGCAAGAAGAGGTGCACGTTCGTGGTCACGCGGTCGAGTGCCGTATCAAT
    GCGGAGGACCCGAATACCTTTCTGCCGAGCCCTGGTAAGATCACTCGTTTTCACGCGCCA
    GGTGGTTTTGGCGTTCGTTGGGAGTCTCACATCTACGCCGGTTACACCGTGCCGCCGTAC
    TATGACAGCATGATTGGTAAACTGATCTGCTATGGCGAAAATCGTGATGTCGCGATCGCC
    CGCATGAAAAACGCGCTGCAAGAGCTGATCATTGATGGCATTAAGACCAATGTGGATTTG
    CAGATCCGCATTATGAACGACGAGAATTTCCAGCACGGCGGTACGAACATTCACTACCTG
    GAAAAGAAACTGGGCCTGCAAGAGAAAGACATCCGCAAGATCAAGAAGCTGATCGAACTG
    GTGGAAGAGTCTGGCATCAGCGAGCTGGAGATCAGCGAAGGTGAAGAGAGCGTCCGTATT
    TCCCGTGCGGCACCGGCAGCGAGCTTTCCGGTTATGCAGCAAGCATACGCCGCTCCGATG
    ATGCAACAGCCGGCACAGAGCAACGCCGCTGCACCGGCGACCGTTCCAAGCATGGAGGCA
    CCGGCAGCGGCCGAGATTTCGGGTCATATCGTGCGTAGCCCGATGGTGGGCACCTTCTAT
    CGCACGCCGTCGCCGGACGCAAAAGCCTTCATCGAAGTCGGCCAGAAGGTCAATGTCGGC
    GACACGCTGTGTATCGTTGAGGCAATGAAAATGATGAACCAGATTGAAGCGGATAAGAGC
    GGTACTGTTAAAGCGATCCTGGTGGAATCCGGCCAGCCTGTTGAGTTCGATGAACCGCTG
    GTTGTGATCGAGTAA
    SEQ ID NO. 11: FUSION ACCDA PROTEIN, E. COLI
    MSWIERIKSNITPTRKASIPEGVWTKCDSCGQVLYRAELERNLEVCPKCD
    HHMRMTARNRLHSLLDEGSLVELGSELEPKDVLKFRDSKKYKDRLASAQK
    ETGEKDALVVMKGTLYGMPVVAAAFEFAFMGGSMGSVVGARFVRAVEQAL
    EDNCPLICFSASGGARMQEALMSLMQMAKTSAALAKMQERGLPYISVLTD
    PTMGGVSASFAMLGDLNIAEPKALIGFAGPRVIEQTVREKLPPGFQRSEF
    LIEKGAIDMIVRRPEMRLKLASILAKLMNLPAPNPEAPREGVVVPPVPDQ
    EPEALSGGGGSGGGGSGGGGSGGGGSAAASLNFLDFEQPIAELEAKIDSL
    TAVSRQDEKLDINIDEEVHRLREKSVELTRKIFADLGAWQIAQLARHPQR
    PYTLDYVRLAFDEFDELAGDRAYADDKAIVGGIARLDGRPVMIIGHQKGR
    ETKEKIRRNFGMPAPEGYRKALRLMQMAERFKMPIITFIDTPGAYPGVGA
    EERGQSEAIARNLREMSRLGVPVVCTVIGEGGSGGALAIGVGDKVNMLQY
    STYSVISPEGCASILWKSADKAPLAAEAMGIIAPRLKELKLIDSIIPEPL
    GGAHRNPEAMAASLKAQLLADLADLDVLSTEDLKNRRYQRLMSYGYA
    SEQ ID NO. 12: FUSION ACCDA NUCLEIC ACID; E. COLI
    ATGAGCTGGATCGAGCGCATCAAGAGCAACATCACCCCGACCCGCAAGGCGAGCATCCCT
    GAAGGCGTCTGGACCAAATGCGATAGCTGCGGTCAGGTTTTGTATCGTGCGGAGCTGGAG
    CGTAACCTGGAAGTGTGCCCGAAATGCGACCATCACATGCGTATGACCGCTCGTAATCGT
    CTGCATAGCCTGCTGGATGAGGGCAGCCTGGTCGAGCTGGGTAGCGAACTGGAACCGAAA
    GATGTTCTGAAATTCCGTGATTCCAAGAAGTATAAGGATCGTTTGGCATCTGCACAAAAA
    GAAACCGGTGAGAAGGACGCACTGGTTGTTATGAAAGGCACCCTGTATGGTATGCCGGTT
    GTTGCTGCGGCGTTCGAGTTTGCGTTTATGGGTGGCAGCATGGGTTCCGTGGTGGGCGCA
    CGCTTTGTGCGTGCCGTGGAGCAGGCGCTGGAGGATAACTGTCCTCTGATTTGTTTCAGC
    GCGAGCGGTGGTGCGCGTATGCAAGAGGCCCTGATGAGCCTGATGCAGATGGCAAAAACC
    TCGGCAGCCCTGGCGAAGATGCAAGAACGCGGCCTGCCGTACATTTCCGTCCTGACCGAC
    CCTACGATGGGCGGTGTCAGCGCCAGCTTTGCGATGCTGGGTGATTTGAACATCGCAGAG
    CCGAAGGCTCTGATTGGTTTTGCTGGTCCGCGTGTTATTGAACAGACGGTTCGCGAAAAG
    TTGCCGCCTGGTTTCCAGCGCAGCGAGTTCCTGATTGAGAAAGGTGCCATCGACATGATC
    GTTCGCCGTCCAGAAATGCGTCTGAAACTGGCGAGCATTCTGGCGAAATTGATGAATCTG
    CCGGCTCCGAATCCTGAAGCACCGCGTGAGGGTGTCGTGGTTCCGCCGGTCCCGGACCAA
    GAGCCGGAGGCTCTGAGCGGCGGAGGTGGCTCTGGTGGAGGCGGTTCAGGAGGCGGTGGC
    AGTGGTGGCGGCGGATCTGCGGCAGCTTCTCTGAACTTCCTGGACTTCGAGCAGCCGATC
    GCCGAACTGGAGGCGAAGATTGACAGCCTGACCGCGGTTAGCCGTCAAGATGAGAAACTG
    GACATTAACATCGACGAAGAGGTCCACCGTTTGCGTGAGAAGTCTGTTGAACTGACTCGC
    AAAATCTTTGCTGATTTGGGCGCATGGCAGATTGCCCAGTTGGCTCGCCACCCACAACGC
    CCATATACCCTGGACTACGTGCGCCTGGCGTTTGACGAGTTCGACGAACTGGCAGGCGAC
    CGCGCCTATGCGGACGATAAAGCAATTGTCGGCGGTATTGCTCGTTTGGATGGCCGTCCG
    GTGATGATTATCGGCCATCAAAAAGGCCGCGAGACAAAGGAAAAGATTCGTCGTAATTTC
    GGAATGCCGGCACCGGAGGGCTACCGCAAGGCCCTGCGTCTGATGCAAATGGCCGAACGC
    TTTAAGATGCCGATTATCACGTTCATTGATACGCCTGGTGCGTACCCAGGCGTTGGTGCG
    GAAGAGCGTGGTCAGAGCGAGGCCATCGCACGTAACCTGCGTGAGATGTCTCGTCTGGGT
    GTGCCGGTCGTTTGCACCGTGATTGGCGAGGGCGGTAGCGGTGGTGCGTTGGCGATCGGT
    GTCGGTGATAAGGTCAACATGCTGCAATACAGCACGTACAGCGTCATTAGCCCGGAAGGT
    TGCGCTTCCATTCTGTGGAAGAGCGCGGATAAAGCACCATTGGCAGCGGAAGCGATGGGT
    ATCATCGCACCGCGTCTGAAAGAACTGAAGTTGATTGATTCTATCATCCCGGAACCGCTG
    GGCGGTGCTCACCGTAATCCGGAGGCGATGGCAGCCAGCCTGAAGGCCCAGCTGCTGGCG
    GACCTGGCGGATCTGGACGTGCTGAGCACGGAGGATCTGAAAAACCGTCGCTATCAGCGC
    TTGATGAGCTATGGCTACGCTTAA
    SEQ ID NO. 13: BICA PROTEIN, SYNECHOCOCCUS SP.
    MQITNKIHFRNIRGDIFGGLTAAVIALPMALAFGVASGAGAEAGLWGAVL
    VGFFAALFGGTPTLISEPTGPMTVVMTAVIAHFTASAATPEEGLAIAFTV
    VMMAGVFQIIFGSLKLGKYVTMMPYTVISGFMSGIGIILVILQLAPFLGQ
    ASPGGGVIGTLQNLPTLLSNIQPGETALALGTVAIIWFMPEKFKKVIPPQ
    LVALVLGTVIAFFVFPPEVSDLRRIGEIRAGFPELVRPSFSPVEFQRMIL
    DAAVLGMLGCIDALLTSVVADSLTRTEHNSNKELIGQGLGNLFSGLFGGI
    AGAGATMGTVVNIQSGGRTALSGLVRAFVLLVVILGAASLTATIPLAVLA
    GIAFKVGVDIIDWSFLKRAHEISPKGALIMYGVILLTVLVDLIVAVGVGV
    FVANVLTIERMSNLQSEKVQTVSDADDNIRLTTTEKRWLDEGQGRVLLFQ
    LSGPMIFGVAKAIAREHNAMGDCDALVFDIGEVPHMGVTASLALENAIEE
    ALDKERQVYIVGAAGQTRRRLEKLKLFKRVPPDKCLMSREEALKNAVLGI
    YPHLADGVTAPSSEMG
    SEQ ID NO. 14: BICA NUCLEIC ACID, SYNECHOCOCCUS SP.
    ATGCAGATTACCAACAAGATCCATTTCCGTAACATTCGTGGCGACATTTTTGGTGGCCTG
    ACCGCTGCTGTGATTGCGCTGCCGATGGCACTGGCTTTTGGTGTGGCAAGTGGTGCAGGT
    GCAGAAGCAGGTCTGTGGGGTGCAGTTCTGGTGGGCTTTTTCGCAGCACTGTTCGGTGGT
    ACGCCGACCCTGATTTCAGAACCGACGGGCCCGATGACCGTGGTTATGACGGCCGTGATC
    GCACATTTTACCGCATCGGCAGCTACGCCGGAAGAAGGCCTGGCTATTGCGTTCACCGTC
    GTGATGATGGCCGGTGTTTTTCAGATTATCTTCGGCAGCCTGAAACTGGGCAAGTATGTT
    ACCATGATGCCGTACACGGTCATCAGTGGTTTTATGTCCGGTATTGGCATTATCCTGGTG
    ATCCTGCAGCTGGCACCGTTCCTGGGTCAAGCCAGTCCGGGCGGTGGCGTTATTGGCACC
    CTGCAGAACCTGCCGACGCTGCTGTCCAATATCCAACCGGGTGAAACCGCCCTGGCACTG
    GGTACGGTCGCGATTATCTGGTTCATGCCGGAAAAGTTCAAGAAGGTTATCCCGCCGCAG
    CTGGTTGCGCTGGTTCTGGGCACCGTCATCGCGTTTTTCGTGTTTCCGCCGGAAGTTAGC
    GATCTGCGTCGCATTGGCGAAATCCGTGCAGGTTTCCCGGAACTGGTGCGTCCGAGCTTT
    TCTCCGGTTGAATTTCAGCGCATGATTCTGGATGCGGCCGTGCTGGGCATGCTGGGTTGC
    ATCGATGCGCTGCTGACCAGCGTTGTCGCCGACTCTCTGACGCGTACCGAACATAACAGC
    AATAAAGAACTGATTGGTCAGGGCCTGGGTAACCTGTTTTCTGGCCTGTTCGGTGGTATT
    GCTGGTGCAGGTGCAACGATGGGCACCGTGGTTAATATCCAAAGTGGTGGCCGTACCGCA
    CTGTCCGGTCTGGTGCGTGCTTTTGTTCTGCTGGTCGTGATTCTGGGTGCAGCTTCTCTG
    ACGGCAACCATTCCGCTGGCTGTGCTGGCAGGCATCGCCTTTAAAGTGGGTGTTGATATT
    ATCGACTGGTCATTCCTGAAACGCGCCCACGAAATCTCGCCGAAGGGCGCACTGATTATG
    TATGGTGTGATCCTGCTGACCGTCCTGGTGGATCTGATTGTTGCGGTCGGCGTGGGTGTT
    TTTGTCGCCAACGTTCTGACCATCGAACGTATGTCAAATCTGCAGTCGGAAAAAGTCCAA
    ACCGTGAGCGATGCGGATGACAACATTCGCCTGACCACGACCGAAAAGCGTTGGCTGGAC
    GAGGGTCAGGGTCGTGTGCTGCTGTTTCAACTGTCTGGCCCGATGATTTTCGGTGTTGCA
    AAAGCTATCGCGCGTGAACATAACGCAATGGGTGATTGCGACGCTCTGGTGTTTGATATT
    GGCGAAGTCCCGCACATGGGTGTGACCGCAAGTCTGGCTCTGGAAAATGCGATTGAAGAA
    GCCCTGGACAAAGAACGCCAGGTTTACATCGTCGGTGCAGCAGGTCAAACCCGTCGCCGT
    CTGGAAAAACTGAAGCTGTTTAAACGCGTGCCGCCGGATAAGTGTCTGATGTCCCGTGAA
    GAAGCACTGAAGAATGCTGTTCTGGGTATCTATCCGCATCTGGCTGACGGTGTTACGGCT
    CCGAGTTCCGAAATGGGCTAA
    SEQ ID NO. 15: MCR DNA ORGANISM NAME: SULFOLOBUS TOKODAII
    ATGTCTCGTC GCACCCTGAA AGCGGCTATC CTGGGCGCCA CCGGCCTGGT TGGTATCGAA   60
    TATGTCCGTA TGCTGTCAAA TCATCCGTAT ATCAAACCGG CGTATCTGGC CGGCAAAGGT  120
    TCAGTTGGCA AACCGTACGG TGAAGTGGTT CGTTGGCAGA CCGTTGGCCA AGTCCCGAAA  180
    GAAATCGCCG ATATGGAAAT TAAACCGACG GACCCGAAAC TGATGGATGA CGTGGATATT  240
    ATCTTTTCGC CGCTGCCGCA GGGTGCGGCC GGTCCGGTTG AAGAACAATT TGCAAAAGAA  300
    GGCTTCCCGG TCATCAGCAA CTCTCCGGAT CATCGTTTCG ATCCGGACGT CCCGCTGCTG  360
    GTGCCGGAAC TGAATCCGCA CACCATTAGT CTGATCGATG AACAGCGCAA ACGTCGCGAA  420
    TGGAAAGGTT TTATTGTTAC CACGCCGCTG TGCACGGCAC AAGGTGCAGC TATCCCGCTG  480
    GGTGCTATCT TCAAAGATTA CAAAATGGAC GGCGCGTTCA TTACCACGAT CCAGAGTCTG  540
    TCCGGTGCAG GTTACCCGGG TATCCCGTCT CTGGATGTCG TGGACAACAT TCTGCCGCTG  600
    GGCGATGGTT ATGACGCGAA AACCATTAAA GAAATCTTCC GTATTCTGTC AGAAGTTAAA  660
    CGCAATGTCG ATGAACCGAA ACTGGAAGAC GTTTCGCTGG CGGCCACCAC GCATCGTATC  720
    GCCACCATTC ATGGCCACTA TGAAGTGCTG TACGTTAGTT TTAAAGAAGA AACCGCAGCT  780
    GAAAAAGTGA AAGAAACGCT GGAAAACTTC CGCGGTGAAC CGCAGGATCT GAAACTGCCG  840
    ACCGCACCGT CCAAACCGAT TATCGTCATG AATGAAGATA CGCGTCCGCA AGTGTACTTT  900
    GATCGCTGGG CTGGCGACAT TCCGGGTATG AGCGTTGTCG TGGGCCGTCT GAAACAGGTG  960
    AACAAACGTA TGATCCGCCT GGTGTCTCTG ATTCACAATA CCGTTCGCGG TGCGGCGGGC 1020
    GGTGGCATCC TGGCTGCTGA ACTGCTGGTT GAAAAAGGTT ACATTGAAAA A 1071
    <212>TYPE: DNA
    <211>LENGTH: 1071
    SEQUENCENAME: SULFOLOBUS TOKODAII MCR DNA
    SEQ ID NO. 16: MCR PROTEIN ORGANISM NAME: SULFOLOBUS TOKODAII
    MSRRTLKAAI LGATGLVGIE YVRMLSNHPY IKPAYLAGKG SVGKPYGEVV RWQTVGQVPK   60
    EIADMEIKPT DPKLMDDVDI IFSPLPQGAA GPVEEQFAKE GFPVISNSPD HRFDPDVPLL  120
    VPELNPHTIS LIDEQRKRRE WKGFIVTTPL CTAQGAAIPL GAIFKDYKMD GAFITTIQSL  180
    SGAGYPGIPS LDVVDNILPL GDGYDAKTIK EIFRILSEVK RNVDEPKLED VSLAATTHRI  240
    ATIHGHYEVL YVSFKEETAA EKVKETLENF RGEPQDLKLP TAPSKPIIVM NEDTRPQVYF  300
    DRWAGDIPGM SVVVGRLKQV NKRMIRLVSL IHNTVRGAAG GGILAAELLV EKGYIEK  357
    <212>TYPE: PRT
    <211>LENGTH: 357
    SEQUENCENAME: SULFOLOBUS TOKODAII MCR PROTEIN
    SEQ ID NO. 17: NEMA DNA ORGANISM NAME: ESCHERICHIA COLI
    ATGTCATCTG AAAAACTGTA TTCCCCACTG AAAGTGGGCG CGATCACGGC GGCAAACCGT   60
    ATTTTTATGG CACCGCTGAC GCGTCTGCGC AGTATTGAAC CGGGTGACAT TCCTACCCCG  120
    TTGATGGCGG AATACTATCG CCAACGTGCC AGTGCCGGTT TGATTATTAG TGAAGCCACG  180
    CAAATTTCTG CCCAGGCAAA AGGATATGCA GGTGCGCCTG GCATCCATAG TCCGGAGCAA  240
    ATTGCCGCAT GGAAAAAAAT CACCGCTGGC GTTCATGCTG AAAATGGTCA TATGGCCGTG  300
    CAGCTGTGGC ACACCGGACG CATTTCTCAC GCCAGCCTGC AACCTGGCGG TCAGGCACCG  360
    GTAGCGCCTT CAGCACTTAG CGCGGGAACA CGTACTTCTC TGCGCGATGA AAATGGTCAG  420
    GCGATCCGTG TTGAAACATC CATGCCGCGT GCGCTTGAAC TGGAAGAGAT TCCAGGTATC  480
    GTCAATGATT TCCGTCAGGC CATTGCTAAC GCGCGTGAAG CCGGTTTTGA TCTGGTAGAG  540
    CTCCACTCTG CTCACGGTTA TTTGCTGCAT CAGTTCCTTT CTCCTTCTTC AAACCATCGT  600
    ACCGATCAGT ACGGCGGCAG CGTGGAAAAT CGCGCACGTT TGGTACTGGA AGTGGTCGAT  660
    GCCGGGATTG AAGAATGGGG TGCCGATCGC ATTGGCATTC GCGTTTCACC AATCGGTACT  720
    TTCCAGAACA CAGATAACGG CCCGAATGAA GAAGCCGATG CACTGTATCT GATTGAACAA  780
    CTGGGTAAAC GCGGCATTGC TTATCTGCAT ATGTCAGAAC CAGATTGGGC GGGGGGTGAA  840
    CCGTATACTG ATGCGTTCCG CGAAAAAGTA CGCGCCCGTT TCCACGGTCC GATTATCGGC  900
    GCAGGTGCAT ACACAGTAGA AAAAGCTGAA ACGCTGATCG GCAAAGGGTT AATTGATGCG  960
    GTGGCATTTG GTCGTGACTG GATTGCGAAC CCGGATCTGG TCGCCCGCTT GCAGCGCAAA 1020
    GCTGAGCTTA ACCCACAGCG TGCCGAAAGT TTCTACGGTG GCGGCGCGGA AGGCTATACC 1080
    GATTACCCGA CGTTGTAA 1098
    <212>TYPE: DNA
    <211>LENGTH: 1098
    SEQUENCENAME: ESCHERICHIA COLI NEMA DNA
    SEQ ID NO. 18: NEMA PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MSSEKLYSPL KVGAITAANR IFMAPLTRLR SIEPGDIPTP LMAEYYRQRA SAGLIISEAT   60
    QISAQAKGYA GAPGIHSPEQ IAAWKKITAG VHAENGHMAV QLWHTGRISH ASLQPGGQAP  120
    VAPSALSAGT RTSLRDENGQ AIRVETSMPR ALELEEIPGI VNDFRQAIAN AREAGFDLVE  180
    LHSAHGYLLH QFLSPSSNHR TDQYGGSVEN RARLVLEVVD AGIEEWGADR IGIRVSPIGT  240
    FQNTDNGPNE EADALYLIEQ LGKRGIAYLH MSEPDWAGGE PYTDAFREKV RARFHGPIIG  300
    AGAYTVEKAE TLIGKGLIDA VAFGRDWIAN PDLVARLQRK AELNPQRAES FYGGGAEGYT  360
    DYPTL  365
    <212>TYPE: PRT
    <211>LENGTH: 365
    SEQUENCENAME: ESCHERICHIA COLI NEMA PROTEIN
    SEQ ID NO. 19: RUTE DNA ORGANISM NAME: ESCHERICHIA COLI
    ATGAACGAAG CCGTTAGCCC AGGTGCGCTT AGCACCCTGT TCACCGATGC CCGCACTCAC   60
    AACGGCTGGC GGGAGACACC CGTCAGCGAT GAGACGTTAC GGGAGATTTA TGCCCTGATG  120
    AAATGGGGGC CGACATCAGC TAACTGTTCT CCGGCACGGA TCGTGTTTAC CCGCACGGCA  180
    GAAGGAAAAG AACGTCTGCG CCCGGCACTT TCCAGCGGCA ATCTGCAAAA AACCCTGACC  240
    GCGCCCGTCA CCGCTATCGT CGCCTGGGAC AGTGAATTTT ATGAACGGTT ACCACTACTG  300
    TTTCCCCACG GTGATGCCCG CAGTTGGTTT ACCTCCAGCC CACAACTTGC CGAAGAAACA  360
    GCGTTTCGCA ACAGTTCCAT GCAGGCGGCC TATCTGATCG TCGCCTGCCG GGCGCTGGGA  420
    CTGGATACCG GCCCGATGTC GGGCTTTGAC CGTCAACACG TGGACGACGC CTTTTTTACG  480
    GGCAGCACGC TGAAGAGCAA TCTGCTGATT AATATCGGCT ATGGCGATAG CAGCAAGCTT  540
    TATGCGCGCC TGCCACGTCT GTCCTTTGAA GAAGCCTGCG GGCTGTTGTA A  591
    <212>TYPE: DNA
    <211>LENGTH: 591
    SEQUENCENAME: ESCHERICHIA COLI RUTE DNA
    SEQ ID NO. 20 RUTE PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MNEAVSPGAL STLFTDARTH NGWRETPVSD ETLREIYALM KWGPTSANCS PARIVFTRTA   60
    EGKERLRPAL SSGNLQKTLT APVTAIVAWD SEFYERLPLL FPHGDARSWF TSSPQLAEET  120
    AFRNSSMQAA YLIVACRALG LDTGPMSGFD RQHVDDAFFT GSTLKSNLLI NIGYGDSSKL  180
    YARLPRLSFE EACGLL  196
    <212>TYPE: PRT
    <211>LENGTH: 196
    SEQUENCENAME: ESCHERICHIA COLI RUTE PROTEIN
    SEQ ID NO. 21: YDFG DNA ORGANISM NAME: ESCHERICHIA COLI
    ATGGTCGTTT TAGTAACTGG AGCAACGGCA GGTTTTGGTG AATGCATTAC TCGTCGTTTT   60
    ATTCAACAAG GGCATAAAGT TATCGCCACT GGCCGTCGCC AGGAACGGTT GCAGGAGTTA  120
    AAAGACGAAC TGGGAGATAA TCTGTATATC GCCCAACTGG ACGTTCGCAA CCGCGCCGCT  180
    ATTGAAGAGA TGCTGGCATC GCTTCCTGCC GAGTGGTGCA ATATTGATAT CCTGGTAAAT  240
    AATGCCGGCC TGGCGTTGGG CATGGAGCCT GCGCATAAAG CCAGCGTTGA AGACTGGGAA  300
    ACGATGATTG ATACCAACAA CAAAGGCCTG GTATATATGA CGCGCGCCGT CTTACCGGGT  360
    ATGGTTGAAC GTAATCATGG TCATATTATT AACATTGGCT CAACGGCAGG TAGCTGGCCG  420
    TATGCCGGTG GTAACGTTTA CGGTGCGACG AAAGCGTTTG TTCGTCAGTT TAGCCTGAAT  480
    CTGCGTACGG ATCTGCATGG TACGGCGGTG CGCGTCACCG ACATCGAACC GGGTCTGGTG  540
    GGTGGTACCG AGTTTTCCAA TGTCCGCTTT AAAGGCGATG ACGGTAAAGC AGAAAAAACC  600
    TATCAAAATA CCGTTGCATT GACGCCAGAA GATGTCAGCG AAGCCGTCTG GTGGGTGTCA  660
    ACGCTGCCTG CTCACGTCAA TATCAATACC CTGGAAATGA TGCCGGTTAC CCAAAGCTAT  720
    GCCGGACTGA ATGTCCACCG TCAGTAA  747
    <212>TYPE: DNA
    <211>LENGTH: 747
    SEQUENCENAME: ESCHERICHIA COLI YDFG DNA
    SEQ ID NO. 22: YDFG PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MVVLVTGATA GFGECITRRF IQQGHKVIAT GRRQERLQEL KDELGDNLYI AQLDVRNRAA   60
    IEEMLASLPA EWCNIDILVN NAGLALGMEP AHKASVEDWE TMIDTNNKGL VYMTRAVLPG  120
    MVERNHGHII NIGSTAGSWP YAGGNVYGAT KAFVRQFSLN LRTDLHGTAV RVTDIEPGLV  180
    GGTEFSNVRF KGDDGKAEKT YQNTVALTPE DVSEAVWWVS TLPAHVNINT LEMMPVTQSY   240
    AGLNVHRQ  248
    <212>TYPE: PRT
    <211>LENGTH: 248
    SEQUENCENAME: ESCHERICHIA COLI YDFG PROTEIN
    SEQ ID NO. 23: MMSB DNA ORGANISM NAME: P. AERUGINOSA
    ATGGCCGACA TTGCGTTTCT GGGTCTGGGC AATATGGGCG GTCCGATGGC CGCGAACCTG   60
    CTGAAAGCCG GCCACCGTGT GAATGTGTTC GACCTGCAAC CAAAAGCGGT CCTGGGCTTG  120
    GTTGAGCAAG GCGCGCAGGG CGCAGACTCT GCTCTGCAAT GTTGTGAGGG TGCGGAGGTC  180
    GTGATTTCTA TGCTGCCAGC AGGCCAGCAT GTGGAAAGCC TGTACCTGGG CGATGATGGT  240
    CTGCTGGCAC GCGTGGCGGG CAAGCCTTTG CTGATTGACT GTAGCACCAT CGCACCGGAA  300
    ACGGCGCGTA AGGTGGCGGA GGCAGCCGCA GCAAAGGGCC TGACGCTGCT GGATGCCCCG  360
    GTTTCGGGCG GTGTCGGTGG TGCCCGTGCA GGTACGCTGT CGTTTATCGT GGGTGGTCCG  420
    GCGGAGGGTT TTGCGCGTGC GCGTCCGGTT CTGGAGAATA TGGGTCGCAA CATTTTCCAC  480
    GCGGGTGATC ACGGCGCTGG TCAGGTGGCG AAAATCTGTA ACAACATGCT GCTGGGTATC  540
    TTGATGGCGG GCACCGCCGA AGCCTTGGCG CTGGGCGTCA AAAACGGTCT GGACCCGGCA  600
    GTGCTGTCCG AAGTGATGAA ACAGAGCAGC GGTGGTAACT GGGCGCTGAA TCTGTACAAT  660
    CCGTGGCCGG GTGTGATGCC GCAGGCCCCA GCCTCTAATG GCTACGCAGG CGGCTTCCAA  720
    GTGCGCCTGA TGAACAAAGA CCTGGGCCTG GCGCTGGCGA ATGCGCAAGC GGTCCAAGCG  780
    AGCACCCCGC TGGGCGCACT GGCCCGTAAC CTGTTTAGCC TGCACGCTCA AGCCGACGCC  840
    GAGCACGAAG GTCTGGACTT CAGCTCTATT CAAAAACTGT ATCGCGGTAA GGATTAG  897
    <212>TYPE: DNA
    <211>LENGTH: 897
    SEQUENCE NAME: P. AERUGINOSA MMSB DNA
    SEQ ID NO. 24: MMSB PROTEIN ORGANISM NAME: P. AERUGINOSA
    MADIAFLGLG NMGGPMAANL LKAGHRVNVF DLQPKAVLGL VEQGAQGADS ALQCCEGAEV   60
    VISMLPAGQH VESLYLGDDG LLARVAGKPL LIDCSTIAPE TARKVAEAAA AKGLTLLDAP  120
    VSGGVGGARA GTLSFIVGGP AEGFARARPV LENMGRNIFH AGDHGAGQVA KICNNMLLGI  180
    LMAGTAEALA LGVKNGLDPA VLSEVMKQSS GGNWALNLYN PWPGVMPQAP ASNGYAGGFQ  240
    VRLMNKDLGL ALANAQAVQA STPLGALARN LFSLHAQADA EHEGLDFSSI QKLYRGKD  298
    <212>TYPE: PRT
    <211>LENGTH: 298
    SEQUENCENAME: P. AERUGINOSA MMSB PROTEIN
    SEQ ID NO. 25: NDSD DNA ORGANISMNAME: PSEUDOMONAS AERUGINOSA
    ATGGGCAAAC AGATCGCCTT CATCGGCCTG GGCCATATGG GCGCACCTAT GGCCACCAAC   60
    CTGCTGAAGG CCGGCTACCT GCTGAATGTG TTCGACCTGG TGCAGAGCGC CGTGGATGGT  120
    TTAGTGGCCG CAGGTGCAAG TGCAGCACGC AGTGCACGCG ATGCCGTTCA GGGTGCCGAC  180
    GTGGTGATCA GCATGCTGCC TGCCAGCCAA CACGTGGAGG GTCTGTACCT GGACGACGAT  240
    GGTCTGCTGG CCCACATTGC CCCTGGCACC TTAGTGCTGG AGTGCAGCAC AATCGCCCCG  300
    ACCAGTGCAC GCAAGATTCA TGCAGCAGCC CGCGAGCGTG GTCTGGCAAT GCTGGACGCA  360
    CCGGTTAGCG GTGGTACAGC AGGTGCCGCA GCAGGCACCC TGACCTTCAT GGTGGGCGGT  420
    GACGCCGAAG CCCTGGAAAA AGCACGCCCG CTGTTTGAGG CAATGGGCCG TAACATCTTC  480
    CATGCCGGCC CTGATGGCGC AGGTCAGGTG GCCAAAGTGT GCAATAACCA GCTGCTGGCA  540
    GTGCTGATGA TCGGTACCGC CGAGGCAATG GCACTGGGCG TGGCAAACGG CTTAGAGGCC  600
    AAGGTGCTGG CAGAAATCAT GCGCCGTAGT AGCGGCGGTA ACTGGGCCCT GGAGGTGTAC  660
    AACCCGTGGC CTGGCGTGAT GGAGAATGCA CCGGCCAGTC GTGACTACAG CGGCGGTTTC  720
    ATGGCACAGC TGATGGCCAA GGACCTGGGC TTAGCCCAAG AGGCAGCCCA AGCCAGCGCC  780
    AGTAGTACCC CGATGGGCAG CTTAGCCCTG AGTCTGTACC GCTTACTGCT GAAGCAGGGC  840
    TACGCCGAAC GCGACTTCAG CGTGGTGCAG AAGCTGTTCG ACCCGACCCA AGGCCAGTAA  900
    <212>TYPE: DNA
    <211>LENGTH: 900
    SEQUENCENAME: P. AERUGINOSA NDSD DNA
    SEQ ID NO. 26: NDSD PROTEIN PSEUDOMONAS AERUGINOSA
    MGKQIAFIGL GHMGAPMATN LLKAGYLLNV FDLVQSAVDG LVAAGASAAR SARDAVQGAD   60
    VVISMLPASQ HVEGLYLDDD GLLAHIAPGT LVLECSTIAP TSARKIHAAA RERGLAMLDA  120
    PVSGGTAGAA AGTLTFMVGG DAEALEKARP LFEAMGRNIF HAGPDGAGQV AKVCNNQLLA  180
    VLMIGTAEAM ALGVANGLEA KVLAEIMRRS SGGNWALEVY NPWPGVMENA PASRDYSGGF  240
    MAQLMAKDLG LAQEAAQASA SSTPMGSLAL SLYRLLLKQG YAERDFSVVQ KLFDPTQGQ  299
    <212>TYPE: PRT
    <211>LENGTH: 299
    SEQUENCENAME: P. AERUGINOSA NDSD PROTEIN
    SEQ ID NO. 27: FABI(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MGFLSGKRIL VTGVASKLSI AYGIAQAMHR EGAELAFTYQ NDKLKGRVEE FAAQLGSDIV   60
    LQCDVAEDAS IDTMFAELGK VWPKFDGFVH SIGFAPGDQL DGDYVNAVTR EGFKIAHDIS  120
    SYSFVAMAKA CRSMLNPGSA LLTLSYLGAE RAIPNYNVMG LAKASLEANV RYMANAMGPE  180
    GVRVNAISAG PIRTLAASGI KDFRKMLAHC EAVTPIRRTV TIEDVGNSAA FLCSDLSAGI  240
    FGEVVHVDGG FSIAAMNELE LK  262
    <212>TYPE: PRT
    <211>LENGTH: 262
    SEQUENCENAME: ESCHERICHIA COLI FABI(TS) PROTEIN
    SEQ ID NO. 28: FABB(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MKRAVITGLG IVSSIGNNQQ EVLASLREGR SGITFSQELK DSGMRSHVWG NVKLDTTGLI   60
    DRKVVRFMSD ASIYAFLSME QAIADAGLSP EAYQNNPRVG LIAGSGGGSP RFQVFGADAM  120
    RGPRGLKAVG PYVVTKAMAS GVSACLATPF KIHGVNYSIS SACATSAHCI GNAVEQIQLG  180
    KQDIVFAGGG EELCWEMACE FDAMGALSTK YNDTPEKASR TYDAHRDGFV IAGGGGMVVV  240
    EELEHALARG AHIYAEIVGY GATSDGADMV APSGEGAVRC MKMAMHGVDT PIDYLNSHGT  300
    STPVGDVKEL AAIREVFGDK SPAISATKVM TGHSLGAAGV QEAIYSLLML EHGFIAPSIN  360
    IEELDEQAAG LNIVTETTDR ELTTVMSNSF GFGGTNATLV MRKLKD  406
    <212>TYPE: PRT
    <211>LENGTH: 406
    SEQUENCENAME: ESCHERICHIA COLI FABB(TS) PROTEIN
    SEQ ID NO. 29: FABD(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MTQFAFVFPG QGSQTVGMLA DMAASYPIVE ETFAEASAAL GYDLWALTQQ GPAEELNKTW   60
    QTQPALLTAS VALYRVWQQQ GGKAPAMMAG HSLGEYSALV CAGVIDFADA VRLVEMRGKF  120
    MQEAVPEGTG AMAAIIGLDD ASIAKACEEA AEGQVVSPVN FNSPGQVVIA GHKEAVERAG  180
    AACKAAGAKR ALPLPVSVPS HCALMKPAAD KLAVELAKIT FNAPTVPVVN NVDVKCETNG  240
    DAIRDALVRQ LYNPVQQTKS VEYMAAQGVE HLYEVGPGKV LTGLTKRIVD TLTASALNEP   300
    SAMAAALEL  309
    <212>TYPE: PRT
    <211>LENGTH: 309
    SEQUENCENAME: ESCHERICHIA COLI FABD(TS) PROTEIN
    SEQ ID NO. 30: RHTA DNA ORGANISM NAME: ESCHERICHIA COLI
    ATGAGCGGTT CATTACGTAA AATGCCGGTC TGGTTACCAA TAGTCATATT GCTCGTTGCC   60
    ATGGCGTCTA TTCAGGGTGG AGCCTCGTTA GCTAAGTCAC TTTTTCCTCT GGTGGGCGCA  120
    CCGGGTGTCA CTGCGCTGCG TCTGGCATTA GGAACGCTGA TCCTCATCGC GTTCTTTAAG  180
    CCATGGCGAC TGCGCTTTGC CAAAGAGCAA CGGTTACCGC TGTTGTTTTA CGGCGTTTCG  240
    CTGGGTGGGA TGAATTATCT TTTTTATCTT TCTATTCAGA CAGTACCGCT GGGTATTGCG  300
    GTGGCGCTGG AGTTCACCGG ACCACTGGCG GTGGCGCTGT TCTCTTCTCG TCGCCCGGTA  360
    GATTTCGTCT GGGTTGTGCT GGCGGTTCTT GGTCTGTGGT TCCTGCTACC GCTGGGGCAA  420
    GACGTTTCCC ATGTCGATTT AACCGGCTGT GCGCTGGCAC TGGGGGCCGG GGCTTGTTGG  480
    GCTATTTACA TTTTAAGTGG GCAACGCGCA GGAGCGGAAC ATGGCCCTGC GACGGTGGCA  540
    ATTGGTTCGT TGATTGCAGC GTTAATTTTC GTGCCAATTG GAGCGCTTCA GGCTGGTGAA  600
    GCACTCTGGC ACTGGTCGGT TATTCCATTG GGTCTGGCTG TCGCTATTCT CTCGACCGCT  660
    CTGCCTTATT CGCTGGAAAT GATTGCCCTC ACCCGTTTGC CAACACGGAC ATTTGGTACG  720
    CTGATGAGCA TGGAACCGGC GCTGGCTGCC GTTTCCGGGA TGATTTTCCT CGGAGAAACA  780
    CTGACACCCA TACAGCTACT GGCGCTCGGC GCTATCATCG CCGCTTCAAT GGGGTCTACG  840
    CTGACAGTAC GCAAAGAGAG CAAAATAAAA GAATTAGACA TTAATTAA  888
    <212>TYPE: DNA
    <211>LENGTH: 888
    SEQUENCENAME: ESCHERICHIA COLI RHTA DNA
    SEQ ID NO. 31: RHTA PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MSGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK   60
    PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV  120
    DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA  180
    IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTFGT  240
    LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN  295
    <212>TYPE: PRT
    <211>LENGTH: 295
    SEQUENCENAME: ESCHERICHIA COLI RHTA PROTEIN
    SEQ ID NO. 32: YDCO DNA ORGANISM NAME: ESCHERICHIA COLI
    ATGCGACTCC TCCGGCAAAA CGGAAGTTTA TCACTTGTGC GTTATAACGG ACAAATGCTA   60
    CGGTGCCTGT ACGCTATAAC GCACGAGGTG ACTATGCGTC TGTTTTCTAT TCCTCCACCC  120
    ACGCTACTGG CGGGGTTTCT GGCGGTATTA ATTGGCTACG CCAGTTCAGC GGCAATAATC  180
    TGGCAAGCAG CGATTGTCGC CGGAGCCACC ACTGCACAAA TCTCTGGCTG GATGACGGCG  240
    CTGGGGCTGG CAATGGGCGT CAGTACGCTG ACTCTGACAT TATGGTATCG CGTACCTGTT  300
    CTCACCGCAT GGTCAACGCC TGGCGCGGCT TTGTTGGTCA CCGGATTGCA GGGACTAACA  360
    CTTAACGAAG CCATCGGCGT TTTTATTGTC ACCAACGCGC TAATAGTCCT CTGCGGCATA  420
    ACGGGACTCT TTGCTCGTCT GATGCGCATT ATTCCGCACT CGCTTGCGGC GGCAATGCTT  480
    GCCGGGATTT TATTACGCTT TGGTTTACAG GCGTTTGCCA GTCTGGACGG TCAATTTACG  540
    TTGTGTGGAA GTATGTTGCT GGTATGGCTG GCAACCAAGG CCGTTGCGCC GCGCTATGCG  600
    GTAATTGCCG CGATGATTAT TGGGATCGTG ATCGTCATCG CGCAAGGTGA CGTTGTCACA  660
    ACTGATGTTG TCTTTAAACC CGTTCTCCCC ACTTATATTA CCCCTGATTT TTCGTTTGCT  720
    CACAGCCTGA GCGTTGCACT CCCCCTTTTT CTGGTGACGA TGGCATCGCA AAACGCACCG  780
    GGTATCGCAG CAATGAAAGC AGCTGGATAT TCGGCTCCTG TTTCGCCATT AATTGTATTT  840
    ACTGGATTGC TGGCACTGGT TTTTTCCCCT TTCGGCGTTT ATTCCGTCGG TATTGCGGCA  900
    ATCACCGCGG CTATTTGCCA AAGCCCGGAA GCGCATCCGG ATAAAGATCA ACGTTGGCTG  960
    GCCGCTGCCG TTGCAGGCAT TTTCTATTTG CTCGCAGGTC TGTTTGGTAG TGCCATTACC 1020
    GGGATGATGG CTGCCCTGCC CGTAAGTTGG ATCCAGATGC TGGCAGGTCT GGCGCTGTTA 1080
    AGTACCATCG GCGGCAGTTT GTATCAGGCG CTGCATAATG AGCGTGAGCG AGACGCGGCG 1140
    GTGGTGGCAT TTCTGGTAAC GGCAAGTGGA TTGACGCTGG TCGGGATTGG TTCTGCGTTT 1200
    TGGGGATTAA TTGCCGGAGG CGTTTGTTAC GTGGTGTTGA ATTTAATCGC TGACAGAAAC 1260
    CGATATTGA 1269
    <212>TYPE: DNA
    <211>LENGTH: 1269
    SEQUENCENAME: ESCHERICHIA COLI YDCO DNA
    SEQ ID NO. 33: YDCO PROTEIN ORGANISM NAME: ESCHERICHIA COLI
    MRLLRQNGSL SLVRYNGQML RCLYAITHEV TMRLFSIPPP TLLAGFLAVL IGYASSAAII   60
    WQAAIVAGAT TAQISGWMTA LGLAMGVSTL TLTLWYRVPV LTAWSTPGAA LLVTGLQGLT  120
    LNEAIGVFIV TNALIVLCGI TGLFARLMRI IPHSLAAAML AGILLRFGLQ AFASLDGQFT  180
    LCGSMLLVWL ATKAVAPRYA VIAAMIIGIV IVIAQGDVVT TDVVFKPVLP TYITPDFSFA  240
    HSLSVALPLF LVTMASQNAP GIAAMKAAGY SAPVSPLIVF TGLLALVFSP FGVYSVGIAA  300
    ITAAICQSPE AHPDKDQRWL AAAVAGIFYL LAGLFGSAIT GMMAALPVSW IQMLAGLALL  360
    STIGGSLYQA LHNERERDAA VVAFLVTASG LTLVGIGSAF WGLIAGGVCY VVLNLIADRN  420
    RY  422
    <212>TYPE: PRT
    <211>LENGTH: 422
    SEQUENCENAME: ESCHERICHIA COLI YDCO PROTEIN
    SEQ ID NO. 34: ACRD ORGANISM NAME: ESCHERICHIA COLI
    MANFFIDRPI FAWVLAILLC LTGTLAIFSL PVEQYPDLAP PNVRVTANYP GASAQTLENT
    VTQVIEQNMT GLDNLMYMSS QSSGTGQASV TLSFKAGTDP DEAVQQVQNQ LQSAMRKLPQ
    AVQNQGVTVR KTGDTNILTI AFVSTDGSMD KQDIADYVAS NIQDPLSRVN GVGDIDAYGS
    QYSMRIWLDP AKLNSFQMTA KDVTDAIESQ NAQIAVGQLG GTPSVDKQAL NATINAQSLL
    QTPEQFRDIT LRVNQDGSEV RLGDVATVEM GAEKYDYLSR FNGKPASGLG VKLASGANEM
    ATAELVLNRL DELAQYFPHG LEYKVAYETT SFVKASIEDV VKTLLEAIAL VFLVMYLFLQ
    NFRATLIPTI AVPVVLMGTF SVLYAFGYSV NTLTMFAMVL AIGLLVDDAI VVVENVERIM
    SEEGLTPREA TRKSMGQIQG ALVGIAMVLS AVFVPMAFFG GTTGAIYRQF SITIVAAMVL
    SVLVAMILTP ALCATLLKPL KKGEHHGQKG FFAWFNQMFN RNAERYEKGV AKILHRSLRW
    IVIYVLLLGG MVFLFLRLPT SFLPLEDRGM FTTSVQLPSG STQQQTLKVV EQIEKYYFTH
    EKDNIMSVFA TVGSGPGGNG QNVARMFIRL KDWSERDSKT GTSFAIIERA TKAFNQIKEA
    RVIASSPPAI SGLGSSAGFD MELQDHAGAG HDALMAARNQ LLALAAENPE LTRVRHNGLD
    DSPQLQIDID QRKAQALGVA IDDINDTLQT AWGSSYVNDF MDRGRVKKVY VQAAAPYRML
    PDDINLWYVR NKDGGMVPFS AFATSRWETG SPRLERYNGY SAVEIVGEAA PGVSTGTAMD
    IMESLVKQLP NGFGLEWTAM SYQERLSGAQ APALYAISLL VVFLCLAALY ESWSVPFSVM
    LVVPLGVIGA LLATWMRGLE NDVYFQVGLL TVIGLSAKNA ILIVEFANEM NQKGHDLFEA
    TLHACRQRLR PILMTSLAFI FGVLPMATST GAGSGGQHAV GTGVMGGMIS ATILAIYFVP
    LFFVLVRRRF PLKPRPE
    SEQ ID NO. 35: ATTA ORGANISM NAME: ESCHERICHIA COLI
    MAHPPLLHLQ DITLSLGGNP LLDGAGFAVG RGERLCLVGR NGSGKSTLLK IAAGVIQPDS
    GSVFVQPGAS LRYLPQEPDL SAYATTADYV VGQIGDPDMA WRATPLLDAL GLTGRESTQN
    LSGGEGRRCA IAGVLAAAPD VLLLDEPTNH LDMPTIEWLE RELLSLGAMV IISHDRRLLS
    TLSRSVVWLD RGVTRRLDEG FGRFEAWREE VLEQEERDAH KLDRKIAREE DWMRYGVTAR
    RKRNVRRVRE LADLRTARKE AIRAPGTLTL NTQLRPHRKL VAVAEDISKA WGEKQVVRHL
    DLRILRGDRL GIVGANGAGK TTLLRMLTGL DQPDSGTISL GPSLNMVTLD QQRRTLNPER
    TLADTLTEGG GDMVQVGTEK RHVVGYMKDF LFRPEQARTP VSALSGGERG RLMLACALAK
    PSNLLVLDEP TNDLDLETLD ILQDMLASCE GTVLLVSHDR DFLDRVATSV LATEGDGNWI
    EYAGGYSDML AQRHQKPLTT ASVVENEPTK PKETTAARGP TKKLSYKDQF ALDNLPKEME
    KLEAQAANCV KNWQIQIYME KTPRSLRNFR LIYRSSKQSW QNLKNAGWNW K
    SEQ ID NO. 36: BCR ORGANISM NAME: ESCHERICHIA COLI
    MTTRQHSSFA IVFILGLLAM LMPLSIDMYL PALPVISAQF GVPAGSTQMT LSTYILGFAL
    GQLIYGPMAD SFGRKPVVLG GTLVFAAAAV ACALANTIDQ LIVMRFFHGL AAAAASVVIN
    ALMRDIYPKE EFSRMMSFVM LVTTIAPLMA PIVGGWVLVW LSWHYIFWIL ALAAILASAM
    IFFLIKETLP PERRQPFHIR TTIGNFAALF RHKRVLSYML ASGFSFAGMF SFLSAGPFVY
    IEINHVAPEN FGYYFALNIV FLFVMTIFNS RFVRRIGALN MFRSGLWIQF IMAAWMVISA
    LLGLGFWSLV VGVAAFVGCV SMVSSNAMAV ILDEFPHMAG TASSLAGTFR FGIGAIVGAL
    LSLATFNSAW PMIWSIAFCA TSSILFCLYA SRPKKR
    SEQ ID NO. 37: CUSA ORGANISM NAME: ESCHERICHIA COLI
    MIEWIIRRSV ANRFLVLMGA LFLSIWGTWT IINTPVDALP DLSDVQVIIK TSYPGQAPQI
    VENQVTYPLT TTMLSVPGAK TVRGFSQFGD SYVYVIFEDG TDPYWARSRV LEYLNQVQGK
    LPAGVSAELG PDATGVGWIY EYALVDRSGK HDLADLRSLQ DWFLKYELKT IPDVAEVASV
    GGVVKEYQVV IDPQRLAQYG ISLAEVKSAL DASNQEAGGS SIELAEAEYM VRASGYLQTL
    DDFNHIVLKA SENGVPVYLR DVAKVQIGPE MRRGIAELNG EGEVAGGVVI LRSGKNAREV
    IAAVKDKLET LKSSLPEGVE IVTTYDRSQL IDRAIDNLSG KLLEEFIVVA VVCALFLWHV
    RSALVAIISL PLGLCIAFIV MHFQGLNANI MSLGGIAIAV GAMVDAAIVM IENAHKRLEE
    WQHQHPDATL DNKTRWQVIT DASVEVGPAL FISLLIITLS FIPIFTLEGQ EGRLFGPLAF
    TKTYAMAGAA LLAIVVIPIL MGYWIRGKIP PESSNPLNRF LIRVYHPLLL KVLHWPKTTL
    LVAALSVLTV LWPLNKVGGE FLPQINEGDL LYMPSTLPGI SAAEAASMLQ KTDKLIMSVP
    EVARVFGKTG KAETATDSAP LEMVETTIQL KPQEQWRPGM TMDKIIEELD NTVRLPGLAN
    LWVPPIRNRI DMLSTGIKSP IGIKVSGTVL ADIDAMAEQI EEVARTVPGV ASALAERLEG
    GRYINVEINR EKAARYGMTV ADVQLFVTSA VGGAMVGETV EGIARYPINL RYPQSWRDSP
    QALRQLPILT PMKQQITLAD VADIKVSTGP SMLKTENARP TSWIYIDARD RDMVSVVHDL
    QKAIAEKVQL KPGTSVAFSG QFELLERANH KLKLMVPMTL MIIFVLLYLA FRRVGEALLI
    ISSVPFALVG GIWLLWWMGF HLSVATGTGF IALAGVAAEF GVVMLMYLRH AIEAVPSLNN
    PQTFSEQKLD EALYHGAVLR VRPKAMTVAV IIAGLLPILW GTGAGSEVMS RIAAPMIGGM
    ITAPLLSLFI IPAAYKLMWL HRHRVRK
    SEQ ID NO. 38: CYNX ORGANISM NAME: ESCHERICHIA COLI
    MLLVLVLIGL NMRPLLTSVG PLLPQLRQAS GMSFSVAALL TALPVVTMGG LALAGSWLHQ
    HVSERRSVAI SLLLIAVGAL MRELYPQSAL LLSSALLGGV GIGIIQAVMP SVIKRRFQQR
    TPLVMGLWSA ALMGGGGLGA AITPWLVQHS ETWYQTLAWW ALPAVVALFA WWWQSAREVA
    SSHKTTTTPV RVVFTPRAWT LGVYFGLING GYASLIAWLP AFYIEIGASA QYSGSLLALM
    TLGQAAGALL MPAMARHQDR RKLLMLALVL QLVGFCGFIW LPMQLPVLWA MVCGLGLGGA
    FPLCLLLALD HSVQPAIAGK LVAFMQGIGF IIAGLAPWFS GVLRSISGNY LMDWAFHALC
    VVGLMIITLR FAPVRFPQLW VKEA
    SEQ ID NO. 39: DEDA ORGANISM NAME: ESCHERICHIA COLI
    MDLIYFLIDF ILHIDVHLAE LVAEYGVWVY AILFLILFCE TGLVVTPFLP GDSLLFVAGA
    LASLETNDLN VHMMVVLMLI AAIVGDAVNY TIGRLFGEKL FSNPNSKIFR RSYLDKTHQF
    YEKHGGKTII LARFVPIVRT FAPFVAGMGH MSYRHFAAYN VIGALLWVLL FTYAGYFFGT
    IPMVQDNLKL LIVGIIVVSI LPGVIEIIRH KRAAARAAK
    SEQ ID NO. 40: EAMA ORGANISM NAME: ESCHERICHIA COLI
    MSRKDGVLAL LVVVVWGLNF VVIKVGLHNM PPLMLAGLRF MLVAFPAIFF VARPKVPLNL
    LLGYGLTISF AQFAFLFCAI NFGMPAGLAS LVLQAQAFFT IMLGAFTFGE RLHGKQLAGI
    ALAIFGVLVL IEDSLNGQHV AMLGFMLTLA AAFSWACGNI FNKKIMSHST RPAVMSLVIW
    SALIPIIPFF VASLILDGSA TMIHSLVTID MTTILSLMYL AFVATIVGYG IWGTLLGRYE
    TWRVAPLSLL VPVVGLASAA LLLDERLTGL QFLGAVLIMT GLYINVFGLR WRKAVKVGS
    SEQ ID NO. 41: EAMB ORGANISM NAME: ESCHERICHIA COLI
    MTPTLLSAFW TYTLITAMTP GPNNILALSS ATSHGFRQST RVLAGMSLGF LIVMLLCAGI
    SFSLAVIDPA AVHLLSWAGA AYIVWLAWKI ATSPTKEDGL QAKPISFWAS FALQFVNVKI
    ILYGVTALST FVLPQTQALS WVVGVSVLLA MIGTFGNVCW ALAGHLFQRL FRQYGRQLNI
    VLALLLVYCA VRIFY
    SEQ ID NO. 42: EMRB ORGANISM NAME: ESCHERICHIA COLI
    MQQQKPLEGA QLVIMTIALS LATFMQVLDS TIANVAIPTI AGNLGSSLSQ GTWVITSFGV
    ANAISIPLTG WLAKRVGEVK LFLWSTIAFA IASWACGVSS SLNMLIFFRV IQGIVAGPLI
    PLSQSLLLNN YPPAKRSIAL ALWSMTVIVA PICGPILGGY ISDNYHWGWI FFINVPIGVA
    VVLMTLQTLR GRETRTERRR IDAVGLALLV IGIGSLQIML DRGKELDWFS SQEIIILTVV
    AVVAICFLIV WELTDDNPIV DLSLFKSRNF TIGCLCISLA YMLYFGAIVL LPQLLQEVYG
    YTATWAGLAS APVGIIPVIL SPIIGRFAHK LDMRRLVTFS FIMYAVCFYW RAYTFEPGMD
    FGASAWPQFI QGFAVACFFM PLTTITLSGL PPERLAAASS LSNFTRTLAG SIGTSITTTM
    WTNRESMHHA QLTESVNPFN PNAQAMYSQL EGLGMTQQQA SGWIAQQITN QGLIISANEI
    FWMSAGIFLV LLGLVWFAKP PFGAGGGGGG AH
    SEQ ID NO. 43: EMRD ORGANISM NAME: ESCHERICHIA COLI
    MKRQRNVNLL LMLVLLVAVG QMAQTIYIPA IADMARDLNV REGAVQSVMG AYLLTYGVSQ
    LFYGPISDRV GRRPVILVGM SIFMLATLVA VTTSSLTVLI AASAMQGMGT GVGGVMARTL
    PRDLYERTQL RHANSLLNMG ILVSPLLAPL IGGLLDTMWN WRACYLFLLV LCAGVTFSMA
    RWMPETRPVD APRTRLLTSY KTLFGNSGFN CYLLMLIGGL AGIAAFEACS GVLMGAVLGL
    SSMTVSILFI LPIPAAFFGA WFAGRPNKRF STLMWQSVIC CLLAGLLMWI PDWFGVMNVW
    TLLVPAALFF FGAGMLFPLA TSGAMEPFPF LAGTAGALVG GLQNIGSGVL ASLSAMLPQT
    GQGSLGLLMT LMGLLIVLCW LPLATRMSHQ GQPV
    SEQ ID NO. 44: EMRKY ORGANISM NAME: ESCHERICHIA COLI
    MAITKSTPAP LTGGTLWCVT IALSLATFMQ MLDSTISNVA IPTISGFLGA STDEGTWVIT
    SFGVANAIAI PVTGRLAQRI GELRLFLLSV TFFSLSSLMC SLSTNLDVLI FFRVVQGLMA
    GPLIPLSQSL LLRNYPPEKR TFALALWSMT VIIAPICGPI LGGYICDNFS WGWIFLINVP
    MGIIVLTLCL TLLKGRETET SPVKMNLPGL TLLVLGVGGL QIMLDKGRDL DWFNSSTIII
    LTVVSVISLI SLVIWESTSE NPILDLSLFK SRNFTIGIVS ITCAYLFYSG AIVLMPQLLQ
    ETMGYNAIWA GLAYAPIGIM PLLISPLIGR YGNKIDMRLL VTFSFLMYAV CYYWRSVTFM
    PTIDFTGIIL PQFFQGFAVA CFFLPLTTIS FSGLPDNKFA NASSMSNFFR TLSGSVGTSL
    TMTLWGRRES LHHSQLTATI DQFNPVFNSS SQIMDKYYGS LSGVLNEINN EITQQSLSIS
    ANEIFRMAAI AFILLTVLVW FAKPPFTAKG VG
    SEQ ID NO. 45: EMRY ORGANISM NAME: ESCHERICHIA COLI
    MAITKSTPAP LTGGTLWCVT IALSLATFMQ MLDSTISNVA IPTISGFLGA STDEGTWVIT
    SFGVANAIAI PVTGRLAQRI GELRLFLLSV TFFSLSSLMC SLSTNLDVLI FFRVVQGLMA
    GPLIPLSQSL LLRNYPPEKR TFALALWSMT VIIAPICGPI LGGYICDNFS WGWIFLINVP
    MGIIVLTLCL TLLKGRETET SPVKMNLPGL TLLVLGVGGL QIMLDKGRDL DWFNSSTIII
    LTVVSVISLI SLVIWESTSE NPILDLSLFK SRNFTIGIVS ITCAYLFYSG AIVLMPQLLQ
    ETMGYNAIWA GLAYAPIGIM PLLISPLIGR YGNKIDMRLL VTFSFLMYAV CYYWRSVTFM
    PTIDFTGIIL PQFFQGFAVA CFFLPLTTIS FSGLPDNKFA NASSMSNFFR TLSGSVGTSL
    TMTLWGRRES LHHSQLTATI DQFNPVFNSS SQIMDKYYGS LSGVLNEINN EITQQSLSIS
    ANEIFRMAAI AFILLTVLVW FAKPPFTAKG VG
    SEQ ID NO. 46: GARP ORGANISM NAME: ESCHERICHIA COLI
    MILDTVDEKK KGVHTRYLIL LIIFIVTAVN YADRATLSIA GTEVAKELQL SAVSMGYIFS
    AFGWAYLLMQ IPGGWLLDKF GSKKVYTYSL FFWSLFTFLQ GFVDMFPLAW AGISMFFMRF
    MLGFSEAPSF PANARIVAAW FPTKERGTAS AIFNSAQYFS LALFSPLLGW LTFAWGWEHV
    FTVMGVIGFV LTALWIKLIH NPTDHPRMSA EELKFISENG AVVDMDHKKP GSAAASGPKL
    HYIKQLLSNR MMLGVFFGQY FINTITWFFL TWFPIYLVQE KGMSILKVGL VASIPALCGF
    AGGVLGGVFS DYLIKRGLSL TLARKLPIVL GMLLASTIIL CNYTNNTTLV VMLMALAFFG
    KGFGALGWPV ISDTAPKEIV GLCGGVFNVF GNVASIVTPL VIGYLVSELH SFNAALVFVG
    CSALMAMVCY LFVVGDIKRM ELQK
    SEQ ID NO. 47: GUDP ORGANISM NAME: ESCHERICHIA COLI
    MSSLSQAASS VEKRTNARYW IVVMLFIVTS FNYGDRATLS IAGSEMAKDI GLDPVGMGYV
    FSAFSWAYVI GQIPGGWLLD RFGSKRVYFW SIFIWSMFTL LQGFVDIFSG FGIIVALFTL
    RFLVGLAEAP SFPGNSRIVA AWFPAQERGT AVSIFNSAQY FATVIFAPIM GWLTHEVGWS
    HVFFFMGGLG IVISFIWLKV IHEPNQHPGV NKKELEYIAA GGALINMDQQ NTKVKVPFSV
    KWGQIKQLLG SRMMIGVYIG QYCINALTYF FITWFPVYLV QARGMSILKA GFVASVPAVC
    GFIGGVLGGI ISDWLMRRTG SLNIARKTPI VMGMLLSMVM VFCNYVNVEW MIIGFMALAF
    FGKGIGALGW AVMADTAPKE ISGLSGGLFN MFGNISGIVT PIAIGYIVGT TGSFNGALIY
    VGVHALIAVL SYLVLVGDIK RIELKPVAGQ
    SEQ ID NO. 48: HSRA ORGANISM NAME: ESCHERICHIA COLI
    MSDKKKRSMA GLPWIAAMAF FMQALDATIL NTALPAIAHS LNRSPLAMQS AIISYTLTVA
    MLIPVSGWLA DRFGTRRIFT LAVSLFTLGS LACALSNSLP QLVVFRVIQG IGGAMMMPVA
    RLALLRAYPR NELLPVLNFV AMPGLVGPIL GPVLGGVLVT WATWHWIFLI NIPIGIAGLL
    YARKHMPNFT TARRRFDITG FLLFGLSLVL FSSGIELFGE KIVASWIALT VIVTSIGLLL
    LYILHARRTP NPLISLDLFK TRTFSIGIVG NIATRLGTGC VPFLMPLMLQ VGFGYQAFIA
    GCMMAPTALG SIIAKSMVTQ VLRRLGYRHT LVGITVIIGL MIAQFSLQSP AMAIWMLILP
    LFILGMAMST QFTAMNTITL ADLTDDNASS GNSVLAVTQQ LSISLGVAVS AAVLRVYEGM
    EGTTTVEQFH YTFITMGIIT VASAAMFMLL KTTDGNNLIK RQRKSKPNRV PSESE
    SEQ ID NO. 49: LEUE ORGANISM NAME: ESCHERICHIA COLI
    MFAEYGVLNY WTYLVGAIFI VLVPGPNTLF VLKNSVSSGM KGGYLAACGV FIGDAVLMFL
    AWAGVATLIK TTPILFNIVR YLGAFYLLYL GSKILYATLK GKNSEAKSDE PQYGAIFKRA
    LILSLTNPKA ILFYVSFFVQ FIDVNAPHTG ISFFILAATL ELVSFCYLSF LIISGAFVTQ
    YIRTKKKLAK VGNSLIGLMF VGFAARLATL QS
    SEQ ID NO. 50: MDLB ORGANISM NAME: ESCHERICHIA COLI
    MRSFSQLWPT LKRLLAYGSP WRKPLGIAVL MMWVAAAAEV SGPLLISYFI DNMVAKNNLP
    LKVVAGLAAA YVGLQLFAAG LHYAQSLLFN RAAVGVVQQL RTDVMDAALR QPLSEFDTQP
    VGQVISRVTN DTEVIRDLYV TVVATVLRSA ALVGAMLVAM FSLDWRMALV AIMIFPVVLV
    VMVIYQRYST PIVRRVRAYL ADINDGFNEI INGMSVIQQF RQQARFGERM GEASRSHYMA
    RMQTLRLDGF LLRPLLSLFS SLILCGLLML FGFSASGTIE VGVLYAFISY LGRLNEPLIE
    LTTQQAMLQQ AVVAGERVFE LMDGPRQQYG NDDRPLQSGT IEVDNVSFAY RDDNLVLKNI
    NLSVPSRNFV ALVGHTGSGK STLASLLMGY YPLTEGEIRL DGRPLSSLSH SALRQGVAMV
    QQDPVVLADT FLANVTLGRD ISEERVWQAL ETVQLAELAR SMSDGIYTPL GEQGNNLSVG
    QKQLLALARV LVETPQILIL DEATASIDSG TEQAIQHALA AVREHTTLVV IAHRLSTIVD
    ADTILVLHRG QAVEQGTHQQ LLAAQGRYWQ MYQLQLAGEE LAASVREEES LSA
    SEQ ID NO. 51: MDTD ORGANISM NAME: ESCHERICHIA COLI
    MTDLPDSTRW QLWIVAFGFF MQSLDTTIVN TALPSMAQSL GESPLHMHMV IVSYVLTVAV
    MLPASGWLAD KVGVRNIFFT AIVLFTLGSL FCALSGTLNE LLLARALQGV GGAMMVPVGR
    LTVMKIVPRE QYMAAMTFVT LPGQVGPLLG PALGGLLVEY ASWHWIFLIN IPVGIIGAIA
    TLLLMPNYTM QTRRFDLSGF LLLAVGMAVL TLALDGSKGT GLSPLTIAGL VAVGVVALVL
    YLLHARNNNR ALFSLKLFRT RTFSLGLAGS FAGRIGSGML PFMTPVFLQI GLGFSPFHAG
    LMMIPMVLGS MGMKRIVVQV VNRFGYRRVL VATTLGLSLV TLLFMTTALL GWYYVLPFVL
    FLQGMVNSTR FSSMNTLTLK DLPDNLASSG NSLLSMIMQL SMSIGVTIAG LLLGLFGSQH
    VSVDSGTTQT VFMYTWLSMA LIIALPAFIF ARVPNDTHQN VAISRRKRSA Q
    SEQ ID NO. 52: MDTG ORGANISM NAME: ESCHERICHIA COLI
    MSPCENDTPI NWKRNLIVAW LGCFLTGAAF SLVMPFLPLY VEQLGVTGHS ALNMWSGIVF
    SITFLFSAIA SPFWGGLADR KGRKLMLLRS ALGMGIVMVL MGLAQNIWQF LILRALLGLL
    GGFVPNANAL IATQVPRNKS GWALGTLSTG GVSGALLGPM AGGLLADSYG LRPVFFITAS
    VLILCFFVTL FCIREKFQPV SKKEMLHMRE VVTSLKNPKL VLSLFVTTLI IQVATGSIAP
    ILTLYVRELA GNVSNVAFIS GMIASVPGVA ALLSAPRLGK LGDRIGPEKI LITALIFSVL
    LLIPMSYVQT PLQLGILRFL LGAADGALLP AVQTLLVYNS SNQIAGRIFS YNQSFRDIGN
    VTGPLMGAAI SANYGFRAVF LVTAGVVLFN AVYSWNSLRR RRIPQVSN
    SEQ ID NO. 53: MDTL ORGANISM NAME: ESCHERICHIA COLI
    MSRFLICSFA LVLLYPAGID MYLVGLPRIA ADLNASEAQL HIAFSVYLAG MAAAMLFAGK
    VADRSGRKPV AIPGAALFII ASVFCSLAET STLFLAGRFL QGLGAGCCYV VAFAILRDTL
    DDRRRAKVLS LLNGITCIIP VLAPVLGHLI MLKFPWQSLF WAMAMMGIAV LMLSLFILKE
    TRPAAPAASD KPRENSESLL NRFFLSRVVI TTLSVSVILT FVNTSPVLLM EIMGFERGEY
    ATIMALTAGV SMTVSFSTPF ALGIFKPRTL MITSQVLFLA AGITLAVSPS HAVSLFGITL
    ICAGFSVGFG VAMSQALGPF SLRAGVASST LGIAQVCGSS LWIWLAAVVG IGAWNMLIGI
    LIACSIVSLL LIMFVAPGRP VAAHEEIHHH A
    SEQ ID NO. 54: MDTM ORGANISM NAME: ESCHERICHIA COLI
    MPRFFTRHAA TLFFPMALIL YDFAAYLSTD LIQPGIINVV RDFNADVSLA PAAVSLYLAG
    GMALQWLLGP LSDRIGRRPV LITGALIFTL ACAATMFTTS MTQFLIARAI QGTSICFIAT
    VGYVTVQEAF GQTKGIKLMA IITSIVLIAP IIGPLSGAAL MHFMHWKVLF AIIAVMGFIS
    FVGLLLAMPE TVKRGAVPFS AKSVLRDFRN VFCNRLFLFG AATISLSYIP MMSWVAVSPV
    ILIDAGSLTT SQFAWTQVPV FGAVIVANAI VARFVKDPTE PRFIWRAVPI QLVGLSLLIV
    GNLLSPHVWL WSVLGTSLYA FGIGLIFPTL FRFTLFSNKL PKGTVSASLN MVILMVMSVS
    VEIGRWLWFN GGRLPFHLLA VVAGVIVVFT LAGLLNRVRQ HQAAELVEEQ
    SEQ ID NO. 55: MHPT ORGANISM NAME: ESCHERICHIA COLI
    MSTRTPSSSS SRLMLTIGLC FLVALMEGLD LQAAGIAAGG IAQAFALDKM QMGWIFSAGI
    LGLLPGALVG GMLADRYGRK RILIGSVALF GLFSLATAIA WDFPSLVFAR LMTGVGLGAA
    LPNLIALTSE AAGPRFRGTA VSLMYCGVPI GAALAATLGF AGANLAWQTV FWVGGVVPLI
    LVPLLMRWLP ESAVFAGEKQ SAPPLRALFA PETATATLLL WLCYFFTLLV VYMLINWLPL
    LLVEQGFQPS QAAGVMFALQ MGAASGTLML GALMDKLRPV TMSLLIYSGM LASLLALGTV
    SSFNGMLLAG FVAGLFATGG QSVLYALAPL FYSSQIRATG VGTAVAVGRL GAMSGPLLAG
    KMLALGTGTV GVMAASAPGI LVAGLAVFIL MSRRSRIQPC ADA
    SEQ ID NO. 56: RHTA ORGANISM NAME: ESCHERICHIA COLI
    MPGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK
    PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV
    DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA
    IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTFGT
    LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN
    SEQ ID NO. 57: RHTB ORGANISM NAME: ESCHERICHIA COLI
    MTLEWWFAYL LTSIILSLSP GSGAINTMTT SLNHGYRGAV ASIAGLQTGL AIHIVLVGVG
    LGTLFSRSVI AFEVLKWAGA AYLIWLGIQQ WRAAGAIDLK SLASTQSRRH LFQRAVFVNL
    TNPKSIVFLA ALFPQFIMPQ QPQLMQYIVL GVTTIVVDII VMIGYATLAQ RIALWIKGPK
    QMKALNKIFG SLFMLVGALL ASARHA
    SEQ ID NO. 58: RHTC ORGANISM NAME: ESCHERICHIA COLI
    MLMLFLTVAM VHIVALMSPG PDFFFVSQTA VSRSRKEAMM GVLGITCGVM VWAGIALLGL
    HLIIEKMAWL HTLIMVGGGL YLCWMGYQML RGALKKEAVS APAPQVELAK SGRSFLKGLL
    TNLANPKAII YFGSVFSLFV GDNVGTTARW GIFALIIVET LAWFTVVASL FALPQMRRGY
    QRLAKWIDGF AGALFAGFGI HLIISR
    SEQ ID NO. 59: YAHN ORGANISM NAME: ESCHERICHIA COLI
    MMQLVHLFMD EITMDPLHAV YLTVGLFVIT FFNPGANLFV VVQTSLASGR RAGVLTGLGV
    ALGDAFYSGL GLFGLATLIT QCEEIFSLIR IVGGAYLLWF AWCSMRRQST PQMSTLQQPI
    SAPWYVFFRR GLITDLSNPQ TVLFFISIFS VTLNAETPTW ARLMAWAGIV LASIIWRVFL
    SQAFSLPAVR RAYGRMQRVA SRVIGAIIGV FALRLIYEGV TQR
    SEQ ID NO. 60: YAJR ORGANISM NAME: ESCHERICHIA COLI
    MNDYKMTPGE RRATWGLGTV FSLRMLGMFM VLPVLTTYGM ALQGASEALI GIAIGIYGLT
    QAVFQIPFGL LSDRIGRKPL IVGGLAVFAA GSVIAALSDS IWGIILGRAL QGSGAIAAAV
    MALLSDLTRE QNRTKAMAFI GVSFGITFAI AMVLGPIITH KLGLHALFWM IAILATTGIA
    LTIWVVPNSS THVLNRESGM VKGSFSKVLA EPRLLKLNFG IMCLHILLMS TFVALPGQLA
    DAGFPAAEHW KVYLATMLIA FGSVVPFIIY AEVKRKMKQV FVFCVGLIVV AEIVLWNAQT
    QFWQLVVGVQ LFFVAFNLME ALLPSLISKE SPAGYKGTAM GVYSTSQFLG VAIGGSLGGW
    INGMFDGQGV FLAGAMLAAV WLTVASTMKE PPYVSSLRIE IPANIAANEA LKVRLLETEG
    IKEVLIAEEE HSAYVKIDSK VTNRFEIEQA IRQA
    SEQ ID NO. 61: YBBP ORGANISM NAME: ESCHERICHIA COLI
    MIARWFWREW RSPSLLIVWL ALSLAVACVL ALGNISDRME KGLSQQSREF MAGDRALRSS
    REVPQAWLEE AQKRGLKVGK QLTFATMTFA GDTPQLANVK AVDDIYPMYG DLQTNPPGLK
    PQAGSVLLAP RLMALLNLKT GDTIDVGDAT LRIAGEVIQE PDSGFNPFQM APRLMMNLAD
    VDKTGAVQPG SRVTWRYKFG GNENQLDGYE KWLLPQLKPE QRWYGLEQDE GALGRSMERS
    QQFLLLSALL TLLLAVAAVA VAMNHYCRSR YDLVAILKTL GAGRAQLRKL IVGQWLMVLT
    LSAVTGGAIG LLFENVLMVL LKPVLPAALP PASLWPWLWA LGTMTVISLL VGLRPYRLLL
    ATQPLRVLRN DVVANVWPLK FYLPIVSVVV VLLLAGLMGG SMLLWAVLAG AVVLALLCGV
    LGWMLLNVLR RMTLKSLPLR LAVSRLLRQP WSTLSQLSAF SLSFMLLALL LVLRGDLLDR
    WQQQLPPESP NYFLINIATE QVAPLKAFLA EHQIVPESFY PVVRARLTAI NDKPTEGNED
    EALNRELNLT WQNTRPDHNP IVAGNWPPKA DEVSMEEGLA KRLNVALGDT VTFMGDTQEF
    RAKVTSLRKV DWESLRPNFY FIFPEGALDG QPQSWLTSFR WENGNGMLTQ LNRQFPTISL
    LDIGAILKQV GQVLEQVSRA LEVMVVLVTA CGMLLLLAQV QVGMRQRHQE LVVWRTLGAG
    KKLLRTTLWC EFAMLGFVSG LVAAIGAETA LAVLQAKVFD FPWEPDWRLW IVLPCSGALL
    LSLFGGWLGA RLVKGKALFR QFAG
    SEQ ID NO. 62: YBIF (RHTA) ORGANISM NAME: ESCHERICHIA COLI
    MPGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK
    PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV
    DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA
    IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTFGT
    LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN
    SEQ ID NO. 63: YBJJ ORGANISM NAME: ESCHERICHIA COLI
    MTVNSSRNAL KRRTWALFMF FFLPGLLMAS WATRTPAIRD ILSVSIAEMG GVLFGLSIGS
    MSGILCSAWL VKRFGTRNVI LVTMSCALIG MMILSLALWL TSPLLFAVGL GVFGASFGSA
    EVAINVEGAA VEREMNKTVL PMMHGFYSLG TLAGAGVGMA LTAFGVPATV HILLAALVGI
    APIYIAIQAI PDGTGKNAAD GTQHGEKGVP FYRDIQLLLI GVVVLAMAFA EGSANDWLPL
    LMVDGHGFSP TSGSLIYAGF TLGMTVGRFT GGWFIDRYSR VAVVRASALM GALGIGLIIF
    VDSAWVAGVS VVLWGLGASL GFPLTISAAS DTGPDAPTRV SVVATTGYLA FLVGPPLLGY
    LGEHYGLRSA MLVVLALVIL AAIVAKAVAK PDTKTQTAME NS
    SEQ ID NO. 64: YCAP ORGANISM NAME: ESCHERICHIA COLI
    MKAFDLHRMA FDKVPFDFLG EVALRSLYTF VLVFLFLKMT GRRGVRQMSL FEVLIILTLG
    SAAGDVAFYD DVPMVPVLIV FITLALLYRL VMWLMAHSEK LEDLLEGKPV VIIEDGELAW
    SKLNNSNMTE FEFFMELRLR GVEQLGQVRL AILETNGQIS VYFFEDDKVK PGLLILPSDC
    TQRYKVVPES ADYACIRCSE IIHMKAGEKQ LCPRCANPEW TKASRAKRVT
    SEQ ID NO. 65: YDCO ORGANISM NAME: ESCHERICHIA COLI
    MRLFSIPPPT LLAGFLAVLI GYASSAAIIW QAAIVAGATT AQISGWMTAL GLAMGVSTLT
    LTLWYRVPVL TAWSTPGAAL LVTGLQGLTL NEAIGVFIVT NALIVLCGIT GLFARLMRII
    PHSLAAAMLA GILLRFGLQA FASLDGQFTL CGSMLLVWLA TKAVAPRYAV IAAMIIGIVI
    VIAQGDVVTT DVVFKPVLPT YITPDFSFAH SLSVALPLFL VTMASQNAPG IAAMKAAGYS
    APVSPLIVFT GLLALVFSPF GVYSVGIAAI TAAICQSPEA HPDKDQRWLA AAVAGIFYLL
    AGLFGSAITG MMAALPVSWI QMLAGLALLS TIGGSLYQAL HNERERDAAV VAFLVTASGL
    TLVGIGSAFW GLIAGGVCYV VLNLIADRNRY
    SEQ ID NO. 66: YDDG ORGANISM NAME: ESCHERICHIA COLI
    MTRQKATLIG LIAIVLWSTM VGLIRGVSEG LGPVGGAAAI YSLSGLLLIF TVGFPRIRQI
    PKGYLLAGSL LFVSYEICLA LSLGYAATHH QAIEVGMVNY LWPSLTILFA ILFNGQKTNW
    LIVPGLLLAL VGVCWVLGGD NGLHYDEIIN NITTSPLSYF LAFIGAFIWA AYCTVTNKYA
    RGFNGITVFV LLTGASLWVY YFLTPQPEMI FSTPVMIKLI SAAFTLGFAY AAWNVGILHG
    NVTIMAVGSY FTPVLSSALA AVLLSAPLSF SFWQGALMVC GGSLLCWLAT RRG
    SEQ ID NO. 67: YDED (EAMA) ORGANISM NAME: ESCHERICHIA COLI
    MSRKDGVLAL LVVVVWGLNF VVIKVGLHNM PPLMLAGLRF MLVAFPAIFF VARPKVPLNL
    LLGYGLTISF AQFAFLFCAI NFGMPAGLAS LVLQAQAFFT IMLGAFTFGE RLHGKQLAGI
    ALAIFGVLVL IEDSLNGQHV AMLGFMLTLA AAFSWACGNI FNKKIMSHST RPAVMSLVIW
    SALIPIIPFF VASLILDGSA TMIHSLVTID MTTILSLMYL AFVATIVGYG IWGTLLGRYE
    TWRVAPLSLL VPVVGLASAA LLLDERLTGL QFLGAVLIMT GLYINVFGLR WRKAVKVGS
    SEQ ID NO. 68: YDGE (MDTI) ORGANISM NAME: ESCHERICHIA COLI
    MAQFEWVHAA WLALAIVLEI VANVFLKFSD GFRRKIFGLL SLAAVLAAFS ALSQAVKGID
    LSVAYALWGG FGIAATLAAG WILFGQRLNR KGWIGLVLLL AGMIMVKLA
    SEQ ID NO. 69: YDHC ORGANISM NAME: ESCHERICHIA COLI
    MQPGKRFLVW LAGLSVLGFL ATDMYLPAFA AIQADLQTPA SAVSASLSLF LAGFAAAQLL
    WGPLSDRYGR KPVLLIGLTI FALGSLGMLW VENAATLLVL RFVQAVGVCA AAVIWQALVT
    DYYPSQKVNR IFAAIMPLVG LSPALAPLLG SWLLVHFSWQ AIFATLFAIT VVLILPIFWL
    KPTTKARNNS QDGLTFTDLL RSKTYRGNVL IYAACSASFF AWLTGSPFIL SEMGYSPAVI
    GLSYVPQTIA FLIGGYGCRA ALQKWQGKQL LPWLLVLFAV SVIATWAAGF ISHVSLVEIL
    IPFCVMAIAN GAIYPIVVAQ ALRPFPHATG RAAALQNTLQ LGLCFLASLV VSWLISISTP
    LLTTTSVMLS TVVLVALGYM MQRCEEVGCQ NHGNAEVAHS ESH
    SEQ ID NO. 70: YDHP ORGANISM NAME: ESCHERICHIA COLI
    MKINYPLLAL AIGAFGIGTT EFSPMGLLPV IARGVDVSIP AAGMLISAYA VGVMVGAPLM
    TLLLSHRARR SALIFLMAIF TLGNVLSAIA PDYMTLMLSR ILTSLNHGAF FGLGSVVAAS
    VVPKHKQASA VATMFMGLTL ANIGGVPAAT WLGETIGWRM SFLATAGLGV ISMVSLFFSL
    PKGGAGARPE VKKELAVLMR PQVLSALLTT VLGAGAMFTL YTYISPVLQS ITHATPVFVT
    AMLVLIGVGF SIGNYLGGKL ADRSVNGTLK GFLLLLMVIM LAIPFLARNE FGAAISMVVW
    GAATFAVVPP LQMRVMRVAS EAPGLSSSVN IGAFNLGNAL GAAAGGAVIS AGLGYSFVPV
    MGAIVAGLAL LLVFMSARKQ PETVCVANS
    SEQ ID NO. 71: YDIN ORGANISM NAME: ESCHERICHIA COLI
    MSQNKAFSTP FILAVLCIYF SYFLHGISVI TLAQNMSSLA EKFSTDNAGI AYLISGIGLG
    RLISILFFGV ISDKFGRRAV ILMAVIMYLL FFFGIPACPN LTLAYGLAVC VGIANSALDT
    GGYPALMECF PKASGSAVIL VKAMVSFGQM FYPMLVSYML LNNIWYGYGL IIPGILFVLI
    TLMLLKSKFP SQLVDASVTN ELPQMNSKPL VWLEGVSSVL FGVAAFSTFY VIVVWMPKYA
    MAFAGMSEAE ALKTISYYSM GSLVCVFIFA ALLKKMVRPI WANVFNSALA TITAAIIYLY
    PSPLVCNAGA FVIGFSAAGG ILQLGVSVMS EFFPKSKAKV TSIYMMMGGL ANFVIPLITG
    YLSNIGLQYI IVLDFTFALL ALITAIIVFI RYYRVFIIPE NDVRFGERKF CTRLNTIKHR
    G
    SEQ ID NO. 72: YDIM ORGANISM NAME: ESCHERICHIA COLI
    MKNPYFPTAL GLYFNYLVHG MGVLLMSLNM ASLETLWQTN AAGVSIVISS LGIGRLSVLL
    FAGLLSDRFG RRPFIMLGMC CYMAFFFGIL QTNNIIIAYV FGFLAGMANS FLDAGTYPSL
    MEAFPRSPGT ANILIKAFVS SGQFLLPLII SLLVWAELWF GWSFMIAAGI MFINALFLYR
    CTFPPHPGRR LPVIKKTTSS TEHRCSIIDL ASYTLYGYIS MATFYLVSQW LAQYGQFVAG
    MSYTMSIKLL SIYTVGSLLC VFITAPLIRN TVRPTTLLML YTFISFIALF TVCLHPTFYV
    VIIFAFVIGF TSAGGVVQIG LTLMAERFPY AKGKATGIYY SAGSIATFTI PLITAHLSQR
    SIADIMWFDT AIAAIGFLLA LFIGLRSRKK TRHHSLKENV APGG
    SEQ ID NO. 73: YDJE ORGANISM NAME: ESCHERICHIA COLI
    MEQYDQIGAR LDRLPLARFH YRIFGIISFS LLLTGFLSYS GNVVLAKLVS NGWSNNFLNA
    AFTSALMFGY FIGSLTGGFI GDYFGRRRAF RINLLIVGIA ATGAAFVPDM YWLIFFRFLM
    GTGMGALIMV GYASFTEFIP ATVRGKWSAR LSFVGNWSPM LSAAIGVVVI AFFSWRIMFL
    LGGIGILLAW FLSGKYFIES PRWLAGKGQI AGAECQLREV EQQIEREKSI RLPPLTSYQS
    NSKVKVIKGT FWLLFKGEML RRTLVAITVL IAMNISLYTI TVWIPTIFVN SGIDVDKSIL
    MTAVIMIGAP VGIFIAALII DHFPRRLFGS TLLIIIAVLG YIYSIQTTEW AILIYGLVMI
    FFLYMYVCFA SAVYIPELWP THLRLRGSGF VNAVGRIVAV FTPYGVAALL THYGSITVFM
    VLGVMLLLCA LVLSIFGIET RKVSLEEISE VN
    SEQ ID NO. 74: YDJF ORGANISM NAME: ESCHERICHIA COLI
    MAAKDRIQAI KQMVANDKKV TVSNLSGIFQ VTEETIRRDL EKLEDEGFLT RTYGGAVLNT
    AMLTENIHFY KRASSFYEEK QLIARKALPF IDNKTTMAAD SSSTVMELLK LLQDRSGLTL
    LTNSAEAIHV LAQSEIKVVS TGGELNKNTL SLQGRITKEI IRRYHVDIMV MSCKGLDINS
    GALDSNEAEA EIKKTMIRQA TEVALLVDHS KFDRKAFVQL ADFSHINYII TDKSPGAEWI
    AFCKDNNIQL VW
    SEQ ID NO. 75: YDJI ORGANISM NAME: ESCHERICHIA COLI
    MLADIRYWEN DATNKHYAIA HFNVWNAEML MGVIDAAEEA KSPVIISFGT GFVGNTSFED
    FSHMMVSMAQ KATVPVITHW DHGRSMEIIH NAWTHGMNSL MRDASAFDFE ENIRLTKEAV
    DFFHPLGIPV EAELGHVGNE TVYEEALAGY HYTDPDQAAE FVERTGCDSL AVAIGNQHGV
    YTSEPQLNFE VVKRVRDAVS VPLVLHGASG ISDADIKTAI SLGIAKINIH TELCQAAMVA
    VKENQDQPFL HLEREVRKAV KERALEKIKL FGSDGKAE
    SEQ ID NO. 76: YDJK ORGANISM NAME: ESCHERICHIA COLI
    MEQITKPHCG ARLDRLPDCR WHSSMFAIVA FGLLVCWSNA VGGLILAQLK ALGWTDNSTT
    ATFSAITTAG MFLGALVGGI IGDKTGRRNA FILYEAIHIA SMVVGAFSPN MDFLIACRFV
    MGVGLGALLV TLFAGFTEYM PGRNRGTWSS RVSFIGNWSY PLCSLIAMGL TPLISAEWNW
    RVQLLIPAIL SLIATALAWR YFPESPRWLE SRGRYQEAEK VMRSIEEGVI RQTGKPLPPV
    VIADDGKAPQ AVPYSALLTG VLLKRVILGS CVLIAMNVVQ YTLINWLPTI FMTQGINLKD
    SIVLNTMSMF GAPFGIFIAM LVMDKIPRKT MGVGLLILIA VLGYIYSLQT SMLLITLIGF
    FLITFVYMYV CYASAVYVPE IWPTEAKLRG SGLANAVGRI SGIAAPYAVA VLLSSYGVTG
    VFILLGAVSI IVAIAIATIG IETKGVSVES LSIDAVANK
    SEQ ID NO. 77: YEAN ORGANISM NAME: ESCHERICHIA COLI
    MTCSTSLSGK NRIVLIAGIL MIATTLRVTF TGAAPLLDTI RSAYSLTTAQ TGLLTTLPLL
    AFALISPLAA PVARRFGMER SLFAALLLIC AGIAIRSLPS PYLLFGGTAV IGGGIALGNV
    LLPGLIKRDF PHSVARLTGA YSLTMGAAAA LGSAMVVPLA LNGFGWQGAL LMLMCFPLLA
    LFLWLPQWRS QQHANLSTSR ALHTRGIWRS PLAWQVTLFL GINSLVYYVI IGWLPAILIS
    HGYSEAQAGS LHGLLQLATA APGLLIPLFL HHVKDQRGIA AFVALMCAVG AVGLCFMPAH
    AITWTLLFGF GSGATMILGL TFIGLRASSA HQAAALSGMA QSVGYLLAAC GPPLMGKIHD
    ANGNWSVPLM GVAILSLLMA IFGLCAGRDK EIR
    SEQ ID NO. 78: YEAS (LEUE) ORGANISM NAME: ESCHERICHIA COLI
    MFAEYGVLNY WTYLVGAIFI VLVPGPNTLF VLKNSVSSGM KGGYLAACGV FIGDAVLMFL
    AWAGVATLIK TTPILFNIVR YLGAFYLLYL GSKILYATLK GKNSEAKSDE PQYGAIFKRA
    LILSLTNPKA ILFYVSFFVQ FIDVNAPHTG ISFFILAATL ELVSFCYLSF LIISGAFVTQ
    YIRTKKKLAK VGNSLIGLMF VGFAARLATL QS
    SEQ ID NO. 79: YEBS ORGANISM NAME: ESCHERICHIA COLI
    MALNTPQITP TKKITVRAIG EELPRGDYQR CPQCDMLFSL PEINSHQSAY CPRCQAKIRD
    GRDWSLTRLA AMAFTMLLLM PFAWGEPLLH IWLLGIRIDA NVMQGIWQMT KQGDAITGSM
    VFFCVIGAPL ILVTSIAYLW FGNRLGMNLR PVLLMLERLK EWVMLDIYLV GIGVASIKVQ
    DYAHIQAGVG LFSFVALVIL TTVTLSHLNV EELWERFYPQ RPATRRDEKL RVCLGCHFTG
    YPDQRGRCPR CHIPLRLRRR HSLQKCWAAL LASIVLLLPA NLLPISIIYL NGGRQEDTIL
    SGIMSLASSN IAVAGIVFIA SILVPFTKVI VMFTLLLSIH FKCQQGLRTR ILLLRMVTWI
    GRWSMLDLFV ISLTMSLINR DQILAFTMGP AAFYFGAAVI LTILAVEWLD SRLLWDAHES
    GNARFDD
    SEQ ID NO. 80: YEDA ORGANISM NAME: ESCHERICHIA COLI
    MRFRQLLPLF GALFALYIIW GSTYFVIRIG VESWPPLMMA GVRFLAAGIL LLAFLLLRGH
    KLPPLRPLLN AALIGLLLLA VGNGMVTVAE HQNVPSGIAA VVVATVPLFT LCFSRLFGIK
    TRKLEWVGIA IGLAGIIMLN SGGNLSGNPW GAILILIGSI SWAFGSVYGS RITLPVGMMA
    GAIEMLAAGV VLMIASMIAG EKLTALPSLS GFLAVGYLAL FGSIIAINAY MYLIRNVSPA
    LATSYAYVNP VVAVLLGTGL GGETLSKIEW LALGVIVFAV VLVTLGKYLF PAKPVVAPVI
    QDASSE
    SEQ ID NO. 90: YEEO ORGANISM NAME: ESCHERICHIA COLI
    MLRHILTAKN LLSNPIFKFP NCLPFLSTVC CICRQFVGEN LCSFADSPSL FEMWFHFLQL
    RSALNISSAL RQVVHGTRWH AKRKSYKVLF WREITPLAVP IFMENACVLL MGVLSTFLVS
    WLGKDAMAGV GLADSFNMVI MAFFAAIDLG TTVVVAFSLG KRDRRRARVA TRQSLVIMTL
    FAVLLATLIH HFGEQIIDFV AGDATTEVKA LALTYLELTV LSYPAAAITL IGSGALRGAG
    NTKIPLLING SLNILNIIIS GILIYGLFSW PGLGFVGAGL GLTISRYIGA VAILWVLAIG
    FNPALRISLK SYFKPLNFSI IWEVMGIGIP ASVESVLFTS GRLLTQMFVA GMGTSVIAGN
    FIAFSIAALI NLPGSALGSA STIITGRRLG VGQIAQAEIQ LRHVFWLSTL GLTAIAWLTA
    PFAGVMASFY TQDPQVKHVV VILIWLNALF MPIWSASWVL PAGFKGARDA RYAMWVSMLS
    MWGCRVVVGY VLGIMLGWGV VGVWMGMFAD WAVRAVLFYW RMVTGRWLWK YPRPEPQKCE
    KKPVVSE
    SEQ ID NO. 91: YEGH ORGANISM NAME: ESCHERICHIA COLI
    MEWIADPSIW AGLITLIVIE LVLGIDNLVF IAILAEKLPP KQRDRARVTG LLLAMLMRLL
    LLASISWLVT LTQPLFSFRS FTFSARDLIM LFGGFFLLFK ATMELNERLE GKDSNNPTQR
    KGAKFWGVVT QIVVLDAIFS LDSVITAVGM VDHLLVMMAA VVIAISLMLM ASKPLTQFVN
    SHPTIVILCL SFLLMIGFSL VAEGFGFVIP KGYLYAAIGF SVMIEALNQL AIFNRRRFLS
    ANQTLRQRTT EAVMRLLSGQ KEDAELDAET ASMLVDHGNQ QIFNPQERRM IERVLNLNQR
    TVSSIMTSRH DIEHIDLNAP EEEIRQLLER NQHTRLVVTD GDDAEDLLGV VHVIDLLQQS
    LRGEPLNLRV LIRQPLVFPE TLPLLPALEQ FRNARTHFAF VVDEFGSVEG IVTLSDVTET
    IAGNLPNEVE EIDARHDIQK NADGSWTANG HMPLEDLVQY VPLPLDEKRE YHTIAGLLME
    YLQRIPKPGE EVQVGDYLLK TLQVESHRVQ KVQIIPLRKD GEMEYEV
    SEQ ID NO. 92: YGGA (ARGO) ORGANISM NAME: ESCHERICHIA COLI
    MFSYYFQGLA LGAAMILPLG PQNAFVMNQG IRRQYHIMIA LLCAISDLVL ICAGIFGGSA
    LLMQSPWLLA LVTWGGVAFL LWYGFGAFKT AMSSNIELAS AEVMKQGRWK IIATMLAVTW
    LNPHVYLDTF VVLGSLGGQL DVEPKRWFAL GTISASFLWF FGLALLAAWL APRLRTAKAQ
    RIINLVVGCV MWFIALQLAR DGIAHAQALF S
    SEQ ID NO. 93: YFCJ ORGANISM NAME: ESCHERICHIA COLI
    MTAVSQTETR SSANFSLFRI AFAVFLTYMT VGLPLPVIPL FVHHELGYGN TMVGIAVGIQ
    FLATVLTRGY AGRLADQYGA KRSALQGMLA CGLAGGALLL AAILPVSAPF KFALLVVGRL
    ILGFGESQLL TGALTWGLGI VGPKHSGKVM SWNGMAIYGA LAVGAPLGLL IHSHYGFAAL
    AITTMVLPVL AWACNGTVRK VPALAGERPS LWSVVGLIWK PGLGLALQGV GFAVIGTFVS
    LYFASKGWAM AGFTLTAFGG AFVVMRVMFG WMPDRFGGVK VAIVSLLVET VGLLLLWQAP
    GAWVALAGAA LTGAGCSLIF PALGVEVVKR VPSQVRGTAL GGYAAFQDIA LGVSGPLAGM
    LATTFGYSSV FLAGAISAVL GIIVTILSFR RG
    SEQ ID NO. 94: YFIK (EAMB) ORGANISM NAME: ESCHERICHIA COLI
    MTPTLLSAFW TYTLITAMTP GPNNILALSS ATSHGFRQST RVLAGMSLGF LIVMLLCAGI
    SFSLAVIDPA AVHLLSWAGA AYIVWLAWKI ATSPTKEDGL QAKPISFWAS FALQFVNVKI
    ILYGVTALST FVLPQTQALS WVVGVSVLLA MIGTFGNVCW ALAGHLFQRL FRQYGRQLNI
    VLALLLVYCA VRIFY
    SEQ ID NO. 95: YHJE ORGANISM NAME: ESCHERICHIA COLI
    MQATATTLDH EQEYTPINSR NKVLVASLIG TAIEFFDFYI YATAAVIVFP HIFFPQGDPT
    AATLQSLATF AIAFVARPIG SAVFGHFGDR VGRKATLVAS LLTMGISTVV IGLLPGYATI
    GIFAPLLLAL ARFGQGLGLG GEWGGAALLA TENAPPRKRA LYGSFPQLGA PIGFFFANGT
    FLLLSWLLTD EQFMSWGWRV PFIFSAVLVI IGLYVRVSLH ESPVFEKVAK AKKQVKIPLG
    TLLTKHVRVT VLGTFIMLAT YTLFYIMTVY SMTFSTAAAP VGLGLPRNEV LWMLMMAVIG
    FGVMVPVAGL LADAFGRRKS MVIITTLIIL FALFAFNPLL GSGNPILVFA FLLLGLSLMG
    LTFGPMGALL PELFPTEVRY TGASFSYNVA SILGASVAPY IAAWLQTNYG LGAVGLYLAA
    MAGLTLIALL LTHETRHQSL
    SEQ ID NO. 96: YIDE ORGANISM NAME: ESCHERICHIA COLI
    MSDIALTVSI LALVAVVGLF IGNVKFRGIG LGIGGVLFGG IIVGHFVSQA GMTLSSDMLH
    VIQEFGLILF VYTIGIQVGP GFFASLRVSG LRLNLFAVLI VIIGGLVTAI LHKLFDIPLP
    VVLGIFSGAV TNTPALGAGQ QILRDLGTPM EMVDQMGMSY AMAYPFGICG ILFTMWMLRV
    IFRVNVETEA QQHESSRTNG GALIKTINIR VENPNLHDLA IKDVPILNGD KIICSRLKRE
    ETLKVPSPDT IIQLGDLLHL VGQPADLHNA QLVIGQEVDT SLSTKGTDLR VERVVVTNEN
    VLGKRIRDLH FKERYDVVIS RLNRAGVELV ASGDISLQFG DILNLVGRPS AIDAVANVLG
    NAQQKLQQVQ MLPVFIGIGL GVLLGSIPVF VPGFPAALKL GLAGGPLIMA LILGRIGSIG
    KLYWFMPPSA NLALRELGIV LFLSVVGLKS GGDFVNTLVN GEGLSWIGYG ALITAVPLIT
    VGILARMLAK MNYLTMCGML AGSMTDPPAL AFANNLHPTS GAAALSYATV YPLVMFLRII
    TPQLLAVLFW SIG
    SEQ ID NO. 97: YIGK (RHTB) ORGANISM NAME: ESCHERICHIA COLI
    MTLEWWFAYL LTSIILSLSP GSGAINTMTT SLNHGYRGAV ASIAGLQTGL AIHIVLVGVG
    LGTLFSRSVI AFEVLKWAGA AYLIWLGIQQ WRAAGAIDLK SLASTQSRRH LFQRAVFVNL
    TNPKSIVFLA ALFPQFIMPQ QPQLMQYIVL GVTTIVVDII VMIGYATLAQ RIALWIKGPK
    QMKALNKIFG SLFMLVGALL ASARHA
    SEQ ID NO. 98: YIGJ (RHTC) ORGANISM NAME: ESCHERICHIA COLI
    MLMLFLTVAM VHIVALMSPG PDFFFVSQTA VSRSRKEAMM GVLGITCGVM VWAGIALLGL
    HLIIEKMAWL HTLIMVGGGL YLCWMGYQML RGALKKEAVS APAPQVELAK SGRSFLKGLL
    TNLANPKAII YFGSVFSLFV GDNVGTTARW GIFALIIVET LAWFTVVASL FALPQMRRGY
    QRLAKWIDGF AGALFAGFGI HLIISR
    SEQ ID NO. 99: YIJE ORGANISM NAME: ESCHERICHIA COLI
    MSAAGKSNPL AISGLVVLTL IWSYSWIFMK QVTSYIGAFD FTALRCIFGA LVLFIVLLLR
    GRGMRPTPFK YTLAIALLQT CGMVGLAQWA LVSGGAGKVA ILSYTMPFWV VIFAALFLGE
    RLRRGQYFAI LIAAFGLFLV LQPWQLDFSS MKSAMLAILS GVSWGASAIV AKRLYARHPR
    VDLLSLTSWQ MLYAALVMSV VALLVPQREI DWQPTVFWAL AYSAILATAL AWSLWLFVLK
    NLPASIASLS TLAVPVCGVL FSWWLLGENP GAVEGSGIVL IVLALALVSR KKKEAVSVKRI
    SEQ ID NO. 100: YJII (KPTA) ORGANISM NAME: ESCHERICHIA COLI
    MAKYNEKELA DTSKFLSFVL RHKPEAIGIV LDREGWADID KLILCAQKAG KRLTRALLDT
    VVATSDKKRF SYSSDGRCIR AVQGHSTSQV AISFAEKTPP QFLYHGTASR FLDEIKKQGL
    IAGERHYVHL SADEATARKV GARHGSPVIL TVKAQEMAKR GLPFWQAENG VWLTSTVAVE
    FLEW
    SEQ ID NO. 101: YJIJ ORGANISM NAME: ESCHERICHIA COLI
    MPSSTHPVER FSFSTALFGM LVLTLGMGLG RFLYTPMLPV MMAEGSFSFS QLSWIASGNY
    AGYLAGSLLF SFGAFHQPSR LRPFLLASAL ASGLLILAMA WLPPFILVLL IRVLAGVASA
    GMLIFGSTLI MQHTRHPFVL AALFSGVGIG IALGNEYVLA GLHFDLSSQT LWQGAGALSG
    MMLIALTLLM PSKKHAITPM PLAKTEQQIM SWWLLAILYG LAGFGYIIVA TYLPLMAKDA
    GSPLLTAHLW TLVGLSIVPG CFGWLWAAKR WGALPCLTAN LLVQAICVLL TLASDSPLLL
    IISSLGFGGT FMGTTSLVMT IARQLSVPGN LNLLGFVTLI YGIGQILGPA LTSMLSNGTS
    ALASATLCGA AALFIAALIS TVQLFKLQVV TS
    SEQ ID NO. 102: YJIO (MDTM) ORGANISM NAME: ESCHERICHIA COLI
    MPRFFTRHAA TLFFPMALIL YDFAAYLSTD LIQPGIINVV RDFNADVSLA PAAVSLYLAG
    GMALQWLLGP LSDRIGRRPV LITGALIFTL ACAATMFTTS MTQFLIARAI QGTSICFIAT
    VGYVTVQEAF GQTKGIKLMA IITSIVLIAP IIGPLSGAAL MHFMHWKVLF AIIAVMGFIS
    FVGLLLAMPE TVKRGAVPFS AKSVLRDFRN VFCNRLFLFG AATISLSYIP MMSWVAVSPV
    ILIDAGSLTT SQFAWTQVPV FGAVIVANAI VARFVKDPTE PRFIWRAVPI QLVGLSLLIV
    GNLLSPHVWL WSVLGTSLYA FGIGLIFPTL FRFTLFSNKL PKGTVSASLN MVILMVMSVS
    VEIGRWLWFN GGRLPFHLLA VVAGVIVVFT LAGLLNRVRQ HQAAELVEEQ
    SEQ ID NO. 103: YKGH ORGANISM NAME: ESCHERICHIA COLI
    MREQIKQDID LIEILFYLKK KIRVILFIMA ICMAMVLLFL YINKDNIKVI YSLKINQTTP
    GILVSCDSNN NFACQTTMTE DVIQRITTFF HTSPDVKNRE IRLEWSGDKR ALPTAEEEIS
    RVQASIIKWY ASEYHNGRQV LDEIQTPSAI NSELYTKMIY LTRNWSLYPN GDGCVTISSP
    EIKNKYPAAI CLALGFFLSI VISVMFCLVK KMVDEYQQNS GQ
    SEQ ID NO. 104: YPJD ORGANISM NAME: ESCHERICHIA COLI
    MQRLEQRSPD AILLLFLIAQ TVDITMPVFA LLALVAYSVS LALIVPGLLQ KNGGWRRMAI
    ISAVIALVCH AIALEARILP DGDSGQNLSL LNVGSLVSLM ICTVMTIVAS RNRGWLLLPI
    VYAFALINLA LATFMPNEYI THLEATPGML VHIGLSLFSY ATLIIAALYA LQLAWIDYQL
    KNKKLAFNQE MPPLMSIERK MFHITQIGVV LLTLTLCTGL FYMHNLFSME NIDKAVLSIV
    AWFVYIVLLW GHYHEGWRGR RVVWFNVAGA VILTLAYFGS RIVQQLIS
    SEQ ID NO. 105: YTFF ORGANISM NAME: ESCHERICHIA COLI
    MPVMISGVLY ALLAGLMWGL IFVGPLIVPE YPAMLQSMGR YLALGLIALP IAWLGRVRLR
    QLARRDWLTA LMLTMMGNLI YYFCLASAIQ RTGAPVSTMI IGTLPVVIPV FANLLYSQRD
    GKLAWGKLAP ALICIGIGLA CVNIAELNHG LPDFDWARYT SGIVLALVSV VCWAWYALRN
    ARWLRENPDK HPMMWATAQA LVTLPVSLIG YLVACYWLNT QTPDFSLPFG PRPLVFISLM
    VAIAVLCSWV GALCWNVASQ LLPTVILGPL IVFETLAGLL YTFLLRQQMP PLMTLSGIAL
    LVIGVVIAVR AKPEKPLTES VSES
    SEQ ID NO. 106: YTFL ORGANISM NAME: ESCHERICHIA COLI
    MLNSILVILC LIAVSAFFSM SEISLAASRK IKLKLLADEG NINAQRVLNM QENPGMFFTV
    VQIGLNAVAI LGGIVGDAAF SPAFHSLFSR YMSAELSEQL SFILSFSLVT GMFILFADLT
    PKRIGMIAPE AVALRIINPM RFCLYVCTPL VWFFNGLANI IFRIFKLPMV RKDDITSDDI
    YAVVEAGALA GVLRKQEHEL IENVFELESR TVPSSMTPRE NVIWFDLHED EQSLKNKVAE
    HPHSKFLVCN EDIDHIIGYV DSKDLLNRVL ANQSLALNSG VQIRNTLIVP DTLTLSEALE
    SFKTAGEDFA VIMNEYALVV GIITLNDVMT TLMGDLVGQG LEEQIVARDE NSWLIDGGTP
    IDDVMRVLDI DEFPQSGNYE TIGGFMMFML RKIPKRTDSV KFAGYKFEVV DIDNYRIDQL
    LVTRIDSKAT ALSPKLPDAK DKEESVA
    SEQ ID NO. 107: CHLOROFLEXUS AGGREGANS (CGMCR)
    <400>785
    MET SER VAL THR GLY ARG LEU ALA GLY LYS ILE ALA LEU ILE THR GLY
    1       5          10          15
    GLY ALA GLY ASN ILE GLY SER GLU MET THR ARG ARG PHE LEU ALA GLU
         20          25          30
    GLY ALA THR VAL ILE ILE SER GLY ARG ASN SER ALA LYS LEU ALA ALA
       35         40           45
    LEU ALA GLU ARG LEU ARG SER GLU ALA GLY VAL PRO ALA LYS ARG ILE
      50         55         60
    ASP LEU GLU VAL MET ASP GLY SER ASP PRO ALA ALA VAL ARG ALA GLY
    65        70          75          80
    VAL ALA ALA ILE ILE GLY ARG HIS GLY HIS ILE ASP ILE LEU VAL ASN
            85           90          95
    ASN ALA GLY SER THR GLY ALA GLN ARG ARG LEU ALA GLU ILE PRO LEU
          100         105         110
    ASN GLU THR ASP ARG ASP LEU ASP ASP GLU GLU ALA LEU SER THR SER
       115         120         125
    VAL ALA ASN LEU LEU GLY MET ALA TRP HIS LEU MET ARG ILE LEU SER
      130         135         140
    PRO HIS MET PRO PRO GLY SER ALA ILE ILE ASN ILE SER THR ILE PHE
    145         150         155         160
    SER ARG ALA GLU TYR TYR GLY ARG ILE PRO TYR VAL VAL PRO LYS ALA
            165         170         175
    ALA LEU ASN THR LEU THR GLN ILE ALA ALA ARG GLU LEU GLY ILE ARG
          180         185         190
    GLY ILE ARG VAL ASN THR ILE PHE PRO GLY PRO ILE GLU SER GLU ARG
        195         200         205
    ILE GLN THR VAL PHE GLN ARG MET ASP GLN LEU LYS GLY ARG PRO GLU
      210         215         220
    GLY ASP THR ALA SER GLN PHE LEU ALA THR MET ARG LEU TYR ARG ALA
    225         230         235         240
    ASN ASP GLN GLY GLN LEU GLU ARG ARG PHE PRO THR ILE CYS ASP VAL
            245         250         255
    ALA ASP ALA ALA VAL PHE LEU ALA SER ASP GLU ALA ALA ALA LEU THR
          260         265         270
    GLY GLU THR ILE GLU VAL THR HIS GLY MET GLU LEU PRO THR SER SER
        275         280         285
    GLU THR SER LEU LEU ALA ARG THR ASP LEU ARG THR ILE ASP ALA ASN
      290         295         300
    GLY ARG THR THR LEU ILE CYS ALA GLY ASP GLN ILE GLU GLU VAL MET
    305         310         315         320
    ALA LEU THR GLY MET LEU ARG THR CYS GLY SER GLU VAL ILE ILE GLY
            325         330         335
    PHE ARG SER GLU ALA ALA LEU ALA GLN PHE GLU GLN ALA ILE GLY GLU
          340         345         350
    SER ARG ARG LEU ALA GLY GLU SER PHE ILE PRO PRO ILE ALA LEU PRO
        355         360         365
    ILE ASP LEU ARG ASN PRO SER THR ILE ASP ALA LEU PHE ASP TRP ALA
      370         375         380
    GLY GLU ASN THR GLY GLY ILE HIS ALA ALA VAL ILE LEU PRO ALA SER
    385         390         395         400
    GLY ARG GLU PRO ALA THR GLN VAL ILE ASP ILE ASP ASP ALA HIS VAL
            405         410         415
    GLN ALA PHE LEU ASN ASP GLU ILE VAL GLY SER ILE ILE ILE ALA SER
          420         425         430
    ARG LEU ALA ARG TYR TRP GLN ALA GLN ARG ILE ALA PRO GLY ALA ARG
        435         440         445
    ALA ARG GLU PRO ARG VAL ILE PHE LEU SER ASN GLY ALA SER THR ALA
      450         455         460
    GLY ASN PRO TYR GLY ARG ILE GLN SER ALA ALA ILE GLU GLN LEU ILE
    465         470         475         480
    ARG VAL TRP ARG HIS GLU ALA ALA LEU ASP TYR GLU ARG ALA THR ALA
            485         490         495
    ALA GLY GLU ARG VAL LEU PRO ALA VAL TRP ALA SER GLN ILE VAL ARG
          500         505         510
    PHE ALA ASN ARG SER LEU GLU GLY LEU GLU PHE ALA CYS ALA TRP THR
        515         520         525
    ALA GLN LEU LEU HIS SER GLN ARG ARG ILE ASN GLU ILE THR LEU THR
      530         535         540
    ILE PRO ALA ASP ILE SER ALA THR THR GLY ALA ARG SER ALA SER VAL
    545         550         555         560
    GLY TRP ALA GLU SER LEU ILE GLY LEU HIS LEU GLY LYS VAL ALA LEU
            565         570         575
    ILE THR GLY GLY SER ALA GLY ILE GLY GLY GLN ILE GLY ARG LEU LEU
          580         585         590
    ALA LEU SER GLY ALA ARG VAL MET LEU ALA ALA ARG ASP PRO HIS LYS
        595         600         605
    LEU GLU GLN ILE GLN ALA THR ILE ARG ALA GLU LEU ALA GLU VAL GLY
      610         615         620
    TYR THR ASP VAL GLU GLU ARG VAL GLN ILE ALA PRO GLY CYS ASP VAL
    625         630         635         640
    SER SER GLU GLU GLN LEU VAL ASP LEU VAL GLU ARG THR LEU ALA ALA
            645         650         655
    PHE GLY THR VAL ASP TYR LEU ILE ASN ASN ALA GLY ILE ALA GLY VAL
          660         665         670
    GLU GLU MET VAL ILE ASP MET PRO VAL GLU GLY TRP ARG ASN THR LEU
        675         680         685
    TYR ALA ASN LEU ILE SER ASN TYR SER LEU MET ARG LYS LEU ALA PRO
      690         695         700
    LEU MET LYS LYS GLN GLY SER GLY TYR VAL LEU ASN VAL SER SER TYR
    705         710         715         720
    PHE GLY GLY GLU LYS ASP ALA ALA ILE PRO TYR PRO ASN ARG ALA ASP
            725         730         735
    TYR ALA VAL SER LYS ALA GLY GLN ARG ALA MET ALA GLU VAL PHE ALA
          740         745         750
    ARG PHE LEU GLY PRO GLU ILE GLN ILE ASN ALA ILE ALA PRO GLY PRO
        755         760         765
    VAL GLU GLY ASP ARG LEU ARG GLY THR GLY GLU ARG PRO GLY LEU PHE
      770         775         780
    ALA ARG ARG ALA ARG LEU ILE LEU GLU ASN LYS ARG LEU ASN GLU LEU
    785         790         795         800
    HIS ALA ALA LEU ILE THR ALA ALA ARG THR ASP ASN ARG PRO MET ARG
            805         810         815
    GLU LEU VAL GLU LEU LEU LEU PRO ASN ASP VAL ALA ALA LEU ALA GLN
          820         825         830
    HIS PRO ALA ALA PRO ASP VAL LEU ARG THR LEU ALA LYS ARG PHE GLN
        835         840         845
    SER GLU GLY ASP PRO ALA ALA SER SER SER SER PHE LEU LEU ASN ARG
      850         855         860
    SER ILE ALA ALA LYS LEU LEU ALA ARG LEU ILE ASN GLY GLY TYR ASP
    865         870         875         880
    LEU PRO ALA ASP ILE PHE ALA ASN LEU ALA VAL PRO PRO ASP PRO PHE
            885         890         895
    PHE THR ARG ALA GLN ILE ASP ARG GLU ALA ARG LYS VAL ARG ASP GLY
          900         905         910
    ILE MET GLY MET LEU TYR LEU GLN ARG MET PRO THR GLU PHE ASP VAL
        915         920         925
    ALA MET ALA THR VAL TYR TYR LEU ALA ASP ARG ASN VAL SER GLY GLU
      930         935         940
    THR PHE HIS PRO SER GLY GLY LEU ARG TYR GLU ARG THR PRO THR GLY
    945         950         955         960
    GLY GLU LEU PHE GLY LEU PRO ALA PRO GLU ARG LEU ALA GLU LEU VAL
              965         970         975
    GLY SER THR VAL TYR LEU ILE GLY GLU HIS LEU THR GLU HIS LEU ASN
            980         985         990
    LEU LEU ALA ARG ALA TYR LEU GLU ARG TYR GLY ALA ARG GLN VAL VAL
          995         1000        1005
    MET ILE VAL GLU THR GLU ALA GLY ALA GLU LYS MET ARG HIS LEU
      1010        1015        1020
    LEU HIS ASP HIS VAL GLU ALA GLY ARG LEU PRO ILE ILE VAL ALA
      1025        1030        1035
    GLY ASP GLN ILE GLU ALA ALA ILE ASP GLN ALA ILE ALA ASN TYR
      1040        1045        1050
    GLY ARG PRO GLY PRO VAL VAL CYS THR PRO PHE ARG PRO LEU PRO
      1055        1060        1065
    SER ALA PRO LEU VAL GLY ARG LYS ASP SER ASP TRP SER THR VAL
      1070        1075        1080
    LEU SER GLU ALA GLU PHE ALA GLU LEU CYS GLU HIS GLN LEU THR
      1085        1090        1095
    HIS HIS PHE ARG VAL ALA ARG LYS ILE ALA LEU SER ASP GLY ALA
      1100        1105        1110
    SER LEU ALA LEU VAL THR PRO GLU THR THR ALA THR SER SER THR
      1115        1120        1125
    GLU GLN PHE ALA LEU ALA ASN PHE VAL LYS THR THR LEU HIS ALA
      1130        1135        1140
    PHE THR ALA THR ILE GLY VAL GLU SER GLU ARG THR ALA GLN ARG
      1145        1150        1155
    ILE LEU ILE ASN GLN VAL ASP LEU THR ARG ARG ALA ARG ALA GLU
      1160        1165        1170
    GLU PRO ARG ASP PRO ARG GLU ARG GLN GLN GLU LEU GLU ARG PHE
      1175        1180        1185
    ILE GLU ALA VAL LEU LEU VAL THR ALA PRO LEU PRO PRO GLU ALA
      1190        1195        1200
    ASP THR ARG TYR ALA GLY ARG ILE HIS ARG GLY ARG ALA ILE THR VAL
      1205        1210        1215
    SEQ ID NO. 108: MCR OSCILLOCHLORIS TRICHOIDES (OTMCR)
    MFMTRLNDKIALITGGAGTIGEVITRRYLEEGATVVMAGRNRDKLDRYRERLITEFHALP
    ERVMVVRMDGSSNAEVRMGIAAVVAHFGRIDILVNNAGSAGARQRLPAIPLLRSELQADE
    TETLADSIGNLIGITWNLIRAAAPFMPAGSSVINISTIFARTDYYGRIPYVVPKAALHAL
    TLAAATELGERGIRVNQINPGPIDSDRIRTVFRRMDELKGVPEQSTADGFFQMMRLRRPN
    AEGDLVKGFPKTLDVANVAVFLGSAESAALSGETLDVTHGMAVPTESRTTLTSRPGLRAV
    DGSGHTTLICVGDQIEEAAALTGVLRACGAEVVIGFRSRAAIARFDHLIERGRHLPSQEH
    VAPVLLYLNPTEPESIDQALRWMATNLDLPTSVIILPAQRQPLPPSVVRASDEEVAYFLR
    DELSGMIVLASRLARFWQQATLAPGNAPIQPRVLFMTNPDDGQGNLYAEILRAGVEQLCR
    VWRHESQLDYTRLAQMDAHPPHIRPVWANQLVRFANNEQENLEYCCAWVAKILLSERTIE
    ELNLYLPRQIGSTTGSRQPSFGWAENLIGLHLGKTALITGGSAGIGSQIARLLALSGARV
    MLCARDERKLIQMRDMIIAELTEVGYNQVESRVQICAGCDVGEEEQLEIAVQRTLDLFGH
    VDYLINNAGIAGAEEMVLDLPLEAWQRTLRTNLISNYSLIRKLAPQMKSRGSGYILNVSS
    YFGGEKYAAIPYPNRADYAVSKAGQRALGEALARLLGPEVQINAMAPGPVEGERLRGSGD
    RPGLFLRRGRLILENKRLNDLHATLIAAERETQVGMRDLLARLLHNDVCALIDDPAAPTH
    LRALAERIWEQSDPNSYARAFFMNANIATKLLARLFNADQIDAQTFHTSQPNLPPEPFFA
    RTQIDREARRVRDGVMSMLYLQRMPTEFDVALATVYYLNDRSVSGETFHPSGGLRHERTP
    TGAELYGSPAPQRLASLAGSTVYLIGESMAAHLEALARAYIERYAATRVVLICATPAGVE
    RFSHHLADHLASGALAILSAEEGIEAALSEALRRFGPPGPVVSTPFQPLPSQPLIGRNDS
    DWSTVLDVAGFSAMCEQQLTHHFRVTRKLSLVAGVSLVLVTPETDSHSSTEQFALANFVK
    TTLHAFTATVGVECERTAHRILVNQVDLGRQARAEEPRSPAEQAQEMERFIDAIMLTTAP
    IPAEEDNRYTGRIYRGRAITV
    SEQ ID NO. 109: CHLOROFLEXUS AURANTIACUS (CAMCR)
    MSGTGRLAGKIALITGGAGNIGSELTRRFLAEGATVIISGRNRAKLTALAERMQAEAGVP
    AKRIDLEVMDGSDPVAVRAGIEAIVARHGQIDILVNNAGSAGAQRRLAEIPLTEAELGPG
    AEETLHASIANLLGMGWHLMRIAAPHMPVGSAVINVSTIFSRAEYYGRIPYVTPKAALNA
    LSQLAARELGARGIRVNTIFPGPIESDRIRTVFQRMDQLKGRPEGDTAHHFLNTMRLCRA
    NDQGALERRFPSVGDVADAAVFLASAESAALSGETIEVTHGMELPACSETSLLARTDLRT
    IDASGRTTLICAGDQIEEVMALTGMLRTCGSEVIIGFRSAAALAQFEQAVNESRRLAGAD
    FTPPIALPLDPRDPATIDAVFDWGAGENTGGIHAAVILPATSHEPAPCVIEVDDERVLNF
    LADEITGTIVIASRLARYWQSQRLTPGARARGPRVIFLSNGADQNGNVYGRIQSAAIGQL
    IRVWRHEAELDYQRASAAGDHVLPPVWANQIVRFANRSLEGLEFACAWTAQLLHSQRHIN
    EITLNIPANISATTGARSASVGWAESLIGLHLGKVALITGGSAGIGGQIGRLLALSGARV
    MLAARDRHKLEQMQAMIQSELAEVGYTDVEDRVHIAPGCDVSSEAQLADLVERTLSAFGT
    VDYLINNAGIAGVEEMVIDMPVEGWRHTLFANLISNYSLMRKLAPLMKKQGSGYILNVSS
    YFGGEKDAAIPYPNRADYAVSKAGQRAMAEVFARFLGPEIQINAIAPGPVEGDRLRGTGE
    RPGLFARRARLILENKRLNELHAALIAAARTDERSMHELVELLLPNDVAALEQNPAAPTA
    LRELARRFRSEGDPAASSSSALLNRSIAAKLLARLHNGGYVLPADIFANLPNPPDPFFTR
    AQIDREARKVRDGIMGMLYLQRMPTEFDVAMATVYYLADRNVSGETFHPSGGLRYERTPT
    GGELFGLPSPERLAELVGSTVYLIGEHLTEHLNLLARAYLERYGARQVVMIVETETGAET
    MRRLLHDHVEAGRLMTIVAGDQIEAAIDQAITRYGRPGPVVCTPFRPLPTVPLVGRKDSD
    WSTVLSEAEFAELCEHQLTHHFRVARKIALSDGASLALVTPETTATSTTEQFALANFIKT
    TLHAFTATIGVESERTAQRILINQVDLTRRARAEEPRDPHERQQELERFIEAVLLVTAPL
    PPEADTRYAGRIHRGRAITV

Claims (26)

What is claimed is:
1. A genetically modified organism capable of producing a chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding a monofunctional malonyl-CoA reductase enzyme capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde and one or more of the following genes: ydfG, mmsB, NDSD, rutE, and nemA.
2. The genetically modified organism of claim 1, wherein ydfG, mmsB, NDSD, rutE, or nemA encodes enzymes which catalyze the conversion of malonate semialdehyde to 3-HP.
3. The genetically modified organism of claim 1, wherein said malonyl-CoA reductase enzyme is not capable of converting malonate semialdehyde to 3-HP.
4. The genetically modified organism of claim 1, wherein said malonyl-CoA reductase gene is derived from Sulfolobus tokodaii.
5. The genetically modified organism of claim 1, wherein ydfG, mmsB, or NDSD encodes enzymes which catalyze the conversion of malonate semialdehyde keto form to 3-HP.
6. The genetically modified organism of claim 1, wherein ydfG is derived from E. coli and mmsB and NDSD are derived from Pseudomonas.
7. The genetically modified organism of claim 1, wherein nemA or rutE encodes enzymes which catalyze the conversion of malonate semialdehyde enol form to 3-HP.
8. The genetically modified organism of claim 1, wherein nemA and rutE are derived from E. coli.
9. The genetically modified organism of claim 1, wherein ydfG, mmsB, NDSD, nemA or rutE encodes enzymes which catalyze the conversion of malonate semialdehyde hydrated form to 3-HP.
10. A genetically modified organism capable of producing a chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding a monofunctional malonyl-CoA reductase enzyme capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde, and one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP, and one or more genes encoding one or more enzymes capable of converting either the malonate semialdehyde enol form or the malonate semialdehyde hydrated form to 3-HP.
11. A genetically modified organism capable of producing a chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding a monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is either: (a) primarily not NADPH-dependent, (b) primarily NADH-dependent, (c) primarily flavin-dependent, (d) less susceptible to 3-HP inhibition at high concentration, or (e) catalyzes a reaction pathway to 3-HP that is substantially irreversible.
12. A genetically modified organism capable of producing a chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding a monofunctional malonyl-CoA reductase enzyme fused to one or more dehydrogenase enzymes.
13. The genetically modified organism of claim 12 wherein the dehydrogenase enzymes are encoded by genes selected from the group consisting of ydfG, mmsB, NDSD, rutE, and nemA.
14. The genetically modified organism of claim 12 comprising polynucleotides encoding a first monofunctional malonyl-CoA reductase enzyme fused to a first dehydrogenase enzyme of a first type, and polynucleotides encoding a second monofunctional malonyl-CoA reductase enzyme fused to a second dehydrogenase enzyme of a second type, wherein said first and second types of dehydrogenase enzymes convert different forms of malonate semialdehyde to 3-HP.
15. The genetically modified organism of claim 14 wherein said first type of dehydrogenase enzyme is encoded to convert malonate semialdehyde enol form to 3-HP and said second type of dehydrogenase enzyme is encoded to convert malonate semialdehyde keto form to 3-HP.
16. The genetically modified organism of claim 14 wherein said first monofunctional malonyl-CoA reductase enzyme is the same as said second monofunctional malonyl-CoA reductase enzyme.
17. The genetically modified organism of claim 14 wherein said first monofunctional malonyl-CoA reductase enzyme is different from said second monofunctional malonyl-CoA reductase enzyme.
18. The genetically modified organism of claim 12 wherein said monofunctional malonyl-CoA reductase enzyme fused to one or more dehydrogenase enzymes is encoded by genes selected from the group consisting of mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, and mcr-nemA-rutE.
19. A method of producing 3-HP using the genetically modified organisms of claim 1, 10, 11, or 12, wherein the organism's reaction pathway converts sugar to malonyl-CoA through a series of intermediate steps, converts malonyl-CoA to malonate semialdehyde, and converts malonate semialdehyde to 3-HP.
20. A method of producing a chemical product using the genetically a modified organisms as in claim 1, 10, 11, or 12.
21. Products made from the genetically modified organisms as in claim 1, 10, 11, or 12.
22. Products made from the methods as in claim 1, 10, 11, or 12.
23. The products of claim 21, wherein said product is selected from the group consisting of acetyl-CoA, malonyl-CoA, malonate semialdehyde, 3-hydroxypropionic acid (3-HP), acrylic acid, 1,3 propanediol, malonic acid, ethyl 3-HP, propiolactone, acrylonitrile, acrylamide, methyl acrylate, a polymer, a superabsorbent polymer, polyacrylic acid, and a consumer product.
24. The method of claim 1, 10, 11, or 12, wherein said chemical product is 3-hydroxypropionic acid or a derivative of 3-HP, 1,4-butanediol, butanol, isobutanol, polyketide chemical product, or C4-C18 fatty acid chain.
25. The method of claim 1, 10, 11, or 12, wherein said chemical product is converted to acrylic acid, acrylates, 1,3-propanediol, malonic acid, ethyl-3-hydroxypropionate, ethyl ethoxy propionate, propiolactone, acrylamide, or acrylonitrile to make consumer products.
26. The method of claim 1, 10, 11, or 12, wherein said chemical product is oligomerized or polymerized to form polyacrylic acid, methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate, and acrylic acid ester to which an alkyl or aryl addition may be made, and/or to which halogens, aromatic amines or amides, and aromatic hydrocarbons may be added to make consumer products.
US14/215,442 2013-03-15 2014-03-17 Monofunctional mcr + 3-hp dehydrogenase Abandoned US20150119601A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/215,442 US20150119601A1 (en) 2013-03-15 2014-03-17 Monofunctional mcr + 3-hp dehydrogenase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361852387P 2013-03-15 2013-03-15
US14/215,442 US20150119601A1 (en) 2013-03-15 2014-03-17 Monofunctional mcr + 3-hp dehydrogenase

Publications (1)

Publication Number Publication Date
US20150119601A1 true US20150119601A1 (en) 2015-04-30

Family

ID=51538165

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/215,379 Active US9447438B2 (en) 2013-03-15 2014-03-17 Acetyl-coA carboxylases
US14/215,508 Abandoned US20150057465A1 (en) 2013-03-15 2014-03-17 Control of growth-induction-production phases
US14/769,413 Active US10047383B2 (en) 2013-03-15 2014-03-17 Bioproduction of chemicals
US14/215,442 Abandoned US20150119601A1 (en) 2013-03-15 2014-03-17 Monofunctional mcr + 3-hp dehydrogenase
US15/269,382 Active US10155937B2 (en) 2013-03-15 2016-09-19 Acetyl-CoA carboxylases
US16/216,588 Active US10815473B2 (en) 2013-03-15 2018-12-11 Acetyl-CoA carboxylases

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US14/215,379 Active US9447438B2 (en) 2013-03-15 2014-03-17 Acetyl-coA carboxylases
US14/215,508 Abandoned US20150057465A1 (en) 2013-03-15 2014-03-17 Control of growth-induction-production phases
US14/769,413 Active US10047383B2 (en) 2013-03-15 2014-03-17 Bioproduction of chemicals

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/269,382 Active US10155937B2 (en) 2013-03-15 2016-09-19 Acetyl-CoA carboxylases
US16/216,588 Active US10815473B2 (en) 2013-03-15 2018-12-11 Acetyl-CoA carboxylases

Country Status (2)

Country Link
US (6) US9447438B2 (en)
WO (1) WO2014146026A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047383B2 (en) 2013-03-15 2018-08-14 Cargill, Incorporated Bioproduction of chemicals
US10337038B2 (en) 2013-07-19 2019-07-02 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10465213B2 (en) 2012-08-10 2019-11-05 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10494654B2 (en) 2014-09-02 2019-12-03 Cargill, Incorporated Production of fatty acids esters
US11345938B2 (en) 2017-02-02 2022-05-31 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003604A (en) * 2009-09-27 2012-09-12 Opx Biotechnologies Inc Method for producing 3-hydroxypropionic acid and other products.
EP3287519B1 (en) 2010-11-22 2020-03-18 Cargill, Incorporated Compositions and methods for 3-hydroxypropionic acid production
WO2014145344A2 (en) * 2013-03-15 2014-09-18 Opx Biotechnologies, Inc. Control of growth-induction-production phases
US10442749B2 (en) 2013-03-15 2019-10-15 Cargill, Incorporated Recovery of 3-hydroxypropionic acid
MX2016008086A (en) * 2013-12-19 2017-03-27 Basf Se Mixtures comprising a superabsorbent polymer (sap) and a biopesticide.
WO2017123692A1 (en) * 2016-01-13 2017-07-20 University Of Florida Research Foundation, Incorporated Microorganisms resistant to nonvolatile side products from acid hydrolysate of lignocellulosic biomass
CN109439606B (en) * 2018-11-14 2022-06-28 中国科学院青岛生物能源与过程研究所 Genetically engineered bacterium for increasing phloroglucinol yield and construction method and application thereof
US20220049279A1 (en) * 2018-12-18 2022-02-17 Alderys Malonic semi-aldehyde-producing yeasts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140330032A1 (en) * 2011-03-22 2014-11-06 Michael D. Lynch Microbial production of chemical products and related compositions, methods and systems
US20150064754A1 (en) * 2013-03-15 2015-03-05 Opx Biotechnologies, Inc. Bioproduction of chemicals

Family Cites Families (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2408889A (en) 1946-10-08 Production of organic compounds
US2469701A (en) 1946-02-13 1949-05-10 American Cyanamid Co Preparation of acrylic acid
US2464768A (en) 1946-02-13 1949-03-15 American Cyanamid Co Preparation of esters of acrylic acid
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3687885A (en) 1970-04-15 1972-08-29 Du Pont Water base paints having an improved balance of anti-drip and leveling qualities
GB1349586A (en) 1970-12-11 1974-04-03 Polysar Ltd Latex composition and process for producing the same
US3872037A (en) 1970-12-11 1975-03-18 Polysar Ltd Improved carboxylic latex for paper coating utilizing butadiene-styrene-acrylic acid-acrolein tetrapolymers
US3904685A (en) 1973-07-20 1975-09-09 Celanese Corp Polyacrylic acid having high chelation value and its production
US3891591A (en) 1973-08-13 1975-06-24 Du Pont Coating compositions
US3915921A (en) 1974-07-02 1975-10-28 Goodrich Co B F Unsaturated carboxylic acid-long chain alkyl ester copolymers and tri-polymers water thickening agents and emulsifiers
US4029577A (en) 1975-11-17 1977-06-14 Betz Laboratories, Inc. Polymers for use in water treatment
DE2757329C2 (en) 1977-12-22 1980-02-07 Basf Ag, 6700 Ludwigshafen Process for the production of polymers of acrylic acid or methacrylic acid
US4268641A (en) 1979-04-24 1981-05-19 Union Carbide Corporation Acrylic acid-acrylate copolymer thickening agents
US4431547A (en) 1981-08-24 1984-02-14 Nalco Chemical Company Use of acrylamide/acrylic acid copolymers for prevention of fouling by Ca3 (PO4)2
US4985518A (en) 1981-10-26 1991-01-15 American Colloid Company Process for preparing water-absorbing resins
JPS58180233A (en) 1982-04-19 1983-10-21 Nippon Shokubai Kagaku Kogyo Co Ltd Absorbing agent
US4685915A (en) 1984-04-06 1987-08-11 The Procter & Gamble Company Disposable diaper having density and basis weight profiled absorbent core
US4734478A (en) 1984-07-02 1988-03-29 Nippon Shokubai Kagaku Kogyo Co., Ltd. Water absorbing agent
US4708997A (en) 1985-07-22 1987-11-24 The Dow Chemical Company Suspending agent for the suspension polymerization of water-soluble monomers
DE3544770A1 (en) 1985-12-18 1987-06-19 Stockhausen Chem Fab Gmbh METHOD AND DEVICE FOR THE CONTINUOUS PRODUCTION OF POLYMERISATES AND COPOLYMERISATES OF ACRYLIC ACID AND / OR METHACRYLIC ACID
US5009653A (en) 1988-03-31 1991-04-23 The Procter & Gamble Company Thin, flexible sanitary napkin
US5135677A (en) 1988-04-11 1992-08-04 Nippon Shokubai Co., Ltd. Process for producing acid-type maleic acid polymer and water-treating agent and detergent additive containing said polymer
US4952505A (en) 1988-08-08 1990-08-28 Florida State University Fermentation of trichoderma reesei and apparatus therefor
US5487989A (en) 1988-08-31 1996-01-30 Bioenergy International, L.C. Ethanol production by recombinant hosts
IT1229506B (en) 1989-01-26 1991-09-03 Sigma Prodotti Chimici Srl POLYMER OF ACRYLIC ACID FREE FROM RESIDUAL SOLVENTS AND PROCEDURE FOR ITS PREPARATION.
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
US5145906A (en) 1989-09-28 1992-09-08 Hoechst Celanese Corporation Super-absorbent polymer having improved absorbency properties
JP2938920B2 (en) 1990-01-31 1999-08-25 住友精化株式会社 Method for producing water absorbent resin
US5350799A (en) 1990-05-31 1994-09-27 Hoechst Celanese Corporation Process for the conversion of fine superabsorbent polymer particles into larger particles
US5342899A (en) 1991-05-16 1994-08-30 The Dow Chemical Company Process for recycling aqueous fluid absorbents fines to a polymerizer
DE4138408A1 (en) 1991-11-22 1993-05-27 Cassella Ag HYDROPHILES, HIGHLY SOURCE HYDROGELS
CA2083346A1 (en) 1991-12-13 1993-06-14 Eric G. Lundquist A catalyzed esterification process
US5142023A (en) 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5827255A (en) 1992-07-27 1998-10-27 The Procter & Gamble Company Sanitary napkin comprising an absorbent core having a density gradient
US5405913A (en) 1993-03-22 1995-04-11 The University Of Akron Free radical copper(II)-enolate polymerization initiators
US5510307A (en) 1993-04-08 1996-04-23 Isp Investments Inc. Free radical initiator delivery system
US5510526A (en) 1993-06-29 1996-04-23 Cargill, Incorporated Lactic acid production, separation and/or recovery process
CA2169170C (en) 1993-08-24 2007-01-09 Masakazu Sugimoto Mutant phosphoenolpyruvate carboxylase, its gene, and production method of amino acid
US5487987A (en) 1993-09-16 1996-01-30 Purdue Research Foundation Synthesis of adipic acid from biomass-derived carbon sources
US5558656A (en) 1993-12-20 1996-09-24 The Procter & Gamble Company Sanitary napkin having an internal shaping component
DE69638080D1 (en) 1995-05-18 2009-12-31 Univ Stellenbosch NUCLEIC ACID FOR A MALAT PERMEASE FROM S.POMBE ENGINEERING AND ITS USES
US5723639A (en) 1995-10-16 1998-03-03 University Of Chicago Esterification of fermentation-derived acids via pervaporation
DE19629372A1 (en) 1996-07-20 1998-01-22 Degussa Malonic acid or salt preparation
KR100509310B1 (en) 1996-11-13 2005-08-22 이 아이 듀폰 디 네모아 앤드 캄파니 Method for the Production of 1,3-Propanediol by recombinant Organisms
SK285201B6 (en) 1996-12-05 2006-08-03 Ajinomoto Co., Inc. Recombinant DNA autonomously replicable in cells of coryneform bacteria, coryneform bacterium and method for producing L-lysine, vector pVK7
AU6169498A (en) 1997-02-13 1998-09-08 James Madison University Methods of making polyhydroxyalkanoates comprising 4-hydroxybutyrate monomer units
US6087140A (en) 1997-02-19 2000-07-11 Wisconsin Alumni Research Foundation Microbial production of 1,2-propanediol from sugar
US6143538A (en) 1997-02-20 2000-11-07 The United States Of America As Represented By The United States Department Of Energy Fatty acyl-CoA reductase
US7125938B2 (en) 1997-03-11 2006-10-24 Carnegie Mellon University Atom or group transfer radical polymerization
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
BE1011197A3 (en) 1997-06-06 1999-06-01 Brussels Biotech En Abrege Bb Process for purification lactic acid.
US6306636B1 (en) 1997-09-19 2001-10-23 Arch Development Corporation Nucleic acid segments encoding wheat acetyl-CoA carboxylase
CA2304309A1 (en) 1997-09-19 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Dna encoding a ras carboxyl-terminal processing protein
US6229046B1 (en) 1997-10-14 2001-05-08 Cargill, Incorported Lactic acid processing methods arrangements and products
AU752105B2 (en) 1997-12-05 2002-09-05 Europaisches Laboratorium Fur Molekularbiologie (Embl) Novel dna cloning method
KR100250830B1 (en) 1997-12-09 2000-04-01 성재갑 Method for producing optically active hydroxycarboxylic acids by autodegradation of polyhydroxyalkanoates
US20030087381A1 (en) 1998-04-13 2003-05-08 University Of Georgia Research Foundation, Inc. Metabolically engineered organisms for enhanced production of oxaloacetate-derived biochemicals
JP4913929B2 (en) 1998-06-12 2012-04-11 味の素株式会社 Method for producing nucleic acid substances
MXPA01001111A (en) 1998-08-04 2002-04-24 Metabolix Inc Polyhydroxyalkanoate production from polyols.
JP4623829B2 (en) 1998-08-18 2011-02-02 メタボリックス,インコーポレイテッド Production of polyhydroxyalkanoates by transgenic microorganisms
CN1207272C (en) 1998-10-30 2005-06-22 催化蒸馏技术公司 Production of amides and/or acids from nitriles
US6297319B1 (en) 1998-11-05 2001-10-02 Nippon Shokubai Co., Ltd. Water-absorbing agent and production process therefor
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
WO2000039287A2 (en) 1998-12-31 2000-07-06 Millennium Pharmaceuticals, Inc. A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
JP2002540090A (en) 1999-03-22 2002-11-26 ピユラク・バイオケム・ベー・ブイ How to purify lactic acid on an industrial scale
JP2002539798A (en) 1999-03-23 2002-11-26 ボード オブ トラスティーズ,オパレイティング ミシガン ステイト ユニバーシティ Synthesis of 1,2,3,4-tetrahydroxybenzene from carbon derived from biomass
WO2000061740A1 (en) 1999-04-10 2000-10-19 Maxygen, Inc. Modified lipid production
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US6852517B1 (en) 1999-08-30 2005-02-08 Wisconsin Alumni Research Foundation Production of 3-hydroxypropionic acid in recombinant organisms
AU7093600A (en) 1999-08-30 2001-03-26 Wisconsin Alumni Research Foundation Production of 3-hydroxypropionic acid in recombinant organisms
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US20020102672A1 (en) 1999-10-04 2002-08-01 Joseph Mizrahi Process for producing a purified lactic acid solution
WO2001031049A2 (en) 1999-10-25 2001-05-03 Kosan Biosciences, Inc. Production of polyketides
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
AU1661901A (en) 1999-11-24 2001-06-04 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
NL1013682C2 (en) 1999-11-26 2001-05-30 Purac Biochem Bv Method and device for purifying an aqueous solution of lactic acid.
US6613553B1 (en) 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
RU2212447C2 (en) 2000-04-26 2003-09-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Strain escherichia coli as producer of amino acid (variants) and method for preparing amino acid (variants)
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6586229B1 (en) 2000-06-01 2003-07-01 North Carolina State University Method for the production of ρ-Hydroxybenzoate in species of pseudomonas and agrobacterium
DE60120415T2 (en) 2000-07-21 2007-01-04 Metabolix, Inc., Cambridge PREPARATION OF POLYHYDROXYALKANOATES FROM POLYOLES
CA2322105A1 (en) 2000-10-23 2002-04-23 Plant Bioscience Limited Antibiotic production (ii)
AU1981802A (en) 2000-11-20 2002-06-03 Cargill Inc 3-hydroxypropionic acid and other organic compounds
US6623944B2 (en) 2001-03-14 2003-09-23 Degussa Ag Process for preparation of D-pantothenic acid and/or salts thereof
EP1392636B1 (en) 2001-05-07 2008-04-23 Cargill, Incorporated Process for preparing carboxylic acids and derivatives thereof
CA2453207A1 (en) 2001-07-06 2003-01-16 454 Corporation Method for isolation of independent, parallel chemical micro-reactions using a porous filter
MY146503A (en) 2001-08-13 2012-08-15 Malaysian Palm Oil Board Method and compositions for the production of transgenic plants
US6723799B2 (en) 2001-08-24 2004-04-20 E I. Du Pont De Nemours And Company Acid-dyeable polymer compositions
EP1445314B1 (en) 2001-10-23 2011-09-14 Ajinomoto Co., Inc. Novel glutamic acid receptor and utilization thereof
WO2003040690A2 (en) 2001-11-02 2003-05-15 Rice University Recycling system for manipulation of intracellular nadh availability
AU2002357355A1 (en) 2001-12-18 2003-06-30 Metabolix, Inc. Methods of making intermediates from polyhydroxyalkanoates
BR0307010A (en) 2002-01-18 2006-04-11 Cargill Inc alanine 2,3-aminomutase
US6709919B2 (en) 2002-05-15 2004-03-23 Taiwan Semiconductor Manufacturing Company Method for making auto-self-aligned top electrodes for DRAM capacitors with improved capacitor-to-bit-line-contact overlay margin
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AR038719A1 (en) 2002-03-01 2005-01-26 Monsanto Technology Llc DNA SEQUENCE OF BACTERIAL SYNTHEASES OF CEROSOUS ESTERES, PROTEINS AND USES OF THE SAME
US20050221457A1 (en) 2002-03-25 2005-10-06 Paraskevas Tsobanakis Methods of manufacturing derivatives of beta-hydroxycarboxylic acids
ES2741964T3 (en) 2002-05-10 2020-02-12 Tepha Inc Bioabsorbable polymer containing 2-hydroxy acid monomers
US7826975B2 (en) 2002-07-10 2010-11-02 The Penn State Research Foundation Method for redesign of microbial production systems
CA2491753A1 (en) 2002-07-10 2004-03-04 The Penn State Research Foundation Method for determining gene knockout strategies
AU2003205041A1 (en) 2002-07-12 2004-01-29 Ajinomoto Co., Inc. Method for producing target substance by fermentation
GB0218019D0 (en) 2002-08-05 2002-09-11 Ciba Spec Chem Water Treat Ltd Production of a fermentation product
CN100471946C (en) 2002-10-04 2009-03-25 纳幕尔杜邦公司 Process for the biological production of 1,3-propanediol with high yield
MXPA05004561A (en) 2002-11-01 2005-07-26 Cargill Inc Process for preparation of 1,3-propanediol.
WO2004044210A2 (en) 2002-11-06 2004-05-27 University Of Florida Materials and methods for the efficient production of acetate and other products
EP1568679A4 (en) 2002-12-06 2012-08-29 Kaneka Corp Process for producing optically active 3-hydroxypropionic ester derivative
BRPI0407600A (en) 2003-02-18 2006-02-14 Metabolic Explorer Sa processes for the preparation of evolved microorganisms and an evolved protein and biotransformation, an evolved gene, an evolved protein, and the use of an evolved microorganism or an evolved protein
US7141154B2 (en) 2003-03-06 2006-11-28 Uchicago Argonne Llc Single-stage separation and esterification of cation salt carboxylates using electrodeionization
US7855321B2 (en) 2003-03-31 2010-12-21 University Of Bristol Plant acyltransferases specific for long-chained, multiply unsaturated fatty acids
DE10314618A1 (en) 2003-04-01 2004-10-14 Degussa Ag Process for the preparation of L-amino acids using strains of the family Enterobacteriaceae
US20040225116A1 (en) 2003-05-08 2004-11-11 Payne Mark S. Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids
DE602004022305D1 (en) 2003-06-26 2009-09-10 Novozymes As PROCESS FOR THE SEPARATION AND RECOVERY OF 3-HYDROXYPROPIONIC ACID AND ACRYLIC ACID
WO2005033287A2 (en) 2003-09-29 2005-04-14 The Regents Of The University Of California Methods for identifying a biosynthetic pathway gene product
FR2862068B1 (en) 2003-11-06 2007-10-12 Metabolic Explorer Sa OPTIMIZED MICROORGANISM STRAINS FOR NADPH CONSUMPTION BIOSYNTHESIS PATHWAYS
US7326557B2 (en) 2003-11-14 2008-02-05 Rice University Increasing intracellular NADPH availability in E. coli
WO2005118719A2 (en) 2003-12-04 2005-12-15 Cargill, Incorporated Production of 3-hydroxypropionic acid using beta-alanine/pyruvate aminotransferase
US7186214B2 (en) 2004-02-12 2007-03-06 Medtronic, Inc. Instruments and methods for accessing an anatomic space
US20070148749A1 (en) 2004-03-26 2007-06-28 Shinzo Yasuda Process for producting 1,3-propanediol and or/3-hydroxypropionic acid
WO2005095320A1 (en) 2004-04-02 2005-10-13 Ciba Specialty Chemicals Water Treatments Limited Preparation of acrylic acid derivatives from alpha or beta-hydroxy carboxylic acids
CA2562176A1 (en) 2004-04-28 2005-11-10 Icos Corporation Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
US20050272135A1 (en) 2004-06-02 2005-12-08 The University Of Chicago Processs for production and purification of fermentation derived organic acids
US7652167B2 (en) 2004-07-19 2010-01-26 Board Of Trustees Of Michigan State University Process for production of organic acid esters
EP1786831A4 (en) 2004-07-30 2008-01-23 Cargill Inc Alanine 2, 3 aminomutases
US7148051B2 (en) 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase
EP3130676A1 (en) 2004-08-27 2017-02-15 Rice University Mutant e. coli strain with increased succinic acid production
JP2008513023A (en) 2004-09-17 2008-05-01 ライス ユニバーシティー Highly succinic acid producing bacteria
US7987056B2 (en) 2004-09-20 2011-07-26 The Regents Of The University Of Colorado, A Body Corporate Mixed-library parallel gene mapping quantitative micro-array technique for genome-wide identification of trait conferring genes
EP1799828B1 (en) 2004-10-12 2013-05-01 Board of Trustees of Michigan State University Biosynthesis of phloroglucinol and preparation of 1,3-dihydroxybenzene therefrom
CA2584108A1 (en) 2004-10-14 2006-04-27 Carnegie Institution Of Washington Development of sensitive fret sensors and methods of using the same
US7273746B2 (en) 2004-11-04 2007-09-25 E.I. Dupont De Nemours And Company Diacylglycerol acyltransferases for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms
US7588931B2 (en) 2004-11-04 2009-09-15 E. I. Du Pont De Nemours And Company High arachidonic acid producing strains of Yarrowia lipolytica
DE102004062294A1 (en) 2004-12-23 2006-07-06 Basf Plant Science Gmbh Process for the preparation of polyunsaturated long-chain fatty acids in transgenic organisms
TWI529181B (en) 2005-02-28 2016-04-11 贏創德固賽有限責任公司 Water-absorbing polymer structures based upon renewable raw materials and process for their production
CN101184844A (en) 2005-03-30 2008-05-21 加拿大国家研究委员会 Identification of a sterol acyltransferase gene
EP1869202B1 (en) 2005-04-12 2018-02-14 E. I. du Pont de Nemours and Company Treatment of biomass to obtain fermentable sugars
US7524660B2 (en) 2005-05-05 2009-04-28 E.I. Du Pont De Nemours And Company Utilization of fructose in microbial production strains
WO2006125000A2 (en) 2005-05-19 2006-11-23 E.I. Du Pont De Nemours And Company Method for the production of resveratrol in a recombinant oleaginous microorganism
EP1907559A1 (en) 2005-07-18 2008-04-09 Basf Se Methionine producing recombinant microorganisms
WO2007093848A2 (en) 2005-08-03 2007-08-23 Affinium Pharmaceuticals, Inc. Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
EP1752532A1 (en) 2005-08-09 2007-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH Extracellular polyhydroxyalkanoates produced by genetically engineered microorganisms
US7846688B2 (en) 2005-08-15 2010-12-07 The Regents Of The University Of Colorado Broad host range vectors for shotgun and expression library cloning in Gram negative bacteria
CN101300356A (en) 2005-09-09 2008-11-05 基因组股份公司 Methods and organisms for the growth-coupled production of succinate
US9297028B2 (en) 2005-09-29 2016-03-29 Butamax Advanced Biofuels Llc Fermentive production of four carbon alcohols
DE102005048818A1 (en) 2005-10-10 2007-04-12 Degussa Ag Microbiological production of 3-hydroxypropionic acid
WO2007047680A2 (en) 2005-10-14 2007-04-26 Cargill, Incorporated Increasing the activity of radical s-adenosyl methionine (sam) enzymes
NZ593809A (en) 2005-10-26 2013-01-25 Butamax Tm Advanced Biofuels Fermentive production of four carbon alcohols
JP5064761B2 (en) 2005-12-21 2012-10-31 富士フイルム株式会社 Higher fatty acid triesters and amide derivatives having diethylenetriamine type metal chelate structure
US8535916B2 (en) 2006-02-13 2013-09-17 Ls9, Inc. Modified microorganisms and uses therefor
WO2007130745A1 (en) 2006-03-15 2007-11-15 Regents Of The University Of Colorado Enhanced alcohol tolerant microorganism and methods of use thereof
CN101473038B (en) 2006-03-15 2014-05-28 Dsmip资产公司 Plant seed oils containing polyunsaturated fatty acids
US20070219390A1 (en) 2006-03-15 2007-09-20 Battelle Memorial Institute Method and apparatus for conversion of beta-hydroxy carbonyl compounds
US7687661B2 (en) 2006-03-15 2010-03-30 Battelle Memorial Institute Method for conversion of β-hydroxy carbonyl compounds
KR101524398B1 (en) 2006-03-15 2015-06-04 디에스엠 아이피 어셋츠 비.브이. Polyunsaturated Fatty Acid Production in Heterologous Organisms Using PUFA Polyketide Synthase Systems
KR20070096348A (en) 2006-03-23 2007-10-02 주식회사 엘지화학 Mutants having a producing ability of 1,4-butanediol and method for preparing 1,4-bdo using the same
US8110670B2 (en) 2006-05-19 2012-02-07 Ls9, Inc. Enhanced production of fatty acid derivatives
MX356086B (en) 2006-05-19 2018-05-11 Reg Life Sciences Llc Production of fatty acids and derivatives thereof.
MY146612A (en) 2006-05-26 2012-09-14 Amyris Inc Production of isoprenoids
DE102006025821A1 (en) 2006-06-02 2007-12-06 Degussa Gmbh An enzyme for the production of Mehylmalonatsemialdehyd or Malonatsemialdehyd
US20080103060A1 (en) 2006-08-08 2008-05-01 Regents Of The University Of Colorado Compositions and methods for chemical reporter vectors
DE102006039203B4 (en) 2006-08-22 2014-06-18 Evonik Degussa Gmbh Process for the preparation of crystallization-purified acrylic acid from hydroxypropionic acid and apparatus therefor
WO2008028002A1 (en) 2006-08-29 2008-03-06 Rice University Increasing nadph-dependent products
WO2008027742A1 (en) 2006-08-30 2008-03-06 Cargill, Incorporated Beta-alanine/alpha-ketoglutarate aminotransferase for 3-hydroxypropionic acid production
US20100028962A1 (en) 2006-09-18 2010-02-04 Qiang Hu Algal Medium Chain Length Fatty Acids and Hydrocarbons
WO2008042958A2 (en) 2006-10-04 2008-04-10 Cargill, Incorporated Carboxylic acids prepared using a salt-splitting process
WO2008130437A2 (en) 2006-10-20 2008-10-30 Arizona Board Of Regents For And On Behalf Of Arizona State University Modified cyanobacteria
AU2007332240B2 (en) 2006-12-15 2012-03-08 Gs Caltex Corporation Method for preparing butanol through butyryl-coa as an intermediate using bacteria
CA2675026A1 (en) 2007-01-12 2008-07-24 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms
WO2008091627A2 (en) 2007-01-22 2008-07-31 Genomatica, Inc. Methods and organisms for growth-coupled production of 3-hydroxypropionic acid
NZ578813A (en) 2007-02-09 2012-04-27 Zeachem Inc Energy efficient methods to produce alcohols and carboxylic acids
WO2008113041A2 (en) 2007-03-14 2008-09-18 Ls9, Inc. Process for producing low molecular weight hydrocarbons from renewable resources
EP2139985A1 (en) 2007-03-23 2010-01-06 Metabolic Explorer Metabolically engineered microorganism useful for the production of 1,2-propanediol
EP2149608A4 (en) 2007-04-16 2013-02-20 Ajinomoto Kk Method for production of organic acid
CN101679187B (en) 2007-06-01 2013-06-05 赢创罗姆有限责任公司 A process for preparing methacrylic acid or methacrylic esters
WO2008149951A1 (en) 2007-06-06 2008-12-11 Kao Corporation Transparent solid soap
US8198055B2 (en) 2007-06-08 2012-06-12 Coskata, Inc. Process for converting syngas to liquid products with microorganisms on two-layer membrane
WO2009006430A1 (en) 2007-06-29 2009-01-08 The Regents Of The University Of California Host cells and methods for producing fatty acid derived compounds
JP2010263790A (en) 2007-09-04 2010-11-25 Ajinomoto Co Inc Amino acid-producing microorganism and method for producing amino acid
KR20090026230A (en) 2007-09-09 2009-03-12 김건 Universal high-speed real-time monitoring device for embedded systems
US20090191599A1 (en) 2007-09-10 2009-07-30 Joule Biotechnologies, Inc. Engineered light-harvesting organisms
JP2009067775A (en) 2007-09-17 2009-04-02 Rohm & Haas Co Method for converting hydroxycarboxylic acid or salt thereof into unsaturated carboxylic acid and/or ester thereof
CA2692266C (en) 2007-09-27 2019-04-16 Ls9, Inc. Reduction of the toxic effect of impurities from raw materials by extractive fermentation
EP2217695A2 (en) 2007-11-10 2010-08-18 Joule Unlimited, Inc. Hyperphotosynthetic organisms
US8048624B1 (en) 2007-12-04 2011-11-01 Opx Biotechnologies, Inc. Compositions and methods for 3-hydroxypropionate bio-production from biomass
WO2009085278A1 (en) 2007-12-21 2009-07-09 Ls9, Inc. Methods and compositions for producing olefins
US8518678B2 (en) 2007-12-21 2013-08-27 Butamax(Tm) Advanced Biofuels Llc Strain comprising increased expression of a CFA coding region for butanol production
WO2009089457A1 (en) 2008-01-11 2009-07-16 Novozymes A/S Methods for producing 3-hydroxypropionic acid and compounds thereof
CA2712779C (en) 2008-01-22 2021-03-16 Genomatica, Inc. Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol
EP2706111A1 (en) 2008-03-03 2014-03-12 Joule Unlimited Technologies, Inc. Engineered CO2 fixing microorganisms producing carbon-based products of interest
DK2262901T3 (en) 2008-03-05 2019-01-21 Genomatica Inc ORGANISMS PRODUCING PRIMARY ALCOHOL
US8598378B2 (en) 2008-03-14 2013-12-03 University Of Hawaii Methods and compositions for extraction and transesterification of biomass components
CN101983239A (en) 2008-03-28 2011-03-02 加利福尼亚大学董事会 Producing dicarboxylic acids using polyketide synthases
TWI456949B (en) 2008-04-30 2014-10-11 Thomson Licensing System and method for switching between phone services
MX2010012192A (en) 2008-05-16 2011-04-26 Ls9 Inc Methods and compositions for producing hydrocarbons.
PL2288710T3 (en) 2008-05-23 2014-11-28 Du Pont DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in in oilseed plants
AU2009256209A1 (en) 2008-06-04 2009-12-10 Butamax(Tm) Advanced Biofuels Llc Deletion mutants for the production of isobutanol
DE102008002309A1 (en) 2008-06-09 2009-12-10 Evonik Degussa Gmbh Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae
AU2009258344B2 (en) 2008-06-09 2013-11-07 Lanzatech Nz, Inc. Production of butanediol by anaerobic microbial fermentation
DE102008002715A1 (en) 2008-06-27 2009-12-31 Evonik Röhm Gmbh 2-hydroxyisobutyric acid producing recombinant cell
US20110190513A1 (en) 2008-07-08 2011-08-04 Lynch Michael D Methods, compositions and systems for biosynthetic bio-production of 1,4-butanediol
US20100021978A1 (en) 2008-07-23 2010-01-28 Genomatica, Inc. Methods and organisms for production of 3-hydroxypropionic acid
US20110244575A1 (en) 2008-07-23 2011-10-06 Lipscomb Tanya E W Methods, systems and compositions for increased microorganism tolerance to and production of 3-hydroxypropionic acid (3-hp)
US20110281314A1 (en) 2008-08-04 2011-11-17 Lynch Michael D Methods, systems and compositions related to microbial bio-production of butanol and/or isobutanol
US20160362710A9 (en) 2008-08-18 2016-12-15 REG Life Sciences, LLC Systems and methods for production of mixed fatty esters
US20130189787A1 (en) 2008-09-15 2013-07-25 Opx Biotechnologies ,Inc. Methods, Systems And Compositions Related To Reduction Of Conversions Of Microbially Produced 3-Hydroxyproplonic Acid (3-HP) To Aldehyde Metabolites
BRPI0913818A2 (en) 2008-10-03 2017-03-28 Agrisoma Biosciences Inc transgenic plant production method, transgenic plant and oil production method
ES2692918T3 (en) 2008-10-07 2018-12-05 REG Life Sciences, LLC Methods and compositions for producing fatty aldehydes
CN102317464B (en) 2008-12-12 2014-10-29 塞莱西翁有限公司 Biological Synthesis of Difunctional Alkanes from Carbohydrate Feedstocks
ES2730713T3 (en) 2008-12-23 2019-11-12 Reg Life Sciences Llc Methods and compositions related to thioesterase enzymes
AU2009330014A1 (en) 2008-12-23 2011-08-11 Matrix Genetics, Llc Modified photosynthetic microorganisms with reduced glycogen and their use in producing carbon-based products
US20120094386A1 (en) 2009-03-11 2012-04-19 Sapphire Energy, Inc. Engineering salt tolerance in photosynthetic microorganisms
KR20120025450A (en) 2009-04-02 2012-03-15 유니버시티 오브 플로리다 리서치 파운데이션, 인크. Engineering the pathway for succinate production
BRPI1014952A2 (en) 2009-04-10 2019-09-24 Ls9 Inc "composition produced by a microorganism and biofuel composition."
CN111808892A (en) 2009-04-27 2020-10-23 基因组股份公司 Production of fatty acid esters
JP4760951B2 (en) 2009-05-08 2011-08-31 トヨタ自動車株式会社 Recombinant microorganism having butanol-producing ability and method for producing butanol
US20110144377A1 (en) 2009-06-16 2011-06-16 E. I. Du Pont Nemours And Company Process for the biological production of 3-hydroxypropionic acid with high yield
US8956834B2 (en) 2009-06-29 2015-02-17 Synthetic Genomics, Inc. Acyl-ACP thioesterase genes and uses therefor
CN102482692A (en) 2009-07-01 2012-05-30 诺维信北美公司 Process for separating and recovering 3-hydroxypropionic acid
US9133406B2 (en) 2009-09-25 2015-09-15 REG Life Sciences, LLC Production of fatty acid derivatives
MX2012003604A (en) 2009-09-27 2012-09-12 Opx Biotechnologies Inc Method for producing 3-hydroxypropionic acid and other products.
US8809027B1 (en) 2009-09-27 2014-08-19 Opx Biotechnologies, Inc. Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase
EP2488652A4 (en) 2009-10-13 2014-04-09 Genomatica Inc Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto
AU2010309840B2 (en) 2009-10-20 2015-07-16 Bayer Cropscience Nv Methods and means to alter lipid biosynthesis by targeting multiple enzymes to suborganelle domains
EP2501820A4 (en) 2009-11-20 2014-05-14 Opx Biotechnologies Inc Methods, systems, and compositions for microbial bio-production of biomolecules using syngas components, or sugars, as feedstocks
US20110125118A1 (en) 2009-11-20 2011-05-26 Opx Biotechnologies, Inc. Production of an Organic Acid and/or Related Chemicals
CA2779884A1 (en) 2009-11-23 2011-05-26 Butamax(Tm) Advanced Biofuels Llc Method for producing butanol using extractive fermentation with electrolyte addition
US8293935B2 (en) 2009-12-02 2012-10-23 Board Of Trustees Of Michigan State University Carboxylic acid recovery and methods related thereto
WO2011081658A2 (en) * 2009-12-15 2011-07-07 Qteros, Inc. Methods and compositions for producing chemical products from c. phytofermentants
US8530221B2 (en) 2010-01-14 2013-09-10 Ls9, Inc. Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells
GB2492256A (en) 2010-01-27 2012-12-26 Opx Biotechnologies Inc Microorganism production of high-valve chemical products, and related compositions, methods and systems
CN101745245B (en) 2010-02-05 2012-05-23 北京化工大学 Multi-level countercurrent rotating bed reaction and rectification device and application thereof
WO2011100667A1 (en) 2010-02-14 2011-08-18 Ls9, Inc. Surfactant and cleaning compositions comprising microbially produced branched fatty alcohols
DK3382015T3 (en) 2010-08-06 2021-11-22 Melt&Marble Ab PROCEDURES AND PRODUCTS FOR PRODUCING GROWTHS
US10138504B2 (en) 2010-08-06 2018-11-27 Lallemand Hungary Liquidity Management Llc Production of malonyl-CoA derived products via anaerobic pathways
US8372610B2 (en) 2010-09-15 2013-02-12 Ls9, Inc. Production of odd chain fatty acid derivatives in recombinant microbial cells
JP2013544500A (en) 2010-09-28 2013-12-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Production of α-olefins using polyketide synthase
AU2011317281A1 (en) 2010-10-18 2013-06-06 Zeachem, Inc. Recovery of organic acid using a complex extraction solvent
JP5605597B2 (en) 2010-11-22 2014-10-15 フロリダ大学 リサーチファウンデーション インコーポレイティッド Genetic manipulation of thermostable Bacillus coagulans for D (-)-lactic acid production
EP3287519B1 (en) 2010-11-22 2020-03-18 Cargill, Incorporated Compositions and methods for 3-hydroxypropionic acid production
US20140121118A1 (en) 2010-11-23 2014-05-01 Opx Biotechnologies, Inc. Methods, systems and compositions regarding multiplex construction protein amino-acid substitutions and identification of sequence-activity relationships, to provide gene replacement such as with tagged mutant genes, such as via efficient homologous recombination
EP2673369B1 (en) 2011-02-07 2017-04-05 William Marsh Rice University Reverse beta oxidation pathway
KR20120108538A (en) 2011-03-24 2012-10-05 삼성전자주식회사 Method of producing 3-hydroxypropionic acid using reduction pathway of malonic semialdehyde
CA2869144A1 (en) 2011-03-30 2012-10-04 Ls9, Inc. Compositions comprising and methods for producing beta-hydroxy fatty acid esters
US20120264902A1 (en) 2011-04-18 2012-10-18 The Regents Of The University Of Colorado, A Body Corporate Methods, Systems and Compositions for Increased Microorganism Tolerance to and Production of 3-Hydroxypropionic Acid (3-HP)
AU2012273005A1 (en) 2011-06-22 2013-05-09 Genomatica, Inc. Microorganism for producing primary alcohols and related compounds and methods related thereto
KR101860442B1 (en) * 2011-06-27 2018-05-24 삼성전자주식회사 Genetic Modification for Production of 3-hydroxypropionic acid
US20140230091A1 (en) 2011-06-28 2014-08-14 Brookhaven Science Associates, Llc Modified plants with increased oil content
CN103717736B (en) 2011-08-04 2015-11-25 三得利控股株式会社 There is fatty acid chain and extend gene promoting active protein, this protein of encoding and uses thereof
AU2012289886A1 (en) 2011-08-04 2014-02-20 Danisco Us Inc. Production of isoprene, isoprenoid precursors, and isoprenoids using acetoacetyl-CoA synthase
BR112014007115A2 (en) 2011-09-27 2017-04-25 Exxonmobil Res & Eng Co acyl-acp wax ester synthases
US8790901B2 (en) 2011-12-14 2014-07-29 Pronutria, Inc. Microorganisms and methods for producing unsaturated fatty acids
US20160024532A1 (en) 2012-02-23 2016-01-28 The Regents Of The University Of California Atp driven direct photosynthetic production of fuels and chemicals
KR102166271B1 (en) 2012-04-02 2020-10-16 알이지 라이프 사이언시스, 엘엘씨 Improved production of fatty acid derivatives
AU2013243602B2 (en) 2012-04-02 2016-11-24 Genomatica, Inc. Car enzymes and improved production of fatty alcohols
US20140179437A1 (en) 2012-06-20 2014-06-26 Zagg Intellectual Property Holding Co., Inc. Gaming accessory for a portable electronic device, gaming systems and methods
US20130345470A1 (en) 2012-06-20 2013-12-26 Opx Biotechnologies, Inc. Purification of 3-Hydroxypropionic Acid from Crude Cell Broth and Production of Acrylamide
US10123953B2 (en) 2012-06-21 2018-11-13 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials
WO2014026162A1 (en) 2012-08-10 2014-02-13 Opx Biotechnologies, Inc. Microorganisms and methods for the production of fatty acids and fatty acid derived products
MX366179B (en) 2012-09-14 2019-07-01 Reg Life Sciences Llc Enzyme variants with improved ester synthase properties.
EP3103867B1 (en) 2013-01-16 2018-05-16 REG Life Sciences, LLC Acyl-acp reductase with improved properties
US9809804B2 (en) 2013-01-23 2017-11-07 Iowa State University Research Foundation, Inc. Materials and methods for characterizing and using KASIII for production of bi-functional fatty acids
CA2905602A1 (en) 2013-03-15 2014-09-18 Sarah M. Hoyt Flash evaporation for product purification and recovery
US9447438B2 (en) 2013-03-15 2016-09-20 Cargill, Incorporated Acetyl-coA carboxylases
US20150044746A1 (en) 2013-03-15 2015-02-12 Opx Biotechnologies, Inc. Method of enhanced bioproduction
US10066245B2 (en) 2013-06-14 2018-09-04 Technical University Of Denmark Microbial production of 3-hydroxypropionic acid
JP6603658B2 (en) 2013-07-19 2019-11-06 カーギル インコーポレイテッド Microorganisms and methods for the production of fatty acids and fatty acid derivatives
US20150056884A1 (en) 2013-08-22 2015-02-26 The Kinetic Concept, LLC Bubble making system
WO2015042626A1 (en) 2013-09-27 2015-04-02 Fts Computertechnik Gmbh Method for detecting a failure of a constituent system in a system-of-systems
EP2993228B1 (en) 2014-09-02 2019-10-09 Cargill, Incorporated Production of fatty acid esters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140330032A1 (en) * 2011-03-22 2014-11-06 Michael D. Lynch Microbial production of chemical products and related compositions, methods and systems
US20150064754A1 (en) * 2013-03-15 2015-03-05 Opx Biotechnologies, Inc. Bioproduction of chemicals

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Broun et al., Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids. Science, 1998, Vol. 282: 1315-1317. *
Chica et al., Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. Curr. Opi. Biotechnol., 2005, Vol. 16: 378-384. *
Devos et al., Practical limits of function prediction. Proteins: Structure, Function, and Genetics. 2000, Vol. 41: 98-107. *
Kisselev L., Polypeptide release factors in prokaryotes and eukaryotes: same function, different structure. Structure, 2002, Vol. 10: 8-9. *
Seffernick et al., Melamine deaminase and Atrazine chlorohydrolase: 98 percent identical but functionally different. J. Bacteriol., 2001, Vol. 183 (8): 2405-2410. *
Sen et al., Developments in directed evolution for improving enzyme functions. Appl. Biochem. Biotechnol., 2007, Vol. 143: 212-223. *
Whisstock et al., Prediction of protein function from protein sequence. Q. Rev. Biophysics., 2003, Vol. 36 (3): 307-340. *
Winkler et al., Asymmetric bioreduction of activated alkenes to industrailly relevant optically active compounds. J. Biotechnol., 2012, Vol. 162: 381-389. *
Wishart et al., A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem., 1995, Vol. 270(45): 26782-26785. *
Witkowski et al., Conversion of b-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with glutamine. Biochemistry, 1999, Vol. 38: 11643-11650. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10465213B2 (en) 2012-08-10 2019-11-05 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10047383B2 (en) 2013-03-15 2018-08-14 Cargill, Incorporated Bioproduction of chemicals
US10815473B2 (en) 2013-03-15 2020-10-27 Cargill, Incorporated Acetyl-CoA carboxylases
US10337038B2 (en) 2013-07-19 2019-07-02 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10494654B2 (en) 2014-09-02 2019-12-03 Cargill, Incorporated Production of fatty acids esters
US11345938B2 (en) 2017-02-02 2022-05-31 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives

Also Published As

Publication number Publication date
US10815473B2 (en) 2020-10-27
US20150057465A1 (en) 2015-02-26
WO2014146026A1 (en) 2014-09-18
US20150056669A1 (en) 2015-02-26
US9447438B2 (en) 2016-09-20
US20190127725A1 (en) 2019-05-02
US10047383B2 (en) 2018-08-14
US20170101638A1 (en) 2017-04-13
US20160138055A1 (en) 2016-05-19
WO2014146026A9 (en) 2014-12-11
US10155937B2 (en) 2018-12-18

Similar Documents

Publication Publication Date Title
US10815473B2 (en) Acetyl-CoA carboxylases
EP2970982B1 (en) Acetyl-coa carboxylase mutations
Litsanov et al. Toward homosuccinate fermentation: metabolic engineering of Corynebacterium glutamicum for anaerobic production of succinate from glucose and formate
EP2841584B1 (en) A method of production of 2,4-dihydroxybutyric acid
MX2012003604A (en) Method for producing 3-hydroxypropionic acid and other products.
US20180087024A1 (en) Genetically engineered c1-utilizing microorganisms and processes for their production and use
WO2013043758A2 (en) Compositions and methods regarding direct nadh utilization to produce 3-hydroxypropionic acid, derived chemicals and further derived products
US20140099676A1 (en) Microorganisms and methods for producing acrylate and other products from homoserine
WO2013052717A2 (en) Microorganisms and methods for producing acrylate and other products from homoserine

Legal Events

Date Code Title Description
AS Assignment

Owner name: OPX BIOTECHNOLOGIES, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIAO, HANS;MERCOGLIANO, CHRISTOPHER PATRICK;WOLTER, TRAVIS ROBERT;AND OTHERS;SIGNING DATES FROM 20070611 TO 20140529;REEL/FRAME:033018/0001

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION